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The prognosis of patients with oral squamous cell carcinoma (OSCC) worsens 
dramatically when tumours metastasise to neck lymph nodes, particularly when 
they spread beyond the node capsule (extracapsular spread, ECS). Although the 
importance of the tumour microenvironment has been well established in OSCC, it 
is poorly understood in the context of ECS and lymph node metastases. This work 
aimed to examine the lymph node tumour microenvironment in ECS and to 
investigate the mechanisms of tumour-stromal crosstalk, which may drive lymph 
node tumour development.  
Stromal and epithelial-mesenchymal transition (EMT) markers in paired 
primary and lymph node tumours with and without ECS were compared by IHC. It 
was found that the stroma of ECS-positive lymph nodes and their matched primary 
tumours have a higher proportion of αSMA-positive myofibroblasts and that 
microvascular vessel density is also elevated in ECS-positive nodes.  
Key stromal cell types including myofibroblasts, senescent fibroblasts, 
cancer-associated fibroblasts (CAF), vascular and lymphatic endothelial cells were 
co-cultured with oral cancer cell lines (OCCL), including those derived from lymph 
node metastases. EMT marker expression was detected in metastatic OCCL, which 
also showed significantly higher migration capacity, but more work is needed to 
determine the impact of fibroblasts on these processes. Both primary and 
metastases-derived OCCL induced tubule formation in lymphatic endothelial cells. 
OCCL, particularly those derived from lymph node metastases, and were also able 
to induce IL-6 and CCL2 secretion in normal oral fibroblasts and exposure of 
endothelial cells to OCCL and fibroblast conditioned media also resulted in a 
significant increase in expression of the inflammatory mediator IL-6. 
The findings of this thesis describe novel data relating to the role of the 
tumour microenvironment in lymph node metastases and ECS. Increased 
understanding of this process will aid the development of new biomarkers and 
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Chapter 1: Introduction and literature review 
1.1. Oral cancer 
Oral cancer is a significant cause of mortality and morbidity worldwide, 
ranking as the 13th most common cause of cancer incidence and mortality in the 
world (Ferlay et al., 2013). In the UK, it accounted for about 6800 cases and 2100 
deaths in 2012 (Cancer Research UK, 2014).  However, there is a large amount of 
geographical variation in incidence. In high-risk developing countries such as India 
and Pakistan oral cancer is the most common cancer in men, contributing up to 25% 
of all reported cancer cases (Warnakulasuriya, 2009). In Western Europe oral cancer 
incidence has increased in recent decades, with the UK reporting a 30% increase in 
the last decade (Cancer Research UK, 2011) and predicting a 25% increase in cases 
in the next two decades (Mistry et al., 2011). As well as occurring more frequently 
in men and with increasing age, tobacco, betel quid and alcohol use have been 
identified as key risk factors. This strong link to lifestyle factors coupled by the 
additional role now found to be played by human papillomavirus (HPV) infection 
may help to explain the projected increase in incidence, but to a large extent, the 
reasons are poorly understood. Despite treatment advances, survival rates remain 
static at 50%, and mortality rates are projected to increase in the next decade in the 
UK due to increasing incidence (Olsen, Parkin and Saseini, 2008). Successful 
treatment of oral cancer is impeded by its propensity to metastasise to locoregional 
sites such as the cervical lymph nodes and the development of extracapsular 
spread. In comparison to other common cancers, the molecular landscape of oral 
cancer is poorly understood, hampering the development of novel treatments and 
prognosticators informing treatment options. 
Oral Squamous Cell Carcinoma (OSCC) originates from the squamous 
epithelial cells of the oral cavity mucosa and is the most common form of oral 
cancer. Oral cavity cancer has been identified as distinct from oropharyngeal cancer 
in terms of both clinicopathological and prognostic characteristics (Shield et al., 
2017). The most common sites of origin are the tongue and floor of mouth, with 
tumours commonly presenting as painless lesions or ulcers in the early stages. 
2 
 
These can develop into large exophytic masses or destructive ulcers with associated 
muscle impairment and pain due to direct invasion of local structures including 
muscle and nerves in the connective tissue (Sapp, Eversole and Wysocki, 2004; 
Soames and Southam, 2005).   
1.1.1. Lymph node metastasis 
Metastasis of OSCC, usually to the cervical lymph nodes depending upon the 
site of the primary tumour, worsens prognosis (Myers et al., 2001; Shaw et al., 
2010). Initial colonisation of lymph nodes by the metastatic deposit is followed by 
secondary growth and proliferation. In some instances, the metastatic tumour can 
grow and infiltrate beyond the capsule of the lymph node resulting in invasion into 
the surrounding adipose tissue and muscle. This phenomenon is termed 
extracapsular spread (ECS) and results in a further significant reduction in patient 
survival and disease-free period (Myers et al., 2001; Greenberg et al., 2003; 
Woolgar et al., 2003; Wenzel et al., 2004; Larsen et al., 2009; Shaw et al., 2010; 
Kokemueller et al., 2011; Michikawa et al., 2011; Joo et al., 2013; Maxwell et al., 
2013; Prabhu et al., 2014; Shibuya et al., 2014). Occasionally, metastasis to more 
distant sites may occur, with lungs and liver being the more frequently involved 
sites (Sapp, Eversole and Wysocki, 2004).  
OSCC is most commonly treated by surgery which may be followed up by 
radiotherapy or chemotherapy (Sapp, Eversole and Wysocki, 2004). The high 
mortality rate associated with lymph node metastasis means identification of 
patients with lymph node involvement is essential to guide treatment strategies. 
Currently, fine needle aspiration, core biopsies, ultrasound or magnetic resonance 
imaging (MRI) scanning and sentinel node biopsies are used to identify patients with 
lymph node involvement without the need for complex surgery. However, evidence 
suggests that these methods are not 100% sensitive (Tandon et al., 2008; Govers et 
al., 2013) and the risks associated with false negative rate means that a large 
number of patients undergo elective neck dissections despite being classified as N0 
clinically (i.e. negative for metastatic tumour clinically). Approximately 30% of N0 
patients undergoing elective neck dissection are found to have lymph node 
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involvement (D’Cruz et al., 2015). Although the identification and removal of 
positive nodes confers a survival benefit (D’Cruz et al., 2015), a large number of 
neck dissections are unnecessary, and patients must deal with the associated 
morbidity. For those with confirmed node involvement either selective or radical 
neck dissection is carried out and may be accompanied by post-operative 
radiotherapy or chemotherapy. Neck dissection may result in neck stiffness and 
constriction, pain, numbness and damage to the spinal accessory nerve which can 
impair shoulder function (Inoue et al., 2006).  
As with all cancers, early and accurate diagnosis is critical to the success of 
treatment. This is even more critical in the context of OSCC as many patients 
present with late stage disease largely due to patient’s delay in consulting a 
physician (McGurk et al., 2005). The morbidity associated with aggressive treatment 
means that the need for accurate prognostic tools is crucial to balance its success 
with maintaining quality of life. 
 
1.2. Extracapsular Spread (ECS) 
1.2.1. Lymph node structure 
The complex lymph node structure and the cell types contained within it 
play a key role in the colonisation, growth and local invasion of OSCC tumours. The 
highly organised structure of a lymph node (Figure 1.1.) facilitates interactions 
between cells of the immune system and foreign antigens but is also the principal 
site of metastasis in OSCC. In normal function, lymph fluid drained from 
surrounding tissues enters the lymph node via the afferent lymph vessels along with 
circulating antigen-presenting cells (APC). Here the subcapsular sinus prevents fluid 
entering the lymph node but APC are able to actively cross it along with their 
antigen cargo and macrophages are capable of sampling antigen for presentation to 
B lymphocytes (Harwood and Batista, 2010). Fluid containing small antigens and 
chemokines are transported around the lymph node via collagen conduits formed 
and covered by fibroblast reticular cells (FRC). Dendritic cells found on these 
conduits are able to sample antigen directly from the fluid (Roozendaal, Mebius and 
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Kraal, 2008). The entire lymph node is also surrounded by a fibrocollagenous 
capsule that supports the lymph node structure.  
Lymphocytes within the lymph node are organised into specific 
compartments in the cortical areas, formed by connecting fibroblast cells. B 
lymphocytes are localised to B cell follicles in the outer cortex, whereas T 
lymphocytes are located in the inner paracortical areas. Within the B cell follicles, 
follicular dendritic cells form a supportive network, and secrete a wide range of 
immune cell modulators (Allen and Cyster, 2008). Naïve lymphocytes enter from 
blood vessels via the high endothelial venules in the paracortex. The inner medulla 
area contains the efferent lymph vessels which drain lymph fluid and lymphocytes 










Figure 1.1. Structure of the lymph node and infiltration by tumour cells. Cancer 
cells enter the lymph node via afferent lymph vessels along with antigen-presenting 
cells. The subcapsular sinus prevents fluid from entering the cortical areas but 
allows active cellular transport, including that of cancer cells. Macrophages in the 
subcapsular sinus are capable of sampling large antigens for presentation to B cells. 
B cell zones are found in the cortex along with follicular dendritic cells (FDC) with T 
cells contained with the paracortex. Collagen conduits formed by fibroblastic 
reticular cells (FRC) carry fluid around the lymph node and blood vessels carrying 
naïve lymphocytes enter via the high endothelial venules (HEV) in the paracortex. 
Lymph fluid is drained from the node via the efferent lymph vessels. The whole 






1.2.2. ECS development 
The routes of lymph node entry used by immune cells are also exploited by 
tumour cells. This is particularly important for OSCC as oral structures (in particular 
tongue) have abundant superficial lymphatic vessels allowing tumour cells to 
adhere and gain access to the lymphatic system. Tumour cells that have invaded 
into lymphatic vessels follow the path of the natural lymph drainage and enter the 
lymph node via the afferent lymph vessels and collect at the subcapsular sinus 
(Nathanson, Shah and Rosso, 2015) (Figure 1.1.). It is thought that complementary 
chemokine expression by tumour cells and the lymphatic endothelial cells lining the 
subcapsular sinus facilitates tumour migration into the cortex (Podgrabinska and 
Skobe, 2014). Once within the cortex, tumour cells proliferate, develop a blood 
vessel network and, in some cases, generate a supportive stroma. Cancer cells can 
migrate and invade through lymph node tissue and break out of the capsule 
surrounding the lymph node into the surrounding adipose and muscle tissue, a 
process termed ECS. The exact mechanism by which ECS occurs is somewhat 
controversial, with mechanical disruption of the capsule due to expanding tumour 
growth and direct invasion into the capsule through collagenase production 
proposed as possible mechanisms (Michikawa et al., 2018). Nevertheless, the high 
connectivity of the lymph node to both lymphatic and circulatory systems also 
means there are multiple routes through which tumour cells can spread to another 
site (Nathanson, Shah and Rosso, 2015). 
1.2.3. Prognostic value of ECS 
Multiple studies investigating prognostic factors in OSCC have highlighted 
ECS as a key indicator of poor survival, increased recurrence and increased rate of 
distant metastasis (Myers et al., 2001; Greenberg et al., 2003; Woolgar et al., 2003; 
Wenzel et al., 2004; Liao et al., 2007; Larsen et al., 2009; Shaw et al., 2010; 
Kokemueller et al., 2011; Michikawa et al., 2011; Joo et al., 2013; Maxwell et al., 
2013; Shibuya et al., 2014; Prabhu et al., 2014; Suton et al., 2017). For example, 
Shaw et al. (2010) reported 5-year survival rates of 65%, 52% and 23% in node 
negative, node positive ECS negative (ECS-) and node positive ECS positive (ECS+) 
patients, respectively. By using retrospective data, these studies do not represent 
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the impact of current treatment strategies; however, they do provide clear 
evidence that ECS is a crucial indicator of particularly poor prognosis, even in 
comparison to patients with lymph node involvement. This is further highlighted by 
the fact that the recent update to TNM classification recommends ECS being taken 
into account and consideration for the tumour to be up-staged. It must be noted 
that for some studies this link was only significant in cases of multiple ECS+ nodes 
(Greenberg et al., 2003) or advanced ECS+ nodes with severely damaged tissue 
architecture (Prabhu et al., 2014). Additionally, a recent study showed that when 
ECS was categorised based on the level of invasion out of the lymph node, patients 
with the highest level of invasion had a significantly poorer survival and recurrence 
rate (Yamada et al., 2016). Conversely, other studies reported no difference in 
survival rate when comparing macroscopic versus microscopic ECS (Woolgar et al., 
2003; Shaw et al., 2010), or the extent of invasion (Greenberg et al., 2003) and it 
has also been reported that patients with smaller size ECS+ nodes have a lower 
survival rate compared to those with large ECS+ nodes (Michikawa et al., 2018). This 
controversy highlights how little is known about the exact mechanism by which ECS 
occurs and invites the possibility that the driving mechanism behind it may vary 
between cases. It also highlights the need for a standardised definition of ECS and 
suggests that the extent of ECS should be reported to allow for better analysis of 
clinical outcomes. 
A comparative analysis of two large scale clinical trials in locally advanced 
head and neck cancer identified ECS as one of only two factors for which concurrent 
postoperative radiation and cisplatin-based chemotherapy conferred a significant 
survival benefit (Bernier et al., 2005). In addition, follow-up studies have shown that 
this benefit is long-term (Cooper et al., 2012), but is also associated with significant 
toxicity. More recently other strategies have been suggested that may confer 
survival benefit for these patients whilst reducing the treatment toxicity (Mermod 
et al., 2016). However, these have yet to be validated in the clinic and so the 
treatment options available to ECS+ patients remain limited.  
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1.2.4. ECS detection 
Currently, the presence of ECS is usually confirmed histologically following 
lymph node removal as part of a neck dissection. Although there have been some 
reports of partially successful detection with 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET)/computed tomography (CT) (Joo et al., 2013) and CT 
scans for central node necrosis (Randall et al., 2015), there is also evidence to 
suggest that pre-operative imaging techniques currently used for ECS diagnosis, 
such as CT and MRI scans, do not have the required reliability or sensitivity 
(Coatesworth and MacLennan, 2002; Woolgar et al., 2003; Shaw et al., 2010; Aiken 
et al., 2015). A recent meta-analysis revealed that the mean sensitivity or specificity 
of these methods does not rise above 0.85, meaning that a significant proportion of 
patients are still being misdiagnosed (Su et al., 2016). Indeed, Coatesworth and 
MacLennan (2002) and Suton et al. (2017) showed the histological presence of ECS 
in a subset of patients declared node negative based on scans and physical 
examination. This false negative reporting could delay the identification of patients 
requiring more aggressive treatment, such as radio- or chemoradiotherapy, 
alongside surgery.  
There have been some reports investigating gene expression signatures that 
can predict ECS. The identified signatures included gene copy number aberrations 
(Michikawa et al., 2011; Peng et al., 2011), epigenetic modifications (Jithesh et al., 
2013), as well as specific changes in RNA and protein expression (Zhou et al., 2006; 
Dhanda et al., 2014; Wang et al., 2015; Mermod et al., 2017) and identified markers 
such as epidermal growth factor receptor (EGFR), α-smooth muscle actin (αSMA) 
and the proto-oncogene MYC. All of these studies utilised primary tumour samples, 
which may suggest the genes identified are predictive of more aggressive disease 
rather than having a direct effect on ECS specifically. On the other hand, predicting 
ECS from features of the primary tumour samples would aid treatment decisions by 
identifying patients likely to develop ECS. However, there are currently no 
molecular biomarkers in clinical use and larger and more wide-ranging clinical 
studies are needed before translation to the clinic can be considered. In addition, 
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multiple markers were often required to reach prognostic significance in these 
studies, which call into question their predictive power.  
In order to develop effective diagnostic and therapeutic tools, the process of 
ECS needs to be understood better, as well as its causes and effects, both within the 
tumour and in its surrounding environment.  
 
1.3. Epithelial-mesenchymal transition (EMT), the tumour 
microenvironment and ECS development 
The ability of cancer cells to migrate and invade through the 
microenvironment is central to the development of ECS. It is well known that EMT 
plays a key role in the acquisition of these abilities in many cancer types including 
OSCC (Krisanaprakornkit and Iamaroon, 2012). EMT was first studied in the context 
of embryology, wound healing and tissue regeneration. However, later research 
showed that it  played an important role in cancer metastasis and could be linked to 
increased recurrence and decreased survival (Krisanaprakornkit and Iamaroon, 
2012).  
During EMT cell-cell adhesion is lost with epithelial adhesion molecules such 
as integrins and E-cadherin being replaced with mesenchymal markers such as N-
cadherin and vimentin in a process of cadherin switching (Wheelock et al., 2008). 
This is followed by a loss of baso-apical polarity and remodelling of the cytoskeleton 
including actin reorganisation and the formation of invadopodia (Takkunen et al., 
2010). Finally, the release of extra-cellular matrix (ECM) degrading enzymes, such as 
matrix metalloproteases (MMPs), leads to a loss of cell-ECM adhesion (Polette et 
al., 2004). The result of these changes is an increase in the migratory and invasive 
ability of the cells and, subsequently, an increase in metastatic potential (see Figure 
1.2.). 
The induction of EMT in cancer cells is complex, involving many cellular and 
genetic processes. A crucial step is the epigenetic down-regulation of the cell-cell 
adhesion molecule E-cadherin due to the binding of transcriptional repressors such 
as slug (Snail Family Zinc Finger 2, SNAI2), snail (Snail Family Zinc Finger 1, SNAI1), 
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TWIST1 (Twist Basic Helix-Loop-Helix Transcription Factor 1) and ZEB1 (Zinc Finger 
E-Box Binding Homeobox 1) (Krisanaprakornkit and Iamaroon, 2012). This is known 
to be triggered by various growth factors including transforming growth factor-β1 
(TGF-β1) and epidermal growth factor (EGF). Both extrinsic and intrinsic factors 
have been found to initiate EMT in many different cancers. For example, cell culture 
media containing secretions from cancer-associated fibroblasts was able to induce 
EMT in breast cancer cells (Lebret et al., 2007) and mutations affecting the TGF-β1 
signalling pathway induced EMT changes in many cancers including gastric, breast, 
colon and pancreatic cancer (Levy and Hill, 2006). Genetic mutations, proteolytic 
cleavage of E-cadherin, micro-RNAs, and cytokine signalling have also been 
implicated in EMT induction (Krisanaprakornkit and Iamaroon, 2012). 
In oral cancer cell lines (OCCL) TGF-β1 (Qiao, Johnson and Gao, 2010; Richter 
et al., 2011; Yu et al., 2011), snail cDNA (Takkunen et al., 2006) and AKT activation 
(Grille et al., 2003) have been used in vitro to induce EMT-like changes. Although 
not always tested, this artificial induction was often accompanied by an increase in 
invasive ability (Richter et al., 2011; Yu et al., 2011), including in an in vivo model 
(Grille et al., 2003). Additionally, OCCL with low E-cadherin/high snail expression 
were found to be more invasive (Yokoyama et al., 2001).   
The link between EMT and metastasis has also been demonstrated in many 
cancer types (Voulgari and Pintzas, 2009). There is also evidence linking EMT to 
metastasis in OSCC. Primary tumour samples with low E-cadherin and high vimentin 
expression correlated with a higher rate of distant metastasis (Nijkamp et al., 2011) 
and high N-cadherin and vimentin expression has been linked to increased rate of 
cervical lymph node metastasis (Ding et al., 2014). In addition, increased expression 
of several EMT transcription factors including slug, TWIST1 and ZEB1 has been 
linked to increased lymph node metastasis in OSCC (Wang et al., 2012; Y. Zhou et 
al., 2015; Yao and Sun, 2017). Through single-cell transcriptome analysis of a cohort 
of OSCC tumours, Puram et al. (2017) identified an EMT expression signature in a 
subset of the malignant cells. Although this was characterised by the expression of 
several classical EMT markers, including vimentin and TGF-β1, cells retained 
expression of epithelial markers, albeit at a reduced level, and lacked expression of 
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most of the EMT transcription factors. Nevertheless, this “partial-EMT” expression 
signature was found to be associated with increased lymph node metastasis and 
ECS when applied to a large TCGA dataset.  
There are few papers reporting on EMT in OSCC lymph node metastases. Lee 
et al. (2014) investigated EMT marker expression in the lymph nodes of ECS+/- 
patents. They found that EMT was a better predictor of poor survival than ECS alone 
as ECS+ patients with a high percentage of tumour cells expressing vimentin had a 
five times worse survival rate compared to ECS- patients. Puram et al. (2017) also 
extended their analysis to a set of matched lymph node metastases and were able 
to identify their partial-EMT signature in a subset of the metastatic cells. 
Furthermore, the proportion of malignant cells expressing this partial-EMT 
signature matched to that seen in the corresponding primary tumour, suggesting 
that EMT state was maintained at the metastatic site. Histology of OSCC lymph 
node tumours revealed tumour nests with partial-EMT markers expressed at in cells 
at the leading edge, surrounded by CAF, suggesting that this altered expression 
state coupled with stromal cell influence may be involved in invasion at the lymph 
node site. 
However, further work is needed to determine to what extent EMT is 
important to ECS and whether alternative mechanisms are involved. Furthermore, it 
is now known that cancers are heavily influenced by the multitudinous cell types 
present in the tumour microenvironment (Figure 1.3.). Fibroblasts, lymphatic and 
vascular endothelial cells, and inflammatory immune cells are all key components of 
the tumour microenvironment and are able to influence cancer development 
through many complex signalling pathways and through their influence on the 
extracellular matrix (ECM) structure. When considering the lymph node tumour 
microenvironment, the role of lymph node specific cells such as FRC and the actions 
of resident immune cells must also be considered. The current evidence relating to 
these cell types and their influence on processes linked to ECS, including EMT, will 





Figure 1.2. Epithelial-mesenchymal transition (EMT). Epithelial cells express cell-
cell (including E-cadherin, tight junction, and desmosome components) and cell-
extracellular matrix (ECM; including integrins) adhesion molecules. These are lost, 
along with basal-apical polarity, during epithelial-mesenchymal transition (EMT). 
After EMT, cells instead express mesenchymal markers such as N-cadherin and 
vimentin (an intermediate filament protein). They also secrete matrix 
metalloproteases (MMPs) which degrade the ECM. Together these changes 






Figure 1.3. Cells and components of the tumour microenvironment. Malignant 
epithelial cancer cells are supported by several stromal cell types that make up the 
tumour microenvironment. Cancer associated fibroblasts (CAF) promote tumour 
development through the secretion of a range of growth factors, proteases and 
cytokines as well as secreting and remodelling the extracellular matrix (ECM). Blood 
and lymphatic vessels are important structures in the tumour microenvironment 
and represent key routes of metastasis. Tumour cells, alongside CAF, recruit 
inflammatory innate immune cells to the tumour site, such as tumour-associated 
macrophage (TAM). TAM themselves are able to promote tumour growth, vessel 








1.4. Fibroblasts in cancer metastasis 
As well as providing structural support in lymph nodes, fibroblasts have 
many active roles within healthy lymph nodes as well as other tissues. They are the 
primary secretors of the ECM and form the connective tissue of all organs. In the 
wound healing process, fibroblasts are activated to differentiate into myofibroblasts 
and play a key role in the rebuilding of the tissue structure. However, this activation 
is reversible and controlled in healthy tissue.  
Cancer is often referred to as a dysregulated wound so it is not surprising 
that fibroblasts are also found in close proximity to tumours. Specifically, the term 
cancer-associated fibroblast (CAF) refers to fibroblast-like cells surrounding the 
epithelial tumour islands (particularly towards the invasive front) and contributing 
to cancer progression through crosstalk with tumour cells. Although this term is 
often used interchangeably with myofibroblast there is a large amount of evidence 
showing that the CAF population is in fact very heterogeneous (Madar, Goldstein 
and Rotter, 2013). The heterogeneity of CAF also means that identifying their 
origins is difficult. Various sources including recruited mesenchymal stem cells, 
resident fibroblasts and differentiated epithelial cancer cells have been suggested 
(Madar, Goldstein and Rotter, 2013). The presence of senescent fibroblasts has also 
been observed in the stroma of a number of different cancers including prostate, 
breast and oral cancers. The specific secretory profile of these cells, termed the 
senescence-associated secretory phenotype (SASP), contains proteases and soluble 
factors, including chemokines and growth factors such as TGF-β1. Through this, 
senescent fibroblasts have been shown to influence cell proliferation, migration and 
invasion in several cancer types (Coppé et al., 2010). It is now known that this 
senescence can develop as a result of a variety of cellular stresses including 
telomeric dysfunction and reactive oxygen species generation. Additionally, 
external factors including cigarette smoke (Coppe et al., 2008) and cancer chemo- 
and radiotherapies designed to induce apoptosis through DNA damage may instead 
promote cellular senescence (Gewirtz, Holt and Elmore, 2008).   
Despite this confusion in definition, several “CAF” markers have been 
suggested and correlated to adverse prognosis and changes to cancer cell 
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behaviour. In OSCC, expression of the myofibroblast marker α-smooth muscle actin 
(αSMA) in the tumour stroma has been linked to poor survival and increased 
recurrence (Kellermann et al., 2007, 2008; Vered, Dobriyan, et al., 2010; Bello et al., 
2011; Marsh et al., 2011).  Expression of αSMA has also been linked to increased 
lymph node metastasis and ECS in OSCC (Kellermann et al., 2007; Marsh et al., 
2011; Dhanda et al., 2014) which suggests there is a connection between stromal 
fibroblast presence, poor survival and ECS occurrence.  However, the origins and 
mechanisms by which CAF are generated in the lymph node have yet to be 
elucidated. 
 However, the data described so far rely upon deducing links between 
factors based purely on observed correlations. In order to back up these finding it is 
necessary to carry out functional studies demonstrating a direct link between the 
presence of fibroblasts and altered cancer cell behaviour, in the context of ECS. 
1.4.1. Effects of fibroblasts on cancer cells – proliferation, EMT induction 
and invasion 
In primary OSCC tumours, there is a large amount of evidence showing that 
CAF have the ability to promote cancer migration, invasion and metastasis (see 1.4 
and individual sections below). Although very few studies have looked at the role of 
fibroblasts in ECS specifically, information from these primary tumour studies is 
useful to predict the role that fibroblasts may play in promoting ECS.  
Proliferation 
Sustained proliferation is crucial for the maintenance and growth of a 
tumour. Both Kellermann et al. (2008) and Sobral et al. (2011) showed that media 
from myofibroblasts enhanced the proliferation of OCCL when compared to normal 
oral fibroblast media. The origin of these fibroblasts was different in each case. 
Kellermann et al. (2008) used TGF-β1 to generate myofibroblasts from a culture of 
primary oral fibroblast and showed that TGF-β1 itself could not induce the same 
changes in the OCCL. This differentiation method was also used by Berndt et al. 
(2014) who attributed the increase in proliferation to EGF receptor (EGFR) 
signalling. In contrast, the myofibroblasts in the Sobral et al. (2011) study were 
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monoclonal cultures derived from individual αSMA and collagen expressing cells 
isolated from patients’ tumour samples. Although this means that induction of 
myofibroblast differentiation was more “natural”, the derivation of monoclonal 
cultures does limit the heterogeneity of the cell population.  
However, aggressive tumours not only display sustained proliferation but 
also the ability to migrate and invade into surrounding tissue and undergo 
metastasis. These changes are especially crucial if ECS is to occur. 
Migration 
Fibroblasts have been shown to influence cancer cell migration in models of 
OSCC primary tumours. Increased migration of primary tumour OCCL in response to 
conditioned media from myofibroblasts, senescent fibroblasts and CAF derived 
from genetically-unstable tumours has been previously demonstrated in our lab 
(Kabir, 2015; Kabir et al., 2016; Melling et al., 2018). Zhou et al. (2014) also showed 
that αSMA-positive CAF could increase the migration of several OCCL compared to 
normal healthy fibroblasts. Additionally, Pal et al. (2013) showed that OCCL 
migrated more in response to fibroblasts treated with cigarette smoke condensate 
which connects to the increased risk of OSCC in smokers. However, none of these 
studies investigated motility in lymph node tumour cells. 
Epithelial-mesenchymal transition (EMT) induction 
As previously discussed, the induction of the EMT process in cancer cells 
enhances their invasive and metastatic ability and so is likely to be important to the 
ECS process. Using immunohistochemical analysis of OSCC patient samples, Ding et 
al. (2014) found a correlation between high αSMA expression and expression of the 
mesenchymal markers vimentin and N-cadherin. These three markers were also 
predictive of lymph node metastasis and higher TMN staging. Puram et al. (2017) 
identified a partial-EMT expression signature in a cohort of OSCC tumours and 
found that cells positive for this signature localised to the leading edge of tumour 
islands and were also surrounded by CAF. This was observed in both primary 
tumours and lymph node metastases and the CAF were also found to be enriched 
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for EMT-promoting ligands such as TGF-β1.  Together this provides strong ex vivo 
evidence linking EMT and CAF presence. 
Berndt et al. (2014) showed that myofibroblast-conditioned media caused 
an upregulation of the mesenchymal marker vimentin. Although this suggests a 
potential link, it is surprising that no significant correlation with any of the other 
investigated EMT markers (E-cadherin, N-cadherin and cytokeratin) was found. 
Using a similar method Sobral et al. (2011) reported an upregulation of the ECM-
degrading enzymes MMP-2 and -9 coupled with an increase in invasion of OCCL in 
response to myofibroblast conditioned medium. Use of indirect co-culture through 
the transfer of conditioned medium allows the transfer of soluble factors. However, 
as the cells in these assays are not in close proximity it also eliminates contact-
dependant signalling and the two-way crosstalk that must occur in a real tumour 
environment.  
A separate study by Dudás, Bitsche, et al. (2011) used an alternative method 
whereby OCCL and fibroblasts are co-cultured separated only by a thin membrane 
using transwell chambers. Using this technique, they saw an increase in vimentin 
expression coupled with a decrease in E-cadherin expression in the OCCL when co-
cultured with fibroblasts. This alteration of cancer cell expression caused by non-
activated fibroblasts could be seen to contradict the studies discussed previously. 
However, the direct co-culture method allows for simultaneous crosstalk between 
the two cell types allowing for the alteration of fibroblast phenotype by cancer cells 
and the authors reported that they were indeed altered into CAF-like cells. Using a 
similar methodology Zhou et al. (2014) showed that CAF cultured in transwells were 
able to induce a decrease in E-cadherin coupled with an increase in vimentin and 
fibronectin in OCCL to a greater extent than NOF from the same patient. This was 
also associated with an increase in migratory ability.  
Invasion 
The prognostic significance and effect of fibroblasts on EMT marker 
expression and migration suggest that they may play an important role in invasion 
and metastasis, processes key to ECS. This has been supported by several studies.  
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The ability of fibroblasts to promote the invasion of OSCC cells was 
demonstrated many years ago by Matsumoto et al. (1989) who showed that, when 
cancer cell lines were grown on a collagen matrix, invasion was only seen when this 
matrix contained fibroblasts or fibroblast conditioned medium. More recent studies 
quantified this observation, showing that the percentage of cells invading into ECM-
like Matrigel matrix coated membranes was significantly increased when 
myofibroblast, senescent fibroblast or CAF cells or conditioned media were present 
on the lower side of the membrane (Lewis et al., 2004; Daly, McIlreavey and Irwin, 
2008; Marsh et al., 2011; Sobral et al., 2011; Li et al., 2015; Kabir et al., 2016; Lin et 
al., 2017; Melling et al., 2018). In addition, Costea et al. (2006) showed that even 
dysplastic oral keratinocytes were induced to invade by the presence of fibroblasts 
highlighting the important role that fibroblasts may play in inducing cancer cell 
aggression in the early stage of tumour development. 
In vitro assays can also provide information on the form of cellular invasion, 
comprising of single cell or collective invasion. In single cell invasion, individual cells 
undergo EMT and use their newly acquired motility and ability to degrade the ECM 
and invade into nearby structures including blood and lymphatic vessels. Collective 
invasion, in contrast, involves the movement of groups of carcinoma cells that 
retain their epithelial phenotype facilitated by the ECM degrading properties of 
myofibroblasts. Most work has focussed on the role of EMT and link of this to 
invasion, however Gaggioli et al. (2007) focussed on the collective invasion process. 
They observed that fibroblasts were able to enhance the invasion of epithelial 
cancer cells more than mesenchymal cancer cells. This invasion was collective, with 
groups of epithelial cells invading through a collagen matrix almost always following 
a leading fibroblast. Interestingly these tracks alone, without the presence of 
fibroblasts, were enough to facilitate collective invasion and blocking ECM-
degrading and remodelling enzymes prevented invasion. Further to this, work in our 
lab has demonstrated the ability of cisplatin-senesced fibroblasts to induce invasion 
of primary tumour-derived OCCL in a 3D de-epitheliarised dermis model of oral 
mucosa and observed the collective invasion of groups of cancer cells into the 
fibroblast filled dermis (Kabir, 2015; Kabir et al., 2016). 
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1.4.2. Effects of cancer cells on fibroblasts 
A complex crosstalk between multiple cell types occurs throughout the body 
and therefore is likely to influence tumour progression as well. This includes the 
ability of cancer cell to manipulate surrounding cells and the suggestion that they 
may play a role in fibroblast activation. TGF-β1, an inducer of myofibroblast 
differentiation, is frequently increased in cancer (Levy and Hill, 2006) which could 
be explained by an increase in TGF-β1 secretion by cancer cells and other cells of 
the tumour microenvironment. Lewis et al. (2004) showed that OCCL medium was 
able to induce myofibroblast differentiation in oral fibroblasts and blocking TGF-β1 
prevented this. Similarly, Dudás, Bitsche, et al. (2011) saw an alteration of 
fibroblasts into CAF when co-cultured with OCCL.  
Senescent CAF have also been identified as a key part of the tumour stroma. 
Hassona et al. (2013) showed that medium from genetically unstable cancer cells 
caused senescence in fibroblasts and, crucially, this equated to the senescent state 
of the CAF at the original tumour site. This senescence was attributed to oxidative 
damage and TGF-β1 signalling. 
There are further examples where crosstalk between fibroblasts and cancer 
cells altered both their behaviours, highlighting the importance of considering other 
cell types when analysing cancer cell behaviour. For example, Hwang et al. (2012) 
found that insulin-like growth factor-II mRNA- binding protein-3 (IMP-3), which is 
needed for ECM remodelling activity and functional invadopodia formation, was 
also required for podoplanin mRNA stabilisation. Loss of either caused a decrease in 
cancer cell invasion and correlated with decreased lymph node metastasis. TGF-β1, 
released by fibroblasts, was found to induce the podoplanin mRNA stabilisation 
activity of IMP-3. A cytokine array revealed that the cancer cells were releasing 
interleukin (IL)-1β, a known TGF-β1 inducer, indicating a crosstalk between the two 
cell types. However, IL-1β depletion experiments were not carried out so it is 
possible that other cancer cell-secreted factors also play a role.  
A further study showed that IL-1α secretion by OCCL induced CCL7 release 
by CAF in a co-culture system. CCL7 was able to bind to chemokine receptors on the 
OCCL to induce increased invasion and migration (Jung et al., 2010). The use of 3D 
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co-culture systems in this study more closely emulates the in vivo situation. These 
examples highlight many of the cell types and molecules discussed in this thesis and 
demonstrate the complexity of the tumour microenvironment signalling network 
and the effect this has on tumour cell behaviour. 
1.4.3. Cancer-associated fibroblast (CAF) heterogeneity 
A significant complicating factor in the investigation of CAF is the 
heterogeneity within their population. As mentioned previously, both 
myofibroblastic and senescent markers have been identified in the CAF population 
but other studies have indicated that CAF may display phenotypes that are even 
more diverse. Costea et al. (2013) used a gene microarray to compare gene 
expression levels in CAF, dysplastic fibroblast and normal fibroblast samples from 
OSCC patients. They identified two distinct CAF subgroups: CAF-N, which were 
similar to normal fibroblasts, and CAF-D, which were more divergent in expression 
levels. CAF-N induced the formation of tumours by oral dysplastic keratinocytes 
faster and to a greater extent than CAF-D when co-injected into mice. CAF-N 
populations were also more migratory, both intrinsically and in response to TGF-β1. 
However, CAF-D populations also played a role in cancer development as they were 
found to be the major secretors of TGF-β1. 
In a separate set of studies, CAF cell lines derived from genetically stable 
OSCC (GS-OSCC) were compared to those from genetically unstable OSCC (GU-
OSCC; defined as tumours with extensive changes in copy number, loss of 
heterozygosity and loss of p53 and p16INK4A). Comparing the expression profiles 
revealed there were extensive differences between the two groups and many of the 
gene changes in GU-OSCC CAF could be linked to poor prognosis (Lim et al., 2011). 
They also observed functional differences, for example only conditioned media 
from GU-OSCC CAF could induce invasion of keratinocytes (Hassona et al., 2013). In 
addition, GU-OSCC CAF appeared to be more senescent and this could be explained 
by the presence of oxidative damage and a lack of antioxidant defences (Hassona et 
al., 2013). In another example of crosstalk, conditioned media from GU-OSCC cells 
could induce senescence in normal fibroblasts. This could be blocked using 
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antioxidants or blocking TGF-β1 suggesting that cancer cells may be playing a role in 
the generation of oxidative damage in these fibroblasts. Interestingly, this cited 
study observed a correlation between senescence and αSMA expression. The SASP 
was also analysed and key molecules involved in invasion were identified including 
MMP-2 (Hassona et al., 2014).  
As stated above, the source and development of CAF and how they 
contribute to ECS is still largely unknown. However, a recent paper from Puram et 
al. (2017) has provided some insight into the lymph node CAF population by 
carrying out single-cell transcriptome analysis of a cohort of OSCC primary tumours 
and five matched lymph node metastases. In the primary tumours, they identified 
several CAF subsets based on their expression profiles: myofibroblasts, resting 
fibroblasts, and CAF which displayed expression of receptors, ligands and ECM 
genes that have been previously associated with CAF, and could be further split into 
two subsets (CAF1 and CAF2) based on their expression of specific markers. 
Although all of these fibroblast types were also present in lymph node tumours, 
myofibroblast and CAF1 cells made up a greater proportion of the population, and 
showed preferential expression of certain ligands and receptors. This suggests that, 
although the different CAF subpopulations appear to the maintained at metastatic 
site, the altered signalling environment of the lymph node site has an effect on the 
specific phenotype of the CAF. 
1.4.4. Fibroblast reticular cells (FRC) 
Fibroblast reticular cells (FRC) are a specialised sub-type of fibroblasts found 
within the lymph node (Figure 1.1). They provide structure and support to the 
lymph node and are crucial to the establishment and maintenance of distinct B and 
T cell zones through their expression of homeostatic chemokines (Chang and Turley, 
2015). FRC produce complex networks of collagen conduits ensheathed in a 
basement membrane and remain densely covering the conduits, allowing for the 
tight control of lymphocyte-antigen interactions. These conduits transport fluid 
containing chemokines and small antigens through the lymph node to the high 
endothelial venules (HEVs) where lymphocytes and monocytes enter the lymph 
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node and can initiate an immune response. Entry into the conduits is tightly 
controlled based on size, facilitating immune cell-antigen interactions whilst also 
preventing pathogens from entering the bloodstream (Roozendaal, Mebius and 
Kraal, 2008).  
Very few studies have investigated the FRC response to metastatic cancer 
and no information is available regarding their role in OSCC specifically. An 
interesting study by Riedel et al. (2016) investigated FRC responses in the tumour 
draining lymph nodes (TDLN) of a mouse melanoma model. They observed an 
enlargement of pre-metastatic TDLN, which was partly attributed to an expansion 
of FRC. Whole genome transcriptome analysis comparing non-draining lymph 
nodes, early and late stage TDLN revealed many alterations in expression including 
the expression of FRC activation markers including podoplanin. Most significantly, 
they observed inflammatory cytokine and chemokine signalling in the late stage 
nodes, which resulted in a disorganised tissue architecture and alteration to 
immune cell composition. Alterations to transporter function, remodelling of 
collagen fibres and changes to cell junction proteins were also found in late stage 
nodes where conduits were widened. The authors suggested this loss of conduit 
integrity may aid the delivery of tumour-derived factors, debris and antigens deep 
into the lymph node to aid subsequent lymph node metastasis. However, the 
impact of FRC on tumour cells and their development once they reach the lymph 
node is unknown.  There is also some evidence to suggest that down-regulation of 
podoplanin signalling may lead to FRC elongation and loss of their contractile 
phenotype allowing the lymph node to expand to facilitate tumour growth (Acton et 
al., 2014). 
 
1.5. The extracellular matrix (ECM) and cancer metastasis 
The extracellular matrix (ECM) forms a scaffold on which all cells reside and 
provides a supportive structure to all tissues. It is made up of fibrous proteins such 
as collagen and fibronectin and globular sugars such as glycosaminoglycans which 
are secreted by fibroblasts (Ziober, Falls and Ziober, 2006). Fibroblasts also secrete 
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enzymes such as matrix metalloproteinases (MMPs) which cleave the ECM proteins, 
allowing for remodelling of the structure or the release of bound signalling 
molecules (Lyons and Jones, 2007). The ECM plays an important role in cancer 
development and has been shown to influence all of the hallmarks of cancer 
including the promotion of angiogenesis, inflammation, invasion and metastasis 
(Pickup, Mouw and Weaver, 2014). Cancer cells must migrate along and invade 
through this dense matrix if they are to metastasise to other sites. Cells bind directly 
to the ECM via adhesion molecules called integrins and alteration to the integrin 
ligands present on the ECM can also influence cancer cell behaviour including the 
promotion of migration and invasion (Lyons and Jones, 2007). In lymph nodes, FRC 
are the key secretors of ECM, which is primarily made up of collagen conduits 
ensheathed in a basement matrix (see section 1.4.4.). Using time-lapse multiphoton 
intravital microscopy through an optical lymph node window in mice, Pereira et al. 
(2018) observed metastasising tumour cells that had entered the lymph node cortex 
associating with conduits suggesting that cancer cells may use this ECM matrix to 
migrate along upon lymph node colonisation.  
The relationship between ECM component expression and cancer 
progression is complex as it is not only changes in expression levels but also 
alteration to the ECM structure and organisation that affect cancer progression 
(Ziober, Falls and Ziober, 2006).  Overexpression of many ECM proteins has been 
reported in OSCC primary tumours (Ziober, Falls and Ziober, 2006) and expression 
signatures made up of ECM proteins including several collagen and laminin isoforms 
have been proposed as biomarkers for OSCC (Ziober et al., 2006; Chen et al., 2008). 
However, scarce data are available regarding the response of the lymph node ECM 
to cancer presence or the effect of CAF presence on ECM deposition in lymph 
nodes. Rizwan et al. (2015) investigated collagen density using a mouse model of 
metastatic breast cancer and found that lymph nodes containing metastatic 
deposits had a higher density of collagen I compared to mice with non-metastatic 
breast cancer or no tumour. They also examined human breast cancer lymph nodes 
with metastasis and saw an up-regulation of collagen, fibronectin and several types 
of integrin compared to tumour-free lymph nodes. 
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Disassembly and reorganisation of ECM proteins is also crucial to the process 
of invasion. Increased expression of MMP enzymes by tumour cells has been linked 
to increased nodal metastasis in OSCC (Baker et al., 2006) and MMP-2 expression by 
CAF has been shown to promote invasion of OCCL in vitro (Hassona et al., 2014). 
Studies in breast cancer have demonstrated an upregulation of these enzymes in 
metastatic lymph nodes compared to tumour-free lymph nodes (Daniele et al., 
2010). MMP-2 and -9 expression has also been identified in OSCC lymph node 
deposits but the significance of this with regard to ECS is unknown (Zhou et al., 
2010).  
 
1.6. Lymphatic and vascular cells in cancer metastasis 
Endothelial cells form both blood and lymphatic vessels, both of which are 
important in facilitating tumour growth as well as providing a route of metastasis 
(Figure 1.3.). It is widely known that tumours have the ability to induce angiogenesis 
and that this is crucial to provide oxygen and nutrients as the tumour grows, and 
also provides a route by which the cancer cells can metastasise. Lymph vessels also 
provide a metastatic route via the drainage of tissue fluid; however, whether the 
tumour can induce the formation of new lymph vessels is more uncertain. In OSCC, 
increased vascular and lymphatic invasion has been linked to increased nodal 
metastasis and ECS occurrence (Jones et al., 2009; Adel et al., 2015). Adel et al. 
(2015) investigated each vessel type separately and found that only lymphatic 
invasion was able to predict survival rates in their cohort, highlighting the 
importance of this metastatic route in OSCC.  
1.6.1. Blood vessels 
Increased vessel density in OSCC carcinomas compared to normal or 
dysplastic tissue has been observed in the primary tumour (Li et al., 2005; 
Shivamallappa et al., 2011) and correlated to increased lymph node metastasis 
(Miyahara et al., 2007; Bolzoni Villaret et al., 2009). In addition, elevated expression 
of factors known to promote angiogenesis, including vascular endothelial growth 
factor (VEGF), have been observed in primary OSCC carcinomas and correlated to 
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increased lymph node metastasis (Li et al., 2005; Jung et al., 2015; Sales et al., 2016; 
Kazakydasan et al., 2017).  
There have been only few studies focussed on angiogenesis within the 
lymph node upon metastasis. A mouse model of OSCC found that vessel density was 
elevated in tumour draining lymph nodes prior to colonisation when metastatic 
tumour cells were implanted into the tongue but not when non-metastatic cells 
were used (Mayorca-Guiliani et al., 2012). Conversely, when Naresh, Nerurkar and 
Borges (2001) double-immunostained for blood vessel and proliferation markers, 
they found that metastatic lymph nodes did not have an elevated level of 
neoangiogenesis compared to non-metastatic lymph nodes in the same patient, 
whereas extensive neoangiogenesis was seen in the corresponding primary tumour. 
They suggested this was because the rich vessel nature of the lymph node meant 
that inducing new vessel growth was not necessary for tumour survival. However, 
this needs to be confirmed in a larger sample size. Another study focussed on blood 
vessels as a route of metastasis from the lymph node using a mouse model of 
metastatic squamous cell carcinoma (Pereira et al., 2018). Time-lapse multiphoton 
intravital microscopy through an optical lymph node window showed that once 
metastasising tumour cells had entered the lymph node cortex they accumulated 
around blood vessels as a result of directed migration and were also observed 
moving inside the vessel lumen. This highlights the importance of considering blood 
vessels as a metastatic route from lymph node metastasis and the potential role of 
this in the development of distant metastasis. 
The role of fibroblasts in vessel formation is another important 
consideration as CAF are known to secrete factors which promote vessel formation 
(Coppé et al., 2010; Cirri and Chiarugi, 2012). Increased αSMA expression and a 
higher blood vessel density have been correlated in primary OSCC tumours and, in a 
mouse model, OSCC cells co-injected with CAF showed elevated blood vessel 
density compared to OSCC cells injected alone or with NOF (Lin et al., 2017). 
Furthermore, in a mouse breast cancer model epithelial tumours co-injected with 
senescent fibroblasts displayed increased tumour vascularisation compared to pre-
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senescent fibroblasts (Coppé et al., 2006). However, this has yet to be 
demonstrated in the context of lymph node metastases. 
In the lymph node, specialised blood vessels called high endothelial venules 
(HEV) are found in the lymph node paracortex, formed of cuboidal endothelial cells 
surrounded by FRC (Figure 1.1). In OSCC lymph nodes with metastatic deposits, an 
increased density of HEVs has been observed and correlated to poor prognosis (Lee 
et al., 2012). However, HEV density has also been found to be elevated during 
lymph node enlargement prior to metastatic colonisation (Shen et al., 2014) and  
elevation of HEV density has been reported in sentinel lymph nodes (SLN) 
regardless of metastatic status compared to non-SLNs (Chung et al., 2012). 
Moreover, Shen et al. (2014) observed tumour deposits adjacent to HEVs suggesting 
this may be an alternative route for lymph node metastasis.  
1.6.2. Lymphatic vessels 
In primary OSCC, high lymph vessel density (LVD) and elevated levels of the 
pro-lymphangiogenic factor VEGF-C have been associated with increased risk of 
lymph node metastasis and decreased survival (Kyzas et al., 2005; Zhao et al., 2008; 
Abdul-Aziz et al., 2017). In addition, co-expression of proliferation and lymph vessel 
markers indicated that neolymphangiogenesis was occurring within the tumour 
(Kyzas et al., 2005; Zhao et al., 2008). This is backed up by the observation in these 
studies that vessels within the tumour were smaller and potentially more immature 
than those surrounding the tumour. However, these studies used only primary 
tumour samples so whether neolymphangiogenesis occurs in metastatic tumours in 
lymph nodes is less clear. Chung et al. (2012) reported an increase in LVD in sentinel 
lymph nodes (SLNs) regardless of metastasis status compared to non-SLN, whereas 
Wakisaka et al. (2015) found that LVD was significantly higher in SLN with 
metastatic deposits compared to tumour-free SLN. Neither report compared 
metastatic tumours in lymph nodes with and without ECS. 
Additionally, functional in vitro studies have shown that metastatic cancer 
cell lines can increase vessel formation and alter gene expression of human 
lymphatic endothelial cells (HLEC) compared to HLEC grown with non-metastatic 
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cancer cell lines. These alterations included expression of VEGF-A and -C and 
increased expression of chemokines known to be involved in attracting cancer cells 
to invade into lymph vessels (Zhuang et al., 2010). This implies that, as with 
fibroblasts, there may be a crosstalk of signals between endothelial and tumour 
cells that alter the behaviour of both cell types. However, validation of these 
findings in a broader range of cell lines is needed to confirm this and link it to the 
lymph node setting. 
In addition, there is evidence that fibroblasts play a role in influencing 
lymphatic endothelial cell behaviour. A correlation between αSMA expression and a 
higher LVD in primary OSCC tumours has been found and correlated with higher 
TMN stage (Ding et al., 2014; Lin et al., 2017). This implicates myofibroblasts in 
vessel formation in OSCC. Furthermore, there is evidence that senescent fibroblasts 
can induce endothelial cell migration and invasion through the secretion of VEGF 
and other chemo-attractants (Coppé et al., 2010).  
There are limited data relating to the role of lymph vessel formation in 
lymph nodes and its role in ECS. However, given the crucial role played by lymph 
vessels in the metastasis of cancer, it is likely that their presence is important in the 
process of ECS. 
1.6.3. Endothelial-mesenchymal transition (EndMT) 
As with EMT, EndMT was first investigated in the context of embryonic 
development but it emerged that this phenotypic transformation also plays a role in 
pathological conditions including cancer and fibrosis. During EndMT, endothelial 
cells lining vessel walls delaminate from their cell layer, acquire a mesenchymal 
phenotype and invade into the surrounding tissue. Endothelial cells may be a 
significant source of CAF. Zeisberg et al. (2007) demonstrated that up to 40% of CAF 
displayed endothelial markers in two mouse models of cancer.  In head and neck 
cancer it has been shown that TWIST1 expression can induce EndMT (Chen et al., 
2014) and it is thought that EMT and EndMT share many of the same signalling 
mechanisms.  Furthermore, EndMT is suspected to play a role in the promotion of 
angiogenesis: firstly as a source of tip cells which lead the growth of sprouting blood 
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vessels but also as a source of supporting cells such as pericytes and smooth muscle 
cells (Welch-Reardon, Wu and Hughes, 2014). However, the exact role of EndMT in 
OSCC tumours has not been investigated. 
 
1.7. Inflammation in cancer metastasis 
Although the immune system plays a key role in cancer prevention, it is now 
known that chronic inflammation increases cancer risk and that the generation of 
an inflammatory microenvironment is a crucial driver of tumour progression. Most, 
if not all, solid tumours generate an inflammatory microenvironment due to the 
secretion of cytokines and chemokines by both cancer cells and stromal cells, 
including CAF. The innate immune cells crucial to this inflammatory response, 
including macrophages, neutrophils and mast cells, have multitudinous effects on 
the tumour and its microenvironment through their secretion of cytokines, 
chemokines, prostaglandins, growth factors and reactive oxygen and nitrogen 
species (Grivennikov, Greten and Karin, 2010).  
Inflammation is an important factor to consider when investigating the 
causes of invasion and metastasis. Innate immune cells secrete factors that induce 
angiogenesis, increase vascular permeability and promote EMT, all factors that 
facilitate the metastasis of tumour cells (Grivennikov, Greten and Karin, 2010). 
Lymph nodes are a central part of the immune system and so the response of both 
native and recruited immune cells to the presence of tumour cells within the lymph 
node is an important consideration and may influence ECS development. Aberrant 
chemokine and cytokine signalling by lymph node FRC (see section 1.4.4.) in 
response to the presence of cancer in a mouse metastatic melanoma model has 
been shown to result a disorganised tissue architecture and alteration to immune 
cell composition (Riedel et al., 2016).  
The importance of inflammation to cancer progression also provides another 
potential avenue of treatment options. It is thought that combining traditional cell-
killing chemotherapies with anti-inflammatory drugs may enhance treatment 
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responses and early clinical trials have shown promise in preventing tumour 
progression (Mantovani et al., 2008).  
As the most common inflammatory cell type found in the tumour 
microenvironment macrophages are particularly important in the context of OSCC 
development both at the primary and lymph node sites. 
1.7.1. Tumour-associated macrophages (TAM) 
Macrophages are derived from blood monocytes, which are recruited to the 
tumour in response to a variety of signals secreted by tumour and stromal cells, 
such as the chemokine CCL2 (MCP-1) and the pro-angiogenic factor VEGF. Aberrant 
chemokine signalling in FRC in response to the presence of cancer has been shown 
to cause an increase in the presence of macrophages in a mouse model of 
metastatic melanoma cancer (Riedel et al., 2016). Macrophages can be polarised to 
two phenotypes: M1 classically activated macrophages which secrete pro-
inflammatory cytokines and contribute to anti-pathogenic and anti-tumour activity, 
and M2 alternatively activated macrophages which are anti-inflammatory and 
promote tissue remodelling and repair (Sica et al., 2008). Tumour-associated 
macrophages (TAM) are usually of the M2 phenotype and are able to aid tumour 
progression through the stimulation of proliferation, secretion of pro-angiogenic 
factors, suppression of anti-tumour immunity and remodelling of the ECM to aid 
invasion and metastasis (Takeya and Komohara, 2016).  
In primary OSCC tumours, high macrophage numbers (determined by 
staining specimens for the pan-macrophage marker CD68 by IHC) have been linked 
to poor prognosis and an increase in lymph node metastasis (Costa et al., 2013; 
Weber et al., 2014; Ni et al., 2015; Yamagata et al., 2017). However, there is some 
disagreement as to whether macrophage densities in the tumour, invasive edge or 
stroma were significant. In addition, in some cases an association with lower 
survival was only found when looking specifically at M2 macrophages using the 
CD163 marker (Fujii et al., 2012; He et al., 2014). 
Only one study has investigated macrophage presence in metastatic lymph 
nodes of oral cancer (Wehrhan et al., 2014). However, this focussed on whether 
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macrophage numbers or polarisation in the lymph node sinus could predict primary 
tumour invasion and grading parameters, with results varying widely depending on 
which macrophage marker ratio was used. Although macrophages were quantified 
in both the tumour and invasive front this was not commented on. Furthermore, 
none of the papers referenced investigated a potential link to ECS occurrence. 
 Macrophages are known to influence a number of processes important to 
invasion and therefore potentially ECS, including EMT. Hu et al. (2016) reported that 
OSCC tumours with high numbers of M2 macrophages also had a lack of E-cadherin 
staining coupled with high vimentin positivity. Furthermore, when they added 
conditioned media from the THP-1 macrophage cell line (induced to become an M2 
phenotype) to OSCC cells they saw a decrease in E-cadherin and increase in 
vimentin protein expression respectively, indicating EMT may have occurred. This 
was also accompanied by an increase in migration and invasion ability.  
Furthermore, macrophages are known to have the ability to induce angio- 
and lymphangiogenesis, which aid metastasis. In OSCC, high macrophage numbers 
have been linked to a higher microvascular density (El-Rouby, 2010) and lymph 
vessel density (Yamagata et al., 2017) ex vivo. There is also evidence that OSCC cells 
can induce expression of M2-macrophage markers in monocytes, including a 
significant increase in VEGF expression (Essa et al., 2016) and macrophages co-
expressing M2 markers and VEGF-C have been observed surrounding invading 
tumour nests in OSCC tissues (Yamagata et al., 2017). 
1.7.2. Cytokine and chemokine signalling in the tumour microenvironment 
Cytokines are the key immune signalling molecules that are released by 
immune, tumour and stromal cells in order to alter their microenvironment. 
Chemokines are cytokines that act as chemoattractants to direct the movement of 
immune cells. There are multitudinous cytokines and chemokines that have been 
shown to facilitate the formation of a pro-tumour immune response and promote 
tumour development, and many have been highlighted as potential biomarkers and 
treatment targets. CAF are known to secrete a wide variety of these molecules 
which have diverse effects on immune cell recruitment and tumour cell behaviour 
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(Turley, Cremasco and Astarita, 2015). In addition, endothelial cells are now being 
recognised as playing an active role in the immune response to tumour presence 
(Young, 2012; Turley, Cremasco and Astarita, 2015), but this remains an 
understudied topic in OSCC.  
As previously discussed in section 1.7.1., the ability to recruit macrophages 
to the tumour microenvironment facilitates tumour development. The chemokine 
CCL2 (also known as monocyte chemoattractant protein-1, MCP-1) is a potent 
chemoattractant of macrophages and is secreted by both tumour and stromal cells. 
CCL2 expression has been observed in OSCC and was reported to be increased in 
lymph nodes with metastatic deposits (Ferreira et al., 2008). Elevated CCL2 
secretion and mRNA expression has also been observed in senesced oral fibroblasts 
and in CAF from genetically-unstable OSCC tumours (Kabir, 2015; Kabir et al., 2016). 
In addition, Li et al. (2014) showed that when oral cancer cells were co-cultured 
with CAF, CCL2 levels were significantly elevated and this could be attributed to the 
CAF.  Stromal CCL2 production has also been shown to be important for the 
promotion of cancer cell migration and invasion.  Migration of oral cancer cells and 
invasion in a 3D model was promoted by the presence of senescent fibroblasts or 
their conditioned media but this was ablated by the addition of an anti-CCL2 
antibody (Kabir, 2015; Kabir et al., 2016). Similarly, Li et al. (2014) found that 
reducing CCL2 expression levels with siRNA significantly decreased the invasive and 
migratory capacity of the cancer cells. This suggests that CCL2 signalling may have 
multiple roles with the tumour microenvironment of OSCC and influence processes 
crucial to ECS. 
Increased expression of certain cytokine molecules are strongly linked to 
cancer progression. One of these is the pro-inflammatory cytokine IL-6, which is 
upregulated in most cancers. Produced by fibroblasts, endothelial cells, immune 
cells and tumour cells, increased IL-6 levels lead to the activation of multitudinous 
signalling pathways that influence tumour survival, invasion, proliferation and 
angiogenesis (Ataie-Kachoie, Pourgholami and Morris, 2013). Elevated IL-6 serum 
levels have been observed in OSCC and are associated with an increased incidence 
of lymph node metastasis and poor survival (Shinriki et al., 2011; Goda et al., 2017). 
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IL-6 is a known component of the SASP and elevated IL-6 secretion and mRNA 
expression has been identified in senescent fibroblasts and CAF from genetically-
unstable OSCC tumours (Kabir, 2015; Kabir et al., 2016). In vitro OSCC studies also 
showed that co-culture of primary tumour-derived OCCL and fibroblasts leads to an 
up-regulation of IL-6 mRNA expression (Dudás, Fullár, et al., 2011; Qin et al., 2018). 
Furthermore, IL-6 has been shown to promote MMP production in oral cancer cells 
in vitro facilitating the invasion process (Sundelin et al., 2005). In addition, IL-6 has 
also been shown to up-regulate the production of both VEGF and VEGF-C in vitro 
and blocking IL-6 inhibited angio- and lymphangiogenesis in a mouse xenograft 
model (Shinriki et al., 2009, 2011). 
Elevated salivary IL-8 (CXCL8) levels have also been identified as a potential 
biomarker for OSCC (Punyani and Sathawane, 2013) and elevated IL-8 in serum and 
OSCC tumour tissues has been linked to poor prognosis (Fujita et al., 2014). This 
negative effect may be explained not just through the neutrophil attracting 
chemokine activity of IL-8, which promotes inflammation, but also through its many 
downstream signalling pathways. These have been shown to stimulate cancer cell 
survival, migration and also promote angiogenesis and stimulate growth factor 
release by macrophage (Waugh and Wilson, 2008). There is also significant interest 
in IL-1 antagonism as a potential treatment strategy for solid tumours including 
OSCC (Wu et al., 2016; Mantovani, Barajon and Garlanda, 2018), due to its central 
role in initiating inflammatory reactions and link to the promotion of metastasis. 
Wu et al. (2016) observed elevated IL-1β expression in OSCC tissues and saw that 
siRNA knockdown of IL-1β or use of an IL-1 receptor 1 (IL-1R1) antagonist reduced 
oral cancer growth in vitro and in an in vivo rat model. Studies linking these 
cytokines to stromal cell signalling are scarce but co-culture of OCCL  and NOF has 
been shown to induce increased IL-1β mRNA expression (Dudás, Bitsche, et al., 
2011) and IL-6/8 mRNA expression has been shown to be up-regulated in 
endothelial cells as a result of co-culture with OCCL (Neiva et al., 2009). 
Cytokines represent a promising area for the identification of novel 
biomarkers and treatment targets for OSCC and research into this area continues to 
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reveal multiple mechanisms by which stromal cells can exert their influence on the 
tumour microenvironment.  
 
1.8. Gaps, issues and impact of current research 
This literature review has detailed the current information regarding the 
response of the lymph node tumour microenvironment to tumour metastasis but 
has also highlighted the lack of specific information related to ECS induction, 
despite its prognostic significance. There is mounting evidence that stromal cells 
have the ability to induce invasion and metastasis of primary tumour OSCC. 
However, direct evidence and specific mechanisms of action with regards to ECS are 
lacking. Moreover, many questions remain unanswered including the source of 
lymph node CAF and the response of the many resident immune cells to the 
presence of metastatic deposits. 
As well as their role in cancer, the source of CAF in ECS is also under debate. 
Whether CAF are recruited by the invading tumour cells or travel with the tumour 
from the primary site is also unknown. Vered, Dayan, et al. (2010) noted that the 
EMT marker and αSMA expression profiles of primary and lymph node tumours 
matched and these correlations were not seen in fibroblasts from a benign lymph 
node. Puram et al. (2017) also identified the same CAF subpopulations in matched 
primary OSCC and lymph node metastasis tumours but observed an alteration in 
the proportion of different subsets and changes to expression of specific markers 
including increased IL-1R1 expression. This suggests that there is a link between the 
nature of cancer-stromal behaviour at both sites but does not explain whether the 
stromal cells are altered in response to the presence of the tumour or if the CAF 
metastasise with the tumour cells. Our experience of histological examination of 
small initial metastatic deposits suggests that these initial tumour foci are devoid of 
surrounding stroma. This suggests that metastatic deposits might be undergoing a 
second EMT and/or inducing new stroma within the lymph node environment.    
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1.8.1. Targeting the tumour microenvironment in extracapsular spread 
Given the importance now placed on the tumour microenvironment in 
promoting many of the processes involved in ECS and the correlation with survival, 
it is not surprising that therapeutic targeting of many of the stromal cell types is 
seen as a promising approach. The greater genetic stability and influence CAF, TAM, 
FRC and endothelial cells have on the ECM, which is often a barrier for the delivery 
of drugs to solid tumours, makes them even more attractive. This could be 
particularly effective if used alongside cancer cell-killing drugs to target both sides 
of the crosstalk events as described above.  
For example, Meng et al. (2014) used a computer algorithm to model the 
interactions of proteins which display altered expression levels in both CAF and 
OSCC cells. They identified a loss of TGFβ receptor III (TGFβRIII) as a common 
occurrence in both cell types. They showed that administration of TGFβRIII slowed 
tumour growth, increased E-cadherin expression and decreased metastasis in an in 
vivo mouse model and that this was more effective if it was administered to both 
the tumour and the stromal fibroblasts. Furthermore, therapies targeted solely at 
cells of the tumour microenvironment, given alongside existing therapies, could also 
have a positive influence on patient survival. Antagonists of the pro-inflammatory 
cytokine IL-6 are currently being trialled as an anti-cancer therapy (Kumari et al., 
2016) and there is enormous potential for the use of anti-inflammatory drugs, 
especially in combination with cancer cell-killing drugs. However, the potential side 
effects of inhibiting normal cell function, particularly the wound healing role of 
myofibroblasts and anti-tumour immune activity must be considered when 
investigating new tumour microenvironment-targeted therapies. 
Given the difficulties faced in the detection of ECS pre-surgery, the tumour 
microenvironment also represents a promising area for the identification of novel 
prognostic biomarkers for use in either primary tumour samples or lymph node 
biopsies. 
It is hoped that understanding the ECS process, the mechanisms 
underpinning it and the role played by stromal cells will lead to better detection 
methods and even improved treatment strategies. This could have a significant 
35 
 
impact on prognostic and therapeutic tools available to clinicians treating OSCC 
patients. 
 
1.9. Aims and Hypothesis 
It is now known that the tumour microenvironment plays a key role in the 
promotion of invasion and metastasis in primary OSCC tumours as well as many 
other cancer types. However, tumour-stromal crosstalk has not been fully explored 
in metastatic lymph nodes to date. In addition, little is known about the nature and 
origins of the lymph node stroma and how this differs from that in primary OSCC. 
However, it seems likely that tumour-stroma crosstalk accelerates the development 
of lymph node tumours. Given the poor prognosis and aggressive nature of ECS 
positive tumours, this study hypothesises that these lymph node tumours have a 
heightened ability to induce a myofibroblastic and vessel rich stroma, which 
promotes tumour growth and the induction of ECS, in part through the induction of 
EMT.  
The specific aims of this project are: 
1. To compare markers of stroma, vascularity and epithelial-mesenchymal 
transition (EMT) in ECS positive and negative tumour sections. Paired primary site 
and lymph node tumour sections will be used to enable multiple comparisons to be 
made, with the aim to determine if the stroma is altered in ECS positive tumours 
and if this equates to what is seen at the primary tumour site. 
2. To generate myofibroblasts and senescent fibroblasts from primary 
normal oral fibroblasts and compare key markers to primary OSCC CAF.  
3. To examine the effect of myofibroblast and senescent fibroblast 
conditioned media on EMT marker expression and migration of oral cancer cell 
lines, including those derived from lymph node tumours. EMT has been shown to 
promote invasion and metastasis in many cancer types and so it was hypothesised 
that it may play a role in promoting ECS. 
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4. To examine the effect of conditioned media from oral cancer cells, 
myofibroblasts and senescent fibroblasts on lymphatic and vascular endothelial 
cells. Both lymph and blood vessels are potential metastatic routes for OSCC and 
new vessel growth facilitates tumour progression in primary OSCC. Therefore, this 
part of the study aims to find out if metastatic tumour cells can alter the vessel 
formation ability and growth of endothelial cells in an in vitro co-culture system.  
5. To examine the effect of co-culture of oral cancer cells, fibroblasts and 
endothelial cells on immune modulation. Inflammation is an important driver of 
cancer progression, including invasion and metastasis. Lymph nodes play a central 
role in immune reactions so it was hypothesised that inflammation also plays a role 
in the progression of OSCC lymph node metastases. This part of the study aims to 
investigate this by assessing pro-inflammatory signalling molecules released by 
stromal cells whilst in a co-culture system. 
Overall, this project aims to improve our understanding of the nature of the 
lymph node tumour microenvironment in OSCC and how this relates to ECS 
induction. Understanding this important clinical process is crucial to advance the 











Chapter 2: Materials and methods 
2.1. Immunohistochemistry (IHC) 
2.1.1. Specimen selection 
The case cohort was selected using the local pathology database and 
retrieved from the archive including tongue and floor of mouth OSCCs with 
matched metastatic lymph nodes with and without ECS (n=40, 10 in each group). 
Immunohistochemistry was then carried out on 4 µm formalin fixed paraffin 
embedded (FFPE) tissue sections (South Sheffield Ethics Approval Committee Ref: 
07/H1309/105). One FFPE block from the primary tumour and one from a lymph 
node metastasis were used from each case for subsequent staining and analysis. 
2.1.2. Haematoxylin and eosin staining 
Sections were dewaxed in xylene followed by incubation in graded ethanol. 
Haematoxylin and eosin (H&E) staining in tissue sections was carried out using a 
Leica ST4040 automated stainer in accordance with the manufacturer’s instructions 
before dehydrating and mounting using DPX and coverslips. Clinicopathological 
characteristics were determined by a registered pathologist. 
2.1.3. IHC protocol 
Sections were dewaxed by placing in xylene for 2 x 5 min followed by 5 min 
each in absolute ethanol and 95% (v/v) ethanol. Endogenous peroxidases were 
blocked by placing sections in 3% (v/v) hydrogen peroxide in methanol for 20 min 
before rinsing briefly in phosphate buffered saline (PBS). Antigen retrieval was 
achieved by pressure cooking (using the Retriever 2100, Aptum Biologics Ltd.) for 20 
min followed by 20 min of cooling in 0.01 M sodium citrate buffer (pH 6) or Tris-
EDTA buffer (10 mM Tris base, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 9) 
before transferring to PBS. Non-specific protein binding sites were blocked using 
100% serum (horse serum for antibodies raised in mouse; goat serum for antibodies 
raised in rabbit) for 30 min at room temperature (RT). Primary antibodies (see Table 
2.1.) were diluted in 100% serum and added to slides overnight at 4°C. 
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After washing twice for 5 min in PBS, slides were incubated for 30 min at RT 
with secondary antibody in accordance with the manufacturer’s instructions 
(VECTASTAIN Elite ABC kit, PK-6101/2, 1 drop in 10 ml PBS). Following two further 5 
min washes in PBS, Avidin Biotin Complex (ABC) solution was prepared and added 
at RT in accordance with the manufacturer’s instructions (VECTASTAIN Elite ABC kit, 
two drops solution A, two drops solution B per 5 ml PBS, incubated at RT for 30 min 
before use). Slides were then washed twice for 5 min in PBS. Colour development 
was achieved using a DAB substrate kit (Vector Laboratories, SK-4100) for 10 min or 
until colour developed before transferring the slides to distilled water to stop the 
reaction. Sections were counterstained in haematoxylin before dehydrating and 
mounting using DPX and coverslips.  
Optimisation of primary antibody concentration was carried out by testing a 
range of dilutions based on guidance from the manufacturer’s data sheet. Negative 
controls (incubated with 100% serum only, with no primary antibody) were included 
in each optimisation experiment and during subsequent staining of clinical 
specimens. Positive controls (previously optimised antibodies with the same host 
species) were also utilised in optimisation experiments to enable troubleshooting in 
cases with no positive staining. Negative control slides were checked for the 
absence of DAB positive staining and were scanned to allow consideration in 
quantification analysis. In addition, for the SNAI1/2 antibody it was possible to 
obtain the peptide from which it was raised, enabling peptide blocking control 










Table 2.1. Details of antibodies used for immunohistochemistry. 
Target Host species Concentration 
and buffer used 
Manufacturer 
α-SMA Mouse mAb 1/100; SC Dako M0851 
CD34 Mouse mAb 1/200; SC Dako M7165 
D2-40 Mouse mAb 1/100; TE Dako M361901-2 
TWIST1 Mouse mAb 1/100; SC Abcam ab50887 
Snail and slug 
(SNAI1/2) 
Rabbit pAb 1/800; SC Abcam ab85936 
ZEB1 Rabbit pAb 1/500; SC Santa Cruz H102 
sc-25388 
Collagen I Rabbit mAb 1/2000; TE Abcam ab138492 
CD68 Mouse mAb 1/500; SC Dako M0814 
mAb: monoclonal; pAb: polyclonal; SC: Sodium citrate; TE: Tris-EDTA 
 
2.1.4. IHC quantification 
Quantitative analysis was performed using the HistoQuest software system 
(TissueGnostics, version 4.0.4). Six regions of interest (ROIs) per slide of equal size 
were selected covering a total area of 3.3 mm2. The percentage positive cells were 
calculated by the software based on a threshold of DAB intensity level set by the 
user (Figure 2.1.). Negative control slides for each marker were also analysed to 
ensure selected thresholds resulted in < 0.5% percentage positivity for these slides. 
For collagen I analysis percentage coverage per ROI was calculated (Figure 
2.2.) and for vessel density the number of vessels was counted by hand and density 
calculated based on the size of ROI. All analysis was carried out blinded to the slide 
identity. Mean results for each specimen were calculated and analysed using 
ANOVA with p<0.05 considered significant. For some specimens analysis of all 
markers was not possible due to tissue damage or because tumour tissue was no 






Figure 2.1. IHC quantification of percentage positive cell number (sections 3.2.2-
5). (A) Screen shot showing HistoQuest (TissueGnostics, version 4.0.4) analysis 
interface with selected region of interest (ROI) with cell nuclei denoted by individual 
outlines. Scale bar 100 µm. Red outlined nuclei are positive and green outlined 
nuclei are negative based on a threshold of DAB intensity set by the user (B). 
Cytoplasmic or nuclei staining setting could be selected. The number of DAB 
positive cells is then generated and the percentage of positive cells can be 





Figure 2.2. IHC quantification of percentage cover of collagen I (section 3.2.2.). 
Example regions of interest (ROIs) of original (left) and analysed (right) images from 
HistoQuest software (TissueGnostics, version 4.0.4). Shaded areas on the analysed 
image are “positive” for collagen I. Both total area of the ROIs and the collagen I 
“positive” area were calculated by the software and used to calculate percentage 











2.2. General tissue culture 
2.2.1. Routine maintenance of cell culture 
A panel of oral cancer cell lines (OCCL) was chosen to represent the 
successive stages of OSCC. H357 represents a non-metastatic primary tumour (site = 
tongue, Stage I, well differentiated, node negative, 74 year old male) and H376 a 
metastatic primary tumour (site = floor of mouth, Stage III, well differentiated, node 
positive, 40 year old female) (Prime et al., 1990; Prime, Game, et al., 1994; Prime, 
Matthews, et al., 1994). Two lymph node tumour derived cell lines were included to 
investigate whether these tumours behave similarly to primary tumours: BICR22 
(neck node derived, primary site tongue (Edington et al., 1995)) and TR146 (neck 
node derived, primary site buccal mucosa, well differentiated (Rupniak et al., 
1985)). 
H357 and H376 cell lines were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) with 10% (v/v) foetal bovine serum (FBS), 1% (v/v) L-glutamine 
(LG) and 1% (v/v) Penicillin/Streptomycin (P/S). BICR22 and TR146 cell lines were 
cultured in keratinocyte growth media (KGM) media comprising a 3:1 ratio of 
DMEM and Ham’s F12 supplemented with 10% (v/v) FBS, 1% (v/v) P/S, 1% (v/v) LG, 
1% (v/v) amphotericin B, 1.8x10-4 M adenine, 0.5 µg/ml hydrocortisone, 10-10 M 
cholera toxin, 5 µg/ml insulin and 10 ng/ml epidermal growth factor (EGF).  
Cells were passaged by washing twice with PBS, adding trypsin/EDTA and 
incubating at 37°C until cells were detached. Trypsin/EDTA was neutralised by 
adding culture medium containing serum and cells were pelleted by centrifuging at 
1000 x g for 5 min. Pellets were resuspended in the appropriate media before being 
plated out at the densities stated. 
Primary normal oral fibroblasts (NOF) were obtained from healthy oral 
mucosa from patients undergoing routine dental procedures with informed, written 
consent (ethics code: 09/H1308/66). Cancer associated fibroblasts (CAF) were 
obtained from OSCC patient tissues removed at the time of surgery (ethics 
reference: 13/NS/0120, STH17021; kindly provided by Amy Harding). Cells were 
isolated using selective trypsinisation, collagen digested (as described in Hearnden 
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et al., 2009) and used within passage 3-10 unless otherwise stated. Cells were 
routinely cultured in DMEM with 10% (v/v) FBS, 1% (v/v) LG and 1% (v/v) P/S and 
passaged as described above. 
Primary human dermal lymphatic endothelial cells (HLEC) were obtained 
from Promocell (Heidelberg, Germany, Catalogue number C-12216) and used within 
passage 2-10. Human dermal microvascular endothelial cells (HMEC) were also 
obtained from Promocell (Heidelberg, Germany, Catalogue number C-12210). Both 
cell types were cultured in MV media (Promocell) and passaged as described above. 
All cells were grown at 37°C in a humidified 5% CO2 in air atmosphere. 
2.2.2. Fibroblast differentiation and senescence 
NOF were seeded at 1 x106 cells/T175 flask. They were serum starved in 
serum free DMEM + 1% (v/v) LG + 1% (v/v) P/S for 24 h, followed by the addition of 
5 ng/ml recombinant TGF-β1 (R&D Systems) in DMEM with 0.5% (v/v) FBS and 1% 
(v/v) LG + 1% (v/v) P/S for 72 h, by which point cells reached 80-90% confluency. 
Myofibroblast differentiation was confirmed by western blot and qRT-PCR to verify 
an increase in αSMA expression. 
Senescent fibroblasts were generated by seeding NOF at 1 x106 cells/T175 
flask and leaving overnight to attach. Senescence was induced by adding 500 µM 
H2O2 in serum free DMEM  + 1% (v/v) LG + 1% (v/v) P/S for 2 h. Serum-containing 
DMEM was then replaced and cells cultured for a further 10 days. NOF derived from 
the same source and cultured in parallel but without the addition of H2O2, were 
used as controls. The senescence-associated β-galactosidase (SA-β-gal) assay kit 
(Abcam, ab65351) was used according to instructions with 20,000 cells seeded per 
well of a 12-well plate in duplicate. The percentage of positively stained cells was 
calculated based on four images per well taken at x 10 magnification and was 
quantified using the ImageJ “Cell Counter” plug-in (version 1.49, NIH, USA).  
Replicative senescent fibroblasts were generated from NOF by prolonged 
culturing. At each passage, 350,000 cells were seeded per T175 flask and grown to 
90% confluence. Senescence was assessed at each passage using a SA-β-gal assay as 
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described above. NOF from the same source but at a passage <10 were used as 
controls. 
2.2.3. Preparation of conditioned media 
Conditioned media was generated from fibroblasts and oral cancer cell lines 
by incubating them with serum-free DMEM (+ 1% (v/v) LG + 1% (v/v) P/S) for 24 h. 
Volumes of media added were 6 ml per T175 flask, 3 ml per T75 flask and 1 ml per 
T25 flask. Upon collection, cells were counted and the volume of media used was 
normalised to the lowest cell count in each experiment so that all conditioned 
media samples were generated from the same number of cells. Conditioned media 
samples were topped up with serum-free DMEM to the lowest equal volume for all 
cell types. Conditioned media was passed through a 0.22 µm sterile filter before 
being added to recipient cells. OCCL were serum starved for 24 h before addition of 
conditioned media. However, primary fibroblasts, HLEC and HMEC were not serum 
starved due to their intolerance to pre-longed serum starvation. Incubation times 
with conditioned media and their subsequent use in experiments is detailed in each 
results chapter and described in methods 2.3-2.6. 
 
2.3. Cell migration assay 
Conditioned media generated from myofibroblasts, senescent fibroblasts or 
patient-derived CAF and NOF control fibroblasts was collected, passed through a 
0.22 µm sterile filter, and normalised for cell number. Conditioned media (500 
µl/well) was added to wells of 24 well, notched companion plates (Falcon, 353504) 
in triplicate per OCCL used and mitomycin C added to a concentration of 1 µg/ml. 
OCCL (serum starved in DMEM for 24 h before experiment) were resuspended in 
DMEM + 1% (v/v) LG + 0.1% (w/v) BSA at a concentration of 10x104/ml. Transwell 
inserts (Falcon, 353097, 8.0 µm pore, PET membrane) were placed in each well 
containing conditioned media and 200 µl of the OCCL cell suspension was added per 
well (in triplicate per conditioned media type) resulting in 20,000 cells per insert. 
Cells were left to migrate at 37°C for 16 h. 
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After 16 h the inserts were washed briefly in PBS before being fixed in 
methanol for 20 min. Membranes were stained by placing them in 0.1% (w/v) 
crystal violet (in 10% (v/v) methanol, 0.22 µm filtered before use) for 20 min, 
followed by two washes in distilled water. Once dry membranes were cut out and 
mounted on glass slides using DPX mountant. 
Four images at x 10 magnification were taken per membrane for 
quantification. Images were converted to binary form and the number of cells 











Figure 2.3. Migration assay quantification using ImageJ. Images of crystal violet 
stained cells from migration assays (A, scale bar 200 µm) were converted to binary 
images by splitting the image channels, selecting the green channel image and 
adjusting the brightness and contrast and image threshold to select cells only (B).  
The “Analyse Particles” function was used quantify the number of cells per image 
with identified particles labelled blue (C). By setting a minimum particle size of 250 
pixels2 membrane pores and other debris were excluded from the cell count 
(example of excluded pores circled in red in detailed view). Analysis carried out 







2.4. Cell proliferation assay 
HMEC or HLEC cells were seeded at a density of 5000 cells/well in a 96 well 
plate. After 24 hrs, cells were washed twice with PBS before the addition of 
conditioned media generated from fibroblasts or OCCL (see section 2.2.3. but 
containing 0.1% (v/v) FBS; 200 µl/well in triplicate) and were then incubated at 37 
°C for 16 h. DMEM + 1% (v/v) LG + 1% (v/v) P/S + 0.1% (v/v) FBS previously 
incubated at 37°C for 24 h was used as a negative control. VEGF-A (for HMEC, 
Thermo PHC9394, 200 ng/ml) and VEGF-C (for HLEC, Peprotech 100-20CB, 
100ng/ml) diluted in DMEM + 1% (v/v) LG + 1% (v/v) P/S + 0.1% (v/v) FBS previously 
incubated at 37°C for 24 h were used as positive controls. 
A standard curve of HLEC or HMEC was generated by plating out 40000 cells 
subsequently diluted 1:2 seven times (in duplicate) and leaving them to attach at 37 
°C for 1 h. All wells were washed x2 with PBS before adding 100 µl SFM followed by 
20 µl MTS reagent (Cell Titer 96® Aqueous One Solution Cell Proliferation Assay 
reagent, Promega G3580). Plates were incubated in the dark at 37 °C for 1 h before 
reading at absorbance 492 nm. Cell numbers for each condition were estimated by 
extrapolating from the standard curve. 
 
2.5. Microtubule formation assay 
Conditioned media containing 0.1% (v/v) FBS was collected, filtered and 
normalised for cell number as described in section 2.2.3. DMEM + 1% (v/v) LG + 1% 
(v/v) P/S + 0.1% (v/v) FBS previously incubated at 37°C for 24 h was used as a 
negative control. VEGF-A (for HMEC, Thermo PHC9394, 200 ng/ml) and VEGF-C (for 
HLEC, Peprotech 100-20CB, 100ng/ml) diluted in DMEM + 1% (v/v) LG + 1% (v/v) P/S 
+ 0.1% (v/v) FBS previously incubated at 37°C for 24 h were used as positive 
controls.  
Growth factor-reduced Matrigel (Corning, 356230) was thawed on ice and 
40 µl added per well of a 96-well plate. Plates were incubated at 37°C for 1 h to 
allow the Matrigel to set. HMEC and HLEC cells were resuspended in each media 
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type and 200 µl of cell suspension added in triplicate to the Matrigel coated plates 
to give final densities of 20,000 cells/well of HMEC and 25,000 cells/well of HLEC.   
Plates were incubated at 37°C for 16 h before being imaged at x 10 
magnification using a light microscope. One image per well was skeletonised by 
tracing over tubules. The number of junctions was then quantified by counting using 














Figure 2.4. Microtubule assay quantification using ImageJ. Images from 
microtubule assays (A) were skeletonised by tracing over visible tubules using GNU 
Image Manipulation Program software (version 2.8.18) (B). The traced layer was 
extracted and placed on a white background for clarity and the number of junctions 
quantified using ImageJ (version 1.49, NIH, USA) “Cell Counter” plug-in (C). Blue 








2.6. Enzyme linked immunosorbent assay (ELISA) 
To generate conditioned media for ELISA analysis conditioned media was 
collected from OCCL or fibroblasts (after 24 h) as described in section 2.2.3. and 
added to NOF, HMEC or HLEC as stated in the text. After 24 h cells were washed x2 
with PBS and serum-free DMEM (+ 1% (v/v) LG + 1% (v/v) P/S) added for a further 
24 h before being collected, normalised for cell number, and used in subsequent 
ELISAs. All experiments involving HMEC or HLEC were carried out using DMEM 
containing 1% (v/v) FBS due to their intolerance to serum starvation.  
ELISAs were performed using BD OptEIA™ kits according to the provided 
instructions (BD Biosciences, IL-6: C555220, CCL2: 555179). Capture antibodies 
diluted 1:250 in 0.1 M sodium carbonate, pH 9.5, were added to 96-well ELISA 
plates (100 µl/well) and incubated overnight at 4°C.  
Plates were washed three times with PBS 0.05% Tween-20 (PBST) before 
blocking with 200 µl/well assay diluent (PBS + 10% (v/v) FBS) for 1 h at RT. 
Recombinant IL-6 and CCL2 were diluted to 300 pg/ml and 500 pg/ml, 
respectively, in assay diluent and serial dilutions (1:2) performed to yield seven 
standard curve solutions. If required, conditioned media was diluted in assay diluent 
to ensure results remained in the standard curve range. After three washes in PBST, 
100 µl of each standard (in duplicate), conditioned media samples (in triplicate) and 
assay diluent alone were added to the plate and incubated at RT for 2 h. 
Working detector solutions were prepared for each kit by diluting 
biotinylated detection antibodies (IL-6 1:250, MCP-1 1:1000) and streptavidin-
horseradish peroxidase conjugate (1:250) in assay diluent. After five washes in 
PBST, 100 µl of this solution was added per well and plates were incubated for 1 h 
at RT. 
Plates were washed seven times in PBST, leaving to soak for 30 sec to 1 min 
each time. 100 µl TMB substrate solution (0.1 mg/ml 3,3’,5,5’-tetramethylbenzidine 
dihydrochloride (TMB) in 0.05 M phosphate-citrate buffer with 2 µl 30% (v/v) H2O2 
per 10ml added immediately before use) was added per well and incubated for 30 
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min (IL-6) or 45 min (CCL2) at RT in the dark. The reaction was stopped by addition 
of 50 µl 2 M H2SO4 per well. Plates were scanned at 450 nm and 570 nm.  
ELISA results were analysed by subtracting 570 nm absorbance values from 
those measured at 450 nm. Conditioned media absorbance values were converted 
into concentrations by interpolating from the standard curve.  
 
2.7. SDS-PAGE and Western Blotting 
2.7.1. Lysate preparation 
Cells were lysed using radioimmunoprecipitation (RIPA) buffer with protease 
inhibitors (completeULTRA tablets, Roche, 1 per 10 ml) and left on ice for 30 min. 
Cell debris was then removed by centrifuging at 15000 x g for 10 min. Protein 
concentrations were determined using a BCA protein assay kit (Pierce, 23227). 
Samples (10 μl of each, diluted in distilled water) in duplicate and a standard curve 
of BSA protein standards were added to a 96 well plate. BCA assay reagent (200 μl) 
was added to all wells and after 30 min incubation at 37°C absorbance was 
measured at 570 nm. 
2.7.2. Gel electrophoresis and membrane transfer 
Samples (20 μg of each, normalised in concentration using distilled water) 
were mixed 1:5 with protein loading buffer (National Diagnostics). Each mixture was 
heated at 95°C for 5 min before loading. Sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) gels prepared according to Table 2.2. were placed in 
running buffer (12 g Tris, 57.5 g glycine, 4 g SDS, to 1 L with H2O) with 500 μl 
antioxidant before loading samples, 20 μg/lane. EZrun protein ladder (5 μl, 
FisherScientific, BP36031) was added to one well per gel. Gels were run at 150 V for 
1 h or until samples reached the bottom of the gel. 
Gels were transferred onto 0.2 µm nitrocellulose membranes using either 
the iBLOT (ThermoScientific) or Trans-Blot Turbo (Bio-Rad) dry transfer systems. 
Success of transfer was confirmed using Ponceau staining. 
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Table 2.2. Details of SDS-PAGE gel constituents. 
 12% Resolving gel 5% stacking gel 
Acrylamide 3 ml 0.975 ml 
Tris 2.5 ml 2.1 ml 
H2O 4.725 ml 4.725 ml 
5% APS 350 µl 17 µl 
TEMED 5 µl 100 µl 
TEMED: tetramethylethylenediamine, APS: ammonium persulphate 
 
2.7.3. Immunodetection and development 
Non-specific antibody binding sites were blocked for 1 h before adding 
primary antibody diluted in blocking buffer (see Table 2.3. for details of blocking 
buffer and antibody dilutions) at 4°C overnight on a rocker. Membranes were then 
washed x 3 in Tris-Buffered Saline with 0.5% (v/v) Tween-20 (TBST) for 5 min on the 
rocker at RT. Secondary antibody (see Table 2.3.) was then added to the 
membranes diluted in blocking buffer as before and incubated at RT on a rocker for 
1 h. Membranes were washed again x 3 in TBST for 5 min on a rocker at RT. Before 
March 2017, membranes were developed using enhanced chemiluminescence (ECL, 
Pierce, 32109) western blotting substrate and x-ray films. From March 2017, 
membranes were analysed using the LI-COR C-Digit blot scanner following 
incubation with ECL for 5 min. This is indicated in individual figure legends.  
Membranes were stripped using Restore Western Blot Stripping Buffer 
(Thermo Scientific, 21059) before blocking and labelling as above.  
Protein expression was normalised relative to β-actin or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Prior to March 2017 ImageJ software (Java, 
v1.48) was used to calculate the band density, however, after March 2017 LI-COR 
Image Studio Lite was used to analyse scanned membranes from the blot scanner 




Table 2.3. Details of antibodies used for Western blotting. 
Target Host species/label Concentration Manufacturer 
Slug 
(SNAI2) 




Rabbit pAb 1/500 in 5% (w/v) milk Thermo, PA5-
11923 
TWIST1 Mouse mAb 1/50 in 5% (w/v) BSA Abcam, ab50887 
ZEB1 Rabbit pAb 1/200 in 5% (w/v) milk Santa Cruz, H102 
E-cadherin Rabbit mAb 1/20000 in 5% (w/v) milk Abcam, ab40772 
Vimentin Mouse mAb 1/2000 in 5% (w/v) milk Abcam, ab8978 
αSMA Mouse mAb 1/1000 in 5% (w/v) milk 
3% (w/v) BSA 
SIGMA, A5228 
β-actin Mouse mAb 1/10000 in 5% (w/v) milk SIGMA, A1978 
GAPDH Rabbit mAb 1/5000 in 5% (w/v) BSA Abcam, ab185059 
Mouse IgG  Horse, HRP labelled 1:3000 Cell signalling, 
#7076 
Rabbit IgG Goat, HRP labelled 1:3000 Cell Signalling, 
#7074 
BSA: bovine serum albumin, HRP: horse radish peroxidase; pAb = polyclonal antibody, mAb = 
monoclonal antibody; antibodies in italics are secondary antibodies  
 
2.8. Quantitative real time polymerase chain reaction (qRT-PCR) 
2.8.1. RNA extraction 
RNA was extracted using the RNeasy mini kit (QIAGEN 74104). Cell lysates 
were collected by scraping cells into RLT buffer containing 10 μl/ml β-
mercaptoethanol (350 μl per well of a 6-well plate). An equal volume of 70% (v/v) 
ethanol was added to the lysate and mixed. The mixture was transferred to a spin 
column and centrifuged at ≥8000 x g for 15 sec, after which the flow-through was 
discarded. RW1 buffer (700 μl) was added, tubes centrifuged at ≥8000 x g for 15 sec 
and flow through discarded. RPE buffer (500 μl) was added, tubes centrifuged at 
≥8000 x g for 15 sec and flow through discarded. This was then repeated but with a 
2 min centrifuge step before replacing the collection tube. RNase-free water (30 μl) 
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was added and tubes centrifuged at ≥8000 x g for 1 min. The eluted solution was 
collected and RNA concentration determined using the Nanodrop 1000 
spectrophotometer (version 3.7.0.). 
2.8.2. cDNA generation 
RNA (500 ng) was diluted to a volume of 10 μl in RNase-free water for each 
sample. Reverse transcriptase (RevT) master mix was prepared using the High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems, 4368813) by 
multiplying volumes shown in Table 2.4. by the number of samples. A RevT negative 
(without reverse transcriptase) master mix was also prepared per sample (see Table 
2.4.) as a negative control. 
Each RNA sample (10 μl) was mixed with 10 μl master mix in PCR tubes, 
briefly centrifuged and then placed in the cDNA thermocycler (BioRad). This was 
repeated using the RevT negative master mix. cDNA was generated by incubation at 
25°C for 10 min, 37°C for 120 min and 85°C for 5 min. 
 
Table 2.4. Reagents used for cDNA generation. 
 Volume (µl) 
RevT positive RevT negative 
10x RT buffer 2 2 
25x dNTP mix (100 mM) 0.8 0.8 
10x RT random primers 2 2 
Reverse transcriptase 1 0 
Nuclease free H2O 3.2 4.2 
Total per reaction 10 10 
 
2.8.3. qRT-PCR run and analysis 
For SYBR green primers (αSMA, p16INK4a, p21/cip1 and U6 reference gene; 
primer sequences listed in Table 2.5.; melt curves included in Appendix B) master 
mixes were prepared for each primer for each sample in triplicate by multiplying 
volumes shown in Table 2.6. For Taqman probe/primers (ThermoFisher: slug 
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(SNAI2), Hs00950344_m1; snail (SNAI1), Hs00195591_m1; TWIST1, Hs01675818_s1; 
ZEB1, H200232783_m1; IL-6, Hs00985639_m1; CCL2/MCP-1, Hs00234140_m1; IL-
1α, Hs00174092_m1; IL-1β, Hs00174097_m1; IL-8, Hs00174103_m1; Col1A1, 
Hs00164004_m1) master mixes were prepared for each target gene in triplicate per 
sample by multiplying volumes shown in Table 2.6. Beta-2-microglobulin (B2M) 
reference gene (Applied Biosystems, 4325797) was included in the same mixture 
per sample (see Table 2.6.). 
qRT-PCR was carried out using the Rotor-Gene Q real-time PCR cycler 
(QIAGEN). SYBR primer or Taqman primer/probe master mix (9 µl) was added to 
PCR tubes along with 1 µl cDNA (in triplicate). Cycle temperatures and times are 
detailed in Table 2.7. 
CT values were calculated using Rotor-Gene analysis software to set a 
threshold. ΔCT values were calculated from the average difference in CT values 
between the target and the reference gene for each triplicate sample. ΔΔCT values 
were then calculated relative to the control sample for each cell line to normalise 
the expression levels using the Livak method (Livak and Schmittgen, 2001) and data 
were analysed using a paired t-test or one-way ANOVA. P values <0.05 were 
considered as statistically significant.  
 
Table 2.5. SYBR green primer sequences. 
Gene Forward primer Reverse Primer 
αSMA 5’ GAAGAAGAGGACAGCACTG 3’ 5’ TCCCATTCCCACCATCAA 3’ 
p16INK4a 5’ AATAACCTTCGGCTGACTGGCTG 3’ 5’ TTATTCGCCTCCAGCAGCGCCCG 3’ 
p21/cip1 5’ AATAATGCCGCCGCCTCTTC 3’ 5’ TTATTGTTCCATCGCTCACG 3’ 








Table 2.6. qRT-PCR primer master mix. 
Taqman SYBR green 
5µl master mix  
(Applied Biosystems 4369016) 
5µl master mix  
(Applied Biosystems 4367659) 
0.5µl target primer/probe 0.5µl forward primer 
0.5µl reference gene 
primer/probe 
0.5µl reverse primer 
3µl RNase-free H2O 3µl RNase-free H2O 
Per well: 9µl Per well: 9µl (ref and target 
primers prepared separately 
and included in separate wells) 
 
Table 2.7. qRT-PCR cycle steps. 
Stages SYBR Taqman 
 Temperature (°C) Time Temperature (°C) Time (min) 
Hold 95 10 min 95 10 min 
Cycle (x40) 95 10 sec 95 10 sec 
60* 45 sec 60 15 sec 
   72* 20 sec 
* fluorescence data acquired at this step for every cycle 
 
2.9. Statistics 
All statistical analysis was carried out using GraphPad Prism software 
(version 7.02, La Jolla, California, USA). Student’s t-test or one-way ANOVA were 
used to compare between pairs/groups of results. Fisher’s exact test and the chi-
squared test for trend were used to test for differences in clinical and pathological 
characteristics between the ECS positive and negative groups. Correlation was used 







Chapter 3: Investigating stromal and EMT markers in ECS 
positive and negative matched lymph node tumours 
3.1. Introduction, hypothesis and aims 
To date few studies have looked in detail at the morphology of OSCC lymph 
node tumour development, the expression of relevant markers, both in the tumour 
and stroma, and how this relates to ECS development. The majority of studies which 
identify markers predictive of ECS have done so only by quantifying their presence 
in the primary tumour (Michikawa et al., 2011; Wang et al., 2015). Although this is 
useful for early identification of patients at risk of developing more aggressive 
disease, the inclusion of lymph node metastases in this work provides a more in 
depth view of how this relates to tumour development within lymph nodes 
themselves. 
As previously discussed in sections 1.3-7, cancer-associated fibroblasts, 
endothelial cells and inflammatory immune cells have been shown to be play a role 
in promoting tumour development and have been linked to poor prognosis in OSCC. 
However, in this study the aim was to compare their abundance in metastatic 
lymph node tumours with and without ECS to elucidate their potential role in ECS 
development. Matched primary tumours were included to investigate the predictive 
power of the abundance of these cell types in the primary tumour and allow 
comparisons to be made between the two sites. Due to the important and now 
established role of epithelial-mesenchymal transition (EMT) in OSCC invasion and 
metastatic spread, markers for EMT were also included in the analysis.  
Given the poor prognosis and aggressive nature of ECS positive tumours, this 
study hypothesises that lymph node tumour deposits have the ability to induce a 
myofibroblastic, inflammatory and vessel rich stroma that promotes disease 
aggression, metastasis and the induction of ECS.  
 
Specific Aims: 
1. To assess the clinical and pathological characteristics of OSCC patients with 
ECS negative (ECS-) and ECS positive (ECS+) lymph node metastases. 
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2. To quantify and compare stromal markers in ECS+ and ECS- lymph node 
metastases and their paired primary tumours using immunohistochemistry. 
Markers to be investigated are: 
 α-smooth muscle actin (αSMA, for myofibroblasts) 
 Collagen I (extracellular matrix protein) 
 CD34 to assess microvascular density (MVD) 
 D2-40 to assess lymphatic vessel density (LVD) 
 Macrophage density at the invasive front using CD68 
3. To quantify and compare markers of epithelial-mesenchymal transition 
(EMT) in tumour and stromal cells in ECS+ and ECS- lymph node metastases 
and their paired primary tumours using immunohistochemistry. Markers to 
be investigated are the EMT-inducing transcription factors slug (SNAI2), snail 
(SNAI1), TWIST1 and ZEB1.  
 
3.2. Results 
3.2.1. Defining the patient cohort 
Cases with neck dissections were identified over a 10-year period using the 
local pathology database. From the metastatic cases, the first 20 patients who had 
undergone a primary OSCC excision with a neck dissection were selected to ensure 
paired primary-metastatic tumour tissue availability for both ECS+ and ECS- groups 
(20 ECS+ and 20 ECS-). Within the 20 patients in each group, equal distribution 
between tongue and floor of mouth (n=10 each) was ensured for the primary 
tumour as these are the two most common sites for OSCC. A detailed analysis was 
then undertaken using IHC for the markers described above using one primary 
tumour and one lymph node metastasis FFPE block from each case (South Sheffield 
Ethics Approval Committee Ref: 07/H1309/105). 
The clinical and pathological characteristics of our cohort are detailed in 
Table 3.1. Sex ratios and age were roughly equivalent between the groups. A higher 
number of patients in the ECS+ group had poorly graded tumours (70% vs. 40%) but 
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this was not significantly different using Fisher’s exact test. Primary tumour size was 
significantly larger in the ECS+ group with nine tumours ≥40 mm in diameter 
compared to only two in the ECS- group (p<0.01, chi-squared test). No significant 
difference in the depth of primary tumour invasion was seen and, although the 
ECS+ group had higher levels of lymphovascular invasion (40% vs. 25%) and 
perineural invasion (40% vs. 30%), this was not significant between the two groups 
using Fisher’s exact test.  
 
Table 3.1. Clinical and pathological characteristics of OSCC patient cohort. 
Clinical factor 
Number of patients (%)  
pN+ ECS- pN+ ECS+ p value 
Total number of patients 20 20 / 
Primary tumour site 
Tongue 

































p = 0.116 















p = 0.009 
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p = 0.741 
 
 
3.2.2. Expression of CAF markers in patients with and without ECS 
The importance of cancer-associated fibroblasts (CAF) in OSCC development 
is well established, as detailed in section 1.4. Elevated expression of the 
myofibroblast marker α-smooth muscle actin (αSMA) is found in CAF and has been 
linked to poor prognosis in OSCC(Kellermann et al., 2007; Marsh et al., 2011). 
Fibroblasts are also key secretors and re-modellers of the extracellular matrix 
(ECM), the structure, physical properties and abundance of which has been 
highlighted as a key factor in OSCC development (Ziober, Falls and Ziober, 2006). 
Therefore, αSMA expression and the abundance of the extracellular matrix 
component collagen I were assessed in our cohort.  
All specimens were stained for the myofibroblast marker αSMA and the 
percentage of positive cells within six regions of interest (ROIs) in the tumour-
adjacent stroma was quantified in all sections (for details on quantification method 
see Figure 2.1.). All 20 ECS+ lymph nodes contained abundant associated stroma 
whereas less stroma was seen in ECS- lymph nodes with four nodes lacking any 
associated stroma. The sections without stroma were excluded from the analysis to 
avoid bias. Staining patterns were variable and ranged from scattered focal staining, 
thin ribbons running through tumour areas, thick bands surrounding tumour islands 
and larger solid areas of positive stroma observed in both groups. Larger areas of 
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staining were more common in the ECS+ group and in ECS+ lymph nodes positive 
staining was often located towards the periphery of the metastatic tumour or 
surrounding invading islands of tumour cells. This strong staining surrounding 
invasive tumour islands was also observed in some primary tumours in both groups.  
Quantification of staining revealed that ECS+ lymph nodes had a significantly 
higher proportion of αSMA positive cells compared to ECS- lymph nodes (p<0.05, 
Figure 3.1. A&C). Matched primary tumours from the ECS+ group also had higher 
αSMA percentage positive cell number compared to primary tumours from the ECS- 
group (p<0.01, Figure 3.1. A&B). Nevertheless, there was a broad range of 
percentage positive cell numbers, particularly in the ECS+ primary tumour and all 
lymph node specimens. However, levels of percentage expression did not correlate 
directly between the matched pairs (R2 = 0.097, p=0.069). 
Collagen I is a key component of the extracellular matrix secreted by 
fibroblasts and has been shown to be elevated in OSCC compared to normal 
mucosa (Ziober, Falls and Ziober, 2006). Staining for collagen I was observed to 
some degree in all specimens, either in thin bands throughout the tumour or 
forming a dense mesh covering the tumour area. Positive staining surrounding 
tumour-associated stromal and immune cells was often observed but dense 
immune cell areas in lymph node specimens did not stain positively (Figure 3.2. A).  
Because collagen is extra-cellular, the use of percentage positive cell number 
was not appropriate. Therefore, the “Total Area Measurements” analysis tool on 
the HistoQuest software was used to first define all colour shades attributable to 
DAB positive staining and then calculate the area within each ROI covered by DAB 
positive staining. From this the percentage collagen I coverage in six ROIs placed in 
representative areas within the tumour site was calculated for all specimens (for 
more details on quantification method see Figure 2.2.). No significant differences in 
percentage coverage between the ECS+ and ECS- groups in either lymph node or 
primary tumours were observed (Figure 3.2. B&C). Additionally, percentage 
coverage of collagen I did not significantly correlate between matched primary and 




Figure 3.1. Immunohistochemical staining of αSMA in ECS+ and ECS- matched 
primary and lymph node tissue specimens. (A) Representative photomicrographs 
of αSMA immunohistochemical staining in ECS+ and ECS- primary and lymph node 
tumour specimens. x 10 magnification, scale bars 200 µm. (B) Quantification data 
from matched primary and lymph node tumours. Data points represent mean 
percentage positive cells from six representative ROIs per sample taken from within 
the tumour-associated stroma. Four ECS- lymph nodes were not included due to the 
absence of tumour-associated stroma. Primary tumour: ECS- n=20, ECS+ n=19; 
lymph node: ECS- n=16, ECS+ n=20. Graphs show overall mean ± SD, analysed by 




Figure 3.2. Immunohistochemical staining of collagen I in ECS+ and ECS- matched 
primary and lymph node tissue specimens. (A) Representative photomicrographs 
of collagen I immunohistochemical staining in ECS+ and ECS- primary and lymph 
node tumour specimens. x 10 magnification, scale bars 200 µm. (B) Quantification 
data from matched primary and lymph node tumours. Data points represent mean 
percentage area covered by DAB positive staining in six representative ROIs per 
sample taken from within the tumour area. Primary tumour: ECS- n=18, ECS+ n=20; 




3.2.3. Comparing vascular and lymphatic density in ECS 
The presence of vascular and lymphatic vessels is important for the 
development of tumours and also provides a potential route for metastasis. 
Although elevated vascular and lymphatic vessel density has been observed in 
primary OSCC and correlated to increased rate of lymph node metastasis (Kyzas et 
al., 2005; Li et al., 2005; Zhao et al., 2008) there are few studies investigating vessel 
density in lymph nodes or relating it to ECS. 
Vascular density was assessed by staining specimens for the vascular 
endothelial cell marker CD34 (Figure 3.3. A). The number of vessels in six ROIs 
placed in representative areas within the tumour area was used to calculate the 
microvascular vessel density (MVD). It was found that the MVD was significantly 
elevated in ECS+ lymph node tumours compared to ECS- (p<0.05, Figure 3.3. C) but 
there was no significant difference in primary tumour MVD between the two groups 
(Figure 3.3. B). The range of MVD values was similar when comparing primary and 
metastatic tumours and there was no correlation between the matched primary 
and lymph node specimens or with αSMA percentage positivity.  
Lymphatic vessel density (LVD) was also calculated by staining sections for 
the lymphatic endothelial cell specific marker D2-40 (also known as podoplanin, 
Figure 3.4. A). Interestingly, strong podoplanin staining was observed in some 
tumours particularly at the invasive edge making vessel identification difficult. 
Therefore, six ROIs were placed in the tumour periphery, vessels counted and LVD 
calculated for each specimen. No significant difference in LVD was observed 
between ECS+ or ECS- patients in primary or lymph node tumours (Figure 3.4. B&C). 
Moreover, there was no significant correlation in LVD between matched primary 




Figure 3.3. Immunohistochemical analysis of microvascular density (MVD) in ECS+ 
and ECS- matched primary and lymph node tissue specimens. (A) Representative 
photomicrographs showing CD34 immunohistochemical staining in ECS+ and ECS- 
primary and lymph node tumour specimens. x 20 magnification, scale bars 100 µm. 
(B) Quantification data from matched primary and lymph node tumours. Data 
points represent mean vessels/mm2 from six representative ROIs per specimen 
taken from within the tumour area. Primary tumour: ECS- n=20, ECS+ n=20; lymph 





Figure 3.4. Immunohistochemical analysis of lymphatic vessel density (LVD) in 
ECS+ and ECS- matched primary and lymph node tissue specimens. (A) 
Representative photomicrographs of D2-40 immunohistochemical staining in ECS+ 
and ECS- primary and lymph node tumour specimens. x 20 magnification, scale bars 
100 µm. (B) Quantification data from matched primary and lymph node tumours. 
Data points represent mean vessels/mm2 from six representative ROIs per sample 
taken from the tumour periphery. Primary tumour: ECS- n=19, ECS+ n=20; lymph 





3.2.4. Analysis of tumour-associated macrophage in ECS 
Tumour-associated macrophages (TAM) are a key members of the tumour 
microenvironment and have diverse effects on tumour progression, including the 
promotion of cancer cell survival and proliferation, as well as modifying the tumour 
microenvironment by the secretion of pro-angiogenic factors and remodelling of 
the ECM (Takeya and Komohara, 2016). Elevated macrophage abundance, 
quantified using the pan-macrophage marker CD68, has been linked to lymph node 
metastasis and poor survival in OSCC (Ni et al., 2015; Weber et al., 2016; Yamagata 
et al., 2017). However, TAM and their influence on the progression of tumours 
within the lymph node have been scarcely reported on. Therefore, the aim of this 
part of the study was to assess macrophage density within the paired cohort of 
OSCC specimens using the CD68 marker.  
Macrophages were most commonly found within the stroma, often along 
the invasive edge or surrounding invading tumour islands and accompanied by 
fibroblasts or in groups of immune cells. However, there was also evidence of 
macrophages scattered within the tumour islands to varying degrees. These staining 
patterns were similar in both lymph node and primary tumour sites (Figure 3.5. A). 
Macrophage density was assessed by calculating the percentage of CD68 positive 
cells within six ROIs placed in the stroma alongside the tumour invasive edge (for 
details on quantification method see Figure 2.1.). This location was picked due to 
the potential importance of these macrophages in inducing invasion and because 
the majority of macrophages are found here. There was no significant difference in 
the mean percentage of positive cells when comparing the ECS- and ECS+ groups in 
either the lymph nodes or corresponding primary tumours. However, when the 
results were separated based on primary tumour site a significant increase in 
macrophage density was observed in the tongue ECS+ group compared the tongue 
ECS- group whereas conversely the floor of mouth ECS+ group showed a lower 
density compared to the floor of mouth ECS- group. This was significant in both 
cases for the primary tumour specimens whereas for lymph nodes only the tongue 
data were significant (p<0.05, Figure 3.5. B&C). Reflecting this converse trend the 




Figure 3.5. Immunohistochemical expression of the pan macrophage marker CD68 
in ECS+ and ECS- matched primary and lymph node tissue specimens. (A) 
Representative photomicrographs of CD68 immunohistochemical staining in ECS+ 
and ECS- primary and lymph node tumour specimens. x 20 magnification, scale bars 
100 µm. (B) Quantification data from matched primary and lymph node tumours. 
Data points represent mean percentage positive cells from six representative ROIs 
per sample taken from stroma adjacent to the tumour invasive edge. Primary 
tumour: ECS- n=19, ECS+ n=19; lymph node: ECS- n=20, ECS+ n=20. Graphs show 
overall mean ± SD, analysed by one-way ANOVA, *p<0.05. 
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3.2.5. Expression of epithelial-mesenchymal transition (EMT) markers in 
ECS 
The ability to migrate and invade is central to ECS and it is well known that 
EMT is an important process by which cells can gain this ability (Krisanaprakornkit 
and Iamaroon, 2012). The first crucial step in this process is the down-regulation of 
the cell-cell adhesion molecule E-cadherin due to the action of transcriptional 
repressors such as slug (SNAI2), snail (SNAI1), TWIST1 and ZEB1 (Krisanaprakornkit 
and Iamaroon, 2012). Decreased expression of E-cadherin and increase in the 
mesenchymal markers N-cadherin and vimentin in primary OSCC has been linked to 
increased metastasis (Nijkamp et al., 2011; Ding et al., 2014). Additionally, 
expression of vimentin at the invasive edge of ECS+ lymph node tumours has been 
linked to particularly poor survival and increased distant metastasis rate (Lee et al., 
2014). However, expression of EMT markers, specifically the EMT-inducing 
transcription factors, in ECS+ and ECS- tumours has not been compared. 
Firstly, expression of the snail family of transcription factors was assessed in 
the patient cohort using an antibody reactive with both snail (SNAI1) and slug 
(SNAI2). Nuclear staining was observed in both tumour and stromal cells (Figure 
3.6.) with some cytoplasmic background staining observed in tumour cells. The 
percentage positive cells in six ROIs (three within the tumour area, three within the 
tumour-associated stroma) were quantified for each sample (for details on 
quantification method see Figure 2.1.). Specimens without a tumour-associated 
stroma (four of the ECS- lymph node specimens) were included in the tumour 
analysis only. Quantification of staining showed a significant decrease in percentage 
positive cell number in ECS+ lymph nodes and the matched primary tumour group. 
This was the case for both tumour and stroma (p<0.01, Figure 3.6. A&B). However, 
there was a large range in percentage positive cell numbers, particularly in the ECS+ 
cases (primary tumour: ECS- 40-98% vs. ECS+ 15-97%; lymph node tumour: ECS- 64-
98% vs. ECS+ 35-98%; primary stroma: ECS- 29-90% vs. ECS+ 5-73%; lymph node 
stroma: ECS- 44-89% vs. ECS+ 5-87%). Percentage positivity did not correlate 
between the matched primary and lymph node tumour cells in samples but stromal 
percentage positivity in the primary tumour did show a weak but significant positive 
correlation with αSMA primary tumour percentage positivity (R2 = 0.174, p<0.05). 
70 
 
Peptide blocking control experiments confirmed that when pre-incubated with the 
peptide by which the antibody was raised, no staining was observed (see Appendix 
A). 
Nuclear staining of TWIST1 and ZEB1 was also observed in both tumour and 
stromal cells (Figure 3.7. A, Figure 3.8. A). The majority of positive cells were 
stromal and had elongated nuclei suggestive of fibroblasts but areas of positive 
tumour cell staining were also observed. Using the same method (mean percentage 
positively stained cells) expression of each marker was quantified from three ROIs 
within the tumour and three in the tumour stroma per specimen (for details on 
quantification method see Figure 2.1.). Specimens without a tumour-associated 
stroma (four of the ECS- lymph node specimens) were included in the tumour 
analysis only. No significant difference in TWIST1 percentage positivity was 
observed between the groups within the tumour or stroma (Figure 3.7. B&C). 
However, percentage positive cell numbers did significantly correlate between the 
matched primary and lymph node pairs in tumour (R2 = 0.455, p<0.0001) and 
stromal sites (R2 = 0.321, p<0.001). Quantification of ZEB1 percentage positivity also 
revealed no significant differences between ECS+ and ECS- groups at either site 
(Figure 3.8. B&C). However, again percentage positivity had a weak but significant 
correlation between the primary and lymph node pairs at tumour (R2 = 0.112, 
p<0.05) and stromal sites (R2 = 0.290, p<0.001). No correlation was observed 
between αSMA and TWIST1 or ZEB1 percentage positivity. 
No correlation between percentage positive cell numbers for the EMT 
markers and blood or lymphatic vessel density were found, with the exception of 
ZEB1 whose percentage positivity in the tumour and stroma of lymph node 
specimens correlated weakly with lymph node MVD (tumour: R2 = 0.185, p<0.01, 
stroma: R2 = 0.109, p<0.05) and SNAI1/2 percentage positivity which correlated 
weakly with primary tumour lymphatic vessel density in the primary tumour and 






Figure 3.6. Immunohistochemical expression of slug and snail (SNAI1/2) in ECS+ 
and ECS- matched primary and lymph node tissue specimens. (A) Representative 
photomicrographs showing SNAI1/2 immunohistochemical staining in ECS+ and 
ECS- primary and lymph node tumour specimens. x 20 magnification, scale bars 100 
µm. (B) Quantification data from matched primary and lymph node tumours. Data 
points represent mean percentage positive cells from three representative ROIs, 
from either within the tumour or the surrounding stroma. Primary tumour: ECS- 
n=19, ECS+ n=19; lymph node: ECS- n=20, ECS+ n=20. Graphs show overall mean ± 





Figure 3.7. Immunohistochemical expression of TWIST1 in ECS+ and ECS- matched 
primary and lymph node tissue specimens. (A) Representative photomicrographs 
showing TWIST1 immunohistochemical staining in ECS+ and ECS- primary and lymph 
node tumour specimens. x 20 magnification, scale bars 100 µm. (B) Quantification 
data from matched primary and lymph node tumours. Data points represent mean 
percentage positive cells from three representative ROIs, from either within the 
tumour or the surrounding stroma. Primary tumour: ECS- n=20, ECS+ n=20; lymph 
node: ECS- n=20, ECS+ n=20. Graphs show overall mean ± SD, analysed by student’s 




Figure 3.8. Immunohistochemical expression of ZEB1 in ECS+ and ECS- matched 
primary and lymph node tissue specimens. (A) Representative photomicrographs 
showing ZEB1 immunohistochemical staining in ECS+ and ECS- primary and lymph 
node tumour specimens. x 20 magnification, scale bars 100 µm. (B) Quantification 
data from matched primary and lymph node tumours. Data points represent mean 
percentage positive cells from three representative ROIs, from either within the 
tumour or the surrounding stroma. Primary tumour: ECS- n=20, ECS+ n=20; lymph 
node: ECS- n=20, ECS+ n=20. Graphs show overall mean ± SD, analysed by student’s 




This chapter describes the results of an immunohistochemical study of 
metastatic OSCC lymph node tumours, with and without ECS, and their matched 
primary tumours. Stromal, vascular, immunological and EMT related markers were 
investigated. A summary of the results for each marker can be found in Table 3.2. A 
significant increase in αSMA positive stroma in both primary and lymph node 
tumours was observed but collagen I coverage did not differ between the groups. 
Additionally, a significant increase in vascular density in ECS+ lymph nodes was 
observed but lymphatic vessel density was not altered in ECS+ tumours compared 
to ECS-. Quantification of macrophage density revealed contrasting trends in 
percentage positivity between tongue and floor of the mouth specimens, with an 
increase seen in the tongue ECS+ group but a decrease in the floor of mouth ECS+ 
group when comparing to the corresponding ECS- group. Antibodies for the snail 
family of EMT inducing transcription factors showed a decrease in percentage 
positivity in ECS+ tumour and stromal areas. However, no difference in TWIST1 or 
ZEB1 markers was observed.  
Both macrophage density and percentage positivity of the majority of EMT 
markers correlated between the matched primary tumour and lymph node pairs. In 
addition, EMT marker percentage positivity correlated with αSMA percentage 















Table 3.2. Summary of IHC results comparing ECS+ and ECS- matched tumours. 
 Increased or decreased in ECS? 
Primary tumour Lymph node 
α-smooth muscle actin 
(αSMA) 
↑ Significantly increased 
(p<0.01) 
↑ Significantly increased 
(p<0.05) 
Collagen I NSD NSD 
Blood vessel density 
(CD34) 
NSD ↑ Significantly increased 
(p<0.05) 
Lymphatic vessel density 
(D2-40) 
NSD NSD 
Macrophages (CD68) NSD (↑ in tongue site 
group, ↓ in floor of 
mouth group, both 
significant: p<0.05) 
NSD (↑ in tongue site 
group, significant: 
p<0.05) 
Slug  and snail (SNAI1/2) ↓ Decreased (in tumour 
and stroma, both 
significant: p<0.01) 
↓ Decreased (in tumour 
and stroma, both 
significant: p<0.01) 
TWIST1 NSD NSD 
ZEB1 NSD NSD 
 
























Chapter 4: Investigating OCCL-fibroblast crosstalk using an in 
vitro co-culture system 
4.1. Introduction, hypothesis and aims 
The presence and importance of cancer-associated fibroblasts (CAF) in 
cancer development and progression is now well established. Previous work has 
shown that both myofibroblasts and senescent fibroblasts are present in CAF 
populations in OSCC (Prime et al., 2016) and are capable of influencing cancer cell 
behaviour through the secretion of a complex mix of proteases, growth factors and 
cytokines. Interestingly, although normal lymph nodes have minimal fibroblasts, 
abundant CAF are present in association with metastatic deposits in lymph nodes. 
Furthermore, data from section 3.2.2. suggest that not only is αSMA expression 
elevated in ECS positive nodes but also that elevated αSMA expression in the 
primary tumour is predictive of ECS. Therefore, the aim of this part of the study was 
to generate both myofibroblasts and senescent fibroblasts to model the CAF 
phenotype experimentally and compare this to patient-derived CAF.   
The influence of CAF is known to extend to many of the hallmarks of cancer 
first described by Hanahan and Weinburg (Hanahan and Weinberg, 2011) including 
the promotion of proliferation, evasion of apoptosis, induction of angiogenesis and 
promotion of invasion and metastasis (Pietras and Ostman, 2010). Given the focus 
of this study on metastatic tumours in lymph nodes and ECS, the effect of CAF on 
mechanisms associated with migration and invasion of oral cancer cells derived 
from both primary and metastatic lymph node tumours was investigated. Of 
particular interest was the ability of CAF to induce epithelial-mesenchymal 
transition (EMT), due to the importance of this process in the attainment of a 
migratory ability in cancer cells.  
The hypothesis behind this part of the study was that exposure of cancer cell 
lines to experimentally and patient-derived CAF conditioned media results in 
functional and gene expression changes suggestive of a more migratory and 
invasive phenotype. More specifically, it was hypothesised that CAF are capable of 
increasing the migratory capacity of metastatic cancer cells and that this is, in part, 
through the induction of EMT. It was also hypothesised that oral cancer cells from 
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primary and lymph node tumours can promote the activation and pro-tumour 
activities of normal oral fibroblasts.  
 
Specific Aims: 
1. To generate CAF-like phenotypes in primary normal oral fibroblasts (NOF) by 
inducing myofibroblast differentiation and senescence, characterise these 
phenotypes and compare them to patient-derived CAF. 
2. To investigate the ability of experimentally-derived myofibroblast and 
senescent fibroblast conditioned media to influence EMT expression in a 
panel of primary tumour and lymph node metastases-derived oral cancer 
cell lines (OCCL). 
3. To assess the migration ability of the OCCL panel using experimentally-
derived myofibroblast and senescent fibroblast conditioned media as a 
chemoattractant.  
4. To compare the EMT expression and migration data obtained using 
experimentally-derived CAF to experiments using patient-derived CAF. 
5. To assess the effect of OCCL conditioned media on the expression of 
differentiation markers and inflammatory cytokines by NOF. 
 
4.2. Results 
4.2.1. Generation and characterisation of myofibroblasts, senescent 
fibroblasts and CAF 
Myofibroblasts and senescent fibroblasts were generated from normal oral 
fibroblasts (NOF) derived from healthy mucosa (ethics ref: 09/H1308/66) by 
exposing them to factors present in the tumour microenvironment that are known 
to induce differentiation to a CAF-like state.  
Incubation of NOF with transforming growth factor-β1 (TGF-β1) causes them 
to differentiate in to a myofibroblast-like state. This has been previously 
characterised by our lab (Elmusrati et al., 2017; Melling et al., 2018). Following 
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incubation with 5 ng/ml human recombinant TGF-β1 for 72 h, fibroblasts appeared 
more spindle shaped (Figure 4.1 A). Alpha-smooth muscle actin (αSMA) is a well-
defined marker of myofibroblast activation and TGF-β1 treated cells expressed 
significantly higher levels of αSMA at both the mRNA (p<0.05, Figure 4.1 B) and 
protein levels (p<0.001, Figure 4.1 C).  
Senescent fibroblast presence in the cancer stroma has been observed in 
OSCC, particularly in genetically unstable tumours where CAF senescence has been 
attributed to reactive oxygen species (ROS) production by cancer cells (Hassona et 
al., 2013). ROS-induced DNA damage causes cells to undergo irreversible growth 
arrest and obtain a senescence-associated secretory phenotype (SASP).  
To model the effect of ROS on fibroblasts, NOF were treated with hydrogen 
peroxide (H2O2) using a treatment protocol previously optimised within our lab 
(Kabir, 2015; Kabir et al., 2016). After a 2 h treatment with 500 µM H2O2 followed 
by 10 days of continued culturing, cells appear enlarged, granular, and displayed 
some multi-nucleation (Figure 4.2. A). Senescence levels were quantified using a 
senescence associated-β-galactosidase (SA-β-gal) assay in which senescent cells 
develop a blue perinuclear precipitate due to augmented expression of lysosomal β-
galactosidase at pH 6.0 (Dimri et al., 1995). H2O2- treated cells had significantly 
higher levels of SA-β-gal positive cells compared to untreated control NOF 
(p<0.0001, Figure 4.2 A&B) with an average of 76% positive cells (compared to 13% 
in control NOF) over seven independent experiments. In addition, the expression of 
the cell cycle arrest markers p16INK4a (p16) and p21/cip-1 (p21) was elevated in 
H2O2-treated cells compared to control fibroblasts although this varied between 
experiments and did not reach significance following three biological repeats 
(p=0.24 (p16); p=0.14 (p21); Figure 4.2. C&D). More detailed characterisation by our 
lab has demonstrated that H2O2-induced senescent fibroblasts show reduced 
proliferation capacity (in the absence of increased apoptosis or necrosis levels) 
compared to non-senescent controls with formation of heterochromatin in nuclei 
shown by immunofluorescence DAPI staining (Kabir, 2015). 
In addition to inducing senescence directly, replicative senescent fibroblasts 
were also generated through prolonged culturing of NOF. The normal culturing 
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range for NOF is a maximum of 10 passages but, for this aim, passage numbers in 
excess of 30 were attained. As for H2O2-treated NOF, replicative senescent 
fibroblasts appeared enlarged, granular and displayed multi-nucleation (Figure 4.3 
A). Results from SA-β-gal assay for senescence showed significant elevation of SA-β-
gal positive cells compared to NOF at passage number below 10 (p<0.001, Figure 
4.3 A&B) with average senescent levels  of 84% compared to 10% in control NOF 
over three independent experiments. In addition, the expression of the cell cycle 
arrest markers p16 and p21 were elevated in replicative senescent fibroblasts 
compared to control fibroblasts, with both reaching significance across three 
independent samples (p<0.05, Figure 4.3. C&D). 
Primary patient-derived CAF were also used to generate conditioned media 
and to provide a comparison by which to judge how well the experimentally derived 
CAF represent the true CAF population. Morphologically CAF appear similar to NOF 
with elongated cell processes (Figure 4.4 A). CAF displayed a fold change in αSMA 
protein and mRNA expression of 1.3 ± 0.5 and 1.8 ± 0.5 respectively, which did not 
reach significance over three independent analyses (Figure 4.4 B&C). Senescence 
levels were also assessed using SA-β-gal assay which showed that CAF had 
significant more SA-β-gal positive cells than NOF across four independent tests 
(p<0.05, Figure 4.5 A&B). However, senescence levels in the third test were 
considerably higher than the remaining tests, which may have affected the overall 
result. To validate the senescence profile of CAF compared to NOF, the mRNA 
expression of the cell cycle arrest markers p16 and p21 was validated by qRT-PCR. 
CAF showed significantly elevated expression of p21 (p<0.0001) but there was no 
significant change in p16 expression (Figure 4.5. C&D). 
In summary, this section of work has demonstrated the generation of CAF-
like cells from NOF, representing both myofibroblastic and senescent phenotypes 
known to be present in the CAF population. Conditioned media from these cells will 
be used in subsequent sections of this chapter to evaluate the influence of cellular 




Figure 4.1. TGF-β1 causes increased αSMA expression and altered morphology in 
oral fibroblasts. αSMA protein levels increase in normal oral fibroblasts (NOF) as a 
result of TGF-β1 treatment. (A) Representative images of NOF treated with 5 ng/ml 
TGF-β1 in DMEM for 72 h or DMEM only (control). x 10 magnification, scale bars 
200 µm. (B) qRT-PCR and (C) representative western blots (developed by x-ray) for 
αSMA show significantly increased αSMA mRNA and protein expression levels in 
TGF-β1 treated NOF compared to untreated controls. qRT-PCR results displayed as 
ΔΔCT values comparing to control and U6 as a reference gene. Western blot relative 
band densitometry compared to GAPDH loading control and analysed using ImageJ. 
Graphs display mean ± SD from six separate experiments, analysed using student’s 





Figure 4.2. Generation of senescent fibroblasts by H2O2 treatment. (A) 
Representative images of untreated normal oral fibroblast controls and senescent 
fibroblasts (induced using 500 µM H2O2 for 2 h followed by 10 days culture) from 
senescence-associated β-galactosidase assay (SA-β-gal, Abcam) with blue indicating 
a senescent cell and arrows indicating multinucleation. x 10 magnification, scale bar 
100 µm. (B) Quantification of percentage SA-β-gal positive cells. Mean of seven 
separate experiments, each calculated from eight images at x 10 magnification per 
condition. (C,D) mRNA expression of p16 and p21 cell cycle arrest markers in control 
and H2O2-treated fibroblasts as determined by qRT-PCR. Results from three 
independent experiments and displayed as ΔΔCT values comparing to control and 





Figure 4.3. Characterisation of replicative senescent fibroblasts. (A) Representative 
images of normal oral fibroblast controls (passage <10) and replicative senescent 
fibroblasts from senescence-associated β-galactosidase assay (SA-β-gal, Abcam) 
with blue indicating a senescent cell and arrows indicating multinucleation. x 10 
magnification, scale bars 100 µm. (B) Quantification of percentage SA-β-gal positive 
cells. Average of three independent experiments, each calculated from eight images 
at x 10 magnification. (C,D) mRNA expression of p16 and p21 cell cycle arrest 
markers in control and replicative senescent fibroblasts as determined by qRT-PCR. 
Results from three independent experiments and displayed as ΔΔCT values 
comparing to control and B2M as a reference gene. Graphs display mean ± SD, 




Figure 4.4. Expression of myofibroblast markers in normal oral fibroblasts (NOF) 
and cancer-associated fibroblasts (CAF). Fibroblasts isolated from healthy and 
cancer patient samples were analysed for myofibroblast markers. (A) 
Representative images of NOF and CAF cells. x 10 magnification, scale bars 100 µm. 
(B) αSMA levels assessed by qRT-PCR displayed as ΔΔCT values comparing to control 
and B2M as a reference gene. (C) Western blot and relative band densitometry for 
αSMA protein levels. GAPDH was included as a loading control (developed and 
analysed using LI-COR scanner and software, inserted ladder images shown at high 
contrast to allow visualisation). Graphs display mean ± SD from three separate 









Figure 4.5. Expression of senescent markers in normal oral fibroblasts (NOF) and 
cancer-associated fibroblasts (CAF). Fibroblasts isolated from healthy and cancer 
patient samples were analysed for senescence markers. (A) Representative images 
from senescence associated-β-galactosidase assay (SA-β-gal) for cellular senescence 
(Abcam) with blue indicating a senescent cell. x 10 magnification, scale bars 100 µm. 
(B) Quantification of SA-β-gal assay results from four separate experiments with 
percentage of SA-β-gal positive cells calculated from eight images at x 10 
magnification. (C) mRNA expression of p16 and p21 cell cycle arrest markers in NOF 
and CAF as determined by qRT-PCR. Results from three independent experiments 
displayed as ΔΔCT values comparing to NOF control and B2M as a reference gene. 
Graphs display mean ± SD, analysed by student’s t-test, *p<0.05, ****p<0.0001. 
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4.2.2. Effect of myofibroblasts on EMT marker expression in OCCL 
Epithelial-mesenchymal transition (EMT) is a key mechanism by which 
cancer cells gain the ability to migrate and invade.  Although it is hypothesised that 
primary OSCC tumour metastasis occurs as a results of cancer cells undergoing EMT, 
it is unknown what happens upon their arrival at the metastatic lymph node site. 
The majority of metastatic OSCCs in lymph nodes appear epithelial in morphology, 
raising the question of whether these metastatic deposits undergo mesenchymal-
epithelial transition (MET) once within the lymph node, and also whether a second 
cycle of EMT is required for ECS to occur considering the stromal desmoplasia seen 
in ECS. This section of the study aimed to determine if media from the 
experimentally derived CAF-like cells described in section 4.2.1. could affect EMT 
marker expression in oral cancer cell lines (OCCL) and if this effect differed between 
primary OSCC and lymph-node metastases derived cells. 
A panel of OCCL were selected to represent the different stages of disease 
and allow comparison with previous work. The cell lines used were H357 (tongue, 
Stage I, well differentiated, node negative), H376 (floor of mouth, Stage III, well 
differentiated, node positive), BICR22 (neck node derived metastatic, primary site 
tongue), and TR146 (neck node derived metastatic, primary site buccal mucosa, well 
differentiated). Conditioned media from myofibroblasts was prepared as detailed in 
section 2.2.3. and incubated with OCCL for 48 h. Media conditioned by untreated 
NOF cultured in parallel was used as a control.  
Western blots for the epithelial marker E-cadherin and mesenchymal marker 
vimentin revealed that both H376 and BICR22 already display a mesenchymal 
signature with TR146 showing weak expression of both markers (Figure 4.6.). The 
non-metastatic primary tumour derived cell line H357 had strong E-cadherin 
expression and a lack of vimentin in keeping with an epithelial phenotype and this 
did not appear to be altered by conditioned media treatment. Protein expression of 
the EMT-inducing transcription factors slug (SNAI2), snail (SNAI1) and ZEB1 was also 
assessed by western blot. It was planned to include TWIST1 protein expression 
analysis but despite optimisation experiments indicating that BICR22 and TR146 
cells express TWIST1, no specific bands were observed when experimental samples 
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were used (see Appendix C for details). Expression of all three remaining 
transcription factors was evident in the majority of cell lines including those with a 
mesenchymal phenotype; however, the H357 non-metastatic primary tumour 
derived cell line lacked ZEB1 expression. An increase in slug protein expression in 
response to myofibroblast conditioned media treatment was seen but this was not 
significant over three separate experiments (p=0.37, Figure 4.7.). 
Expression of slug, snail, TWIST1 and ZEB1 were also analysed by qRT-PCR. 
Expression of snail and ZEB1 in H357 cells could only just be detected (cycle 
numbers >35) so these markers were not used for further analysis for this cell line. 
Although small increases were observed for most markers, these did not reach 
significance in most cases with the exception of slug and ZEB1, which increased in 
TR146 and BICR22 cell lines, respectively, as a result of treatment with 















Figure 4.6. Protein levels of EMT markers in OCCL treated with myofibroblast-
conditioned media. Cell lysates collected from OCCL treated with conditioned 
media from untreated normal oral fibroblasts (NOF, N) or myofibroblasts (myo, M) 
and analysed by western blot for (A) E-cadherin (E-cad.) and (B) vimentin (Vim.), 
(developed by x-ray). For each marker a representative blot is shown and below 
densitometry graphs (analysed using ImageJ) showing mean relative expression of 
blots from three separate experiments. β-actin was included as a loading control for 




Figure 4.7. Protein levels of EMT-inducing transcription factors in OCCL treated 
with myofibroblast-conditioned media. Cell lysates collected from OCCL treated 
with conditioned media from untreated normal oral fibroblasts (NOF, N) or 
myofibroblasts (myo, M) and analysed by western blot for (A) slug, (B) snail and (C) 
ZEB1 (developed by x-ray). For each marker a representative blot is shown and 
below densitometry graphs (analysed using ImageJ) showing mean relative 
expression of blots from three separate experiments (n=1 for snail). β-actin was 
included as a loading control for each blot. Graphs display mean ± SD, analysed by 




Figure 4.8. mRNA expression of EMT markers in OCCL treated with myofibroblast-
conditioned media. Cell lysates collected from OCCL treated with conditioned 
media from untreated normal oral fibroblasts (NOF) or myofibroblasts (myofib). 
mRNA levels of EMT markers slug, snail, TWIST1 and ZEB1 were measured by qRT-
PCR using Taqman probes. H357 produced very high ΔCT values (>35) for snail and 
ZEB1 so were not included in the analysis. ΔΔCT values plotted relative to control 
cells of each type and B2M reference gene. Controls normalised to 1 in each case 
but basal expression was not equal in each cell line. Graphs display mean ± SD from 







4.2.3. Effect of senescent fibroblasts on EMT marker expression in OCCL 
Senescent fibroblasts are also a key component of the tumour stroma, 
contributing to the large array of secreted molecules in the tumour 
microenvironment.  The same OCCL as used in myofibroblast experiments (section 
4.2.2.) were incubated with conditioned media (generated as described in section 
2.2.3.) from either H2O2-induced or replicative senescent fibroblasts for 48 h.  
Western blots for the epithelial marker E-cadherin and mesenchymal marker 
vimentin confirmed earlier results showing that H376, BICR22 and TR146 already 
express mesenchymal markers (Figure 4.9.). Despite this, EMT-inducing 
transcription factor protein expression was observed in all cell lines although there 
was variation between the different markers. H357 cells expressed higher levels of 
slug and snail markers and lower levels of ZEB1 as was seen for myofibroblast 
experiments. However, no significant increases in expression as a result of H2O2-
induced senescent fibroblast conditioned media treatment was observed after 
three experiments despite a large increase in slug expression in one repeat (Figure 
4.10.). 
mRNA analysis of H2O2-induced senescent fibroblast conditioned media 
treated OCCL revealed small increases in expression of each of the EMT-inducing 
transcription factors. However, as seen previously there was a large variation 
between the samples. Only snail expression in H376 and ZEB1 expression in TR146 
significantly increased (p<0.05, Figure 4.11.). There was no obvious difference 
between the primary and metastatic cell lines and the significant increases seen did 
not match those observed in myofibroblast conditioned media experiments. As 
stated previously, expression of snail and ZEB1 in H357 cells could only just be 
detected (cycle numbers >35) so these markers were not used for further analysis 
for this cell line.  
OCCL incubated with conditioned media from replicative senescent 
fibroblasts were compared to those incubated with normal oral fibroblasts of the 
same origin but at passage numbers below 10. The same pattern of E-cadherin and 
vimentin expression was seen as observed previously (Figure 4.12.). Protein levels 
of EMT transcription factors were also compared and, as observed previously, H357 
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cells expressed higher levels of slug and snail than ZEB1. However, no significant 
change in any of the markers assessed was found following conditioned media 
treatment.  
There was a large variation in the response of cell lines in terms of mRNA 
expression. Significant decreases in snail, slug and ZEB1 mRNA levels were observed 
in the TR146 cell line as a result of treatment with replicative senescent fibroblast 
















Figure 4.9. Protein levels of EMT markers in OCCL treated with H2O2-induced 
senescent fibroblast conditioned media. Cell lysates collected from OCCL treated 
with conditioned media from untreated normal oral fibroblasts (NOF, N) or H2O2-
induced senescent fibroblasts (H2O2, H). OCCL lysates analysed by western blot for 
(A) E-cadherin (E-cad.) and (B) vimentin (Vim.), (developed by x-ray). For each 
marker a representative blot is shown and below densitometry graphs (analysed 
using ImageJ) showing relative expression as a mean of blots from three separate 
experiments. β-actin was included as a loading control for each blot. Graphs display 




Figure 4.10. Protein levels of EMT-inducing transcription factors in OCCL treated 
with H2O2-induced senescent fibroblast conditioned media. Cell lysates collected 
from OCCL treated with conditioned media from untreated normal oral fibroblasts 
(NOF, N) or H2O2-induced senescent fibroblasts (H2O2, H). OCCL lysates analysed by 
western blot for (A) slug, (B) snail and (C) ZEB1 (developed by x-ray). For each 
marker a representative blot is shown and below densitometry graphs (analysed 
using ImageJ) showing relative expression as a mean of blots from three separate 
experiments. β-actin was included as a loading control for each blot. Graphs display 




Figure 4.11. mRNA expression of EMT markers in OCCL treated with H2O2-induced 
senescent fibroblast conditioned media. Cell lysates collected from OCCL treated 
with conditioned media from untreated normal oral fibroblasts (NOF) or H2O2-
induced senescent fibroblasts (H2O2). mRNA levels of EMT markers slug, snail, 
TWIST1 and ZEB1 measured by qRT-PCR using Taqman probes. H357 produced very 
high ΔCT values (>35) for snail and ZEB1 so were not included in the analysis. ΔΔCT 
values plotted relative to control cells of each type and B2M reference gene. 
Controls normalised to 1 in each case but basal expression was not equal in each 
cell line. Graphs display mean ± SD from four separate experiments, analysed by 







Figure 4.12. Protein levels of EMT markers in OCCL treated with replicative 
senescent fibroblast conditioned media. Cell lysates collected from OCCL treated 
with conditioned media from untreated normal oral fibroblasts (NOF, N) or 
replicative senescent fibroblasts (RS). OCCL lysates analysed by western blot for (A) 
E-cadherin (E-cad.) and (B) vimentin (Vim.), (developed by x-ray). For each marker a 
representative blot is shown and below densitometry graphs (analysed using 
ImageJ) showing relative expression as a mean of blots from three separate 
experiments. β-actin was included as a loading control for each blot. Graphs display 




Figure 4.13. Protein levels of EMT-inducing transcription factors in OCCL treated 
with replicative senescent fibroblast conditioned media. Cell lysates collected from 
OCCL treated with conditioned media from untreated normal oral fibroblasts (NOF, 
N) or replicative senescent fibroblasts (RS). OCCL lysates analysed by western blot 
for (A) slug, (B) snail, and (C) ZEB1 (developed by x-ray). For each marker a 
representative blot is shown and below densitometry graphs (analysed using 
ImageJ) showing relative expression as a mean of blots from three separate 
experiments (n=2 for snail). β-actin was included as a loading control for each blot. 




Figure 4.14. mRNA expression of EMT markers in OCCL treated with replicative 
senescent fibroblast conditioned media. Cell lysates collected from OCCL treated 
with conditioned media from untreated normal oral fibroblasts (NOF) or replicative 
senescent fibroblasts (RS). mRNA levels of EMT markers slug, snail, TWIST1 and 
ZEB1 measured by qRT-PCR using Taqman probes. H357 produced very high ΔCT 
values (>35) for snail and ZEB1 so were not included in the analysis. ΔΔCT values 
plotted relative to control cells of each type and B2M reference gene. Controls 
normalised to 1 in each case but basal expression was not equal in each cell line. 
Graphs display mean ± SD from three separate experiments (n=2 for TR146), 






4.2.4. Effect of CAF on EMT marker expression in H357 cells 
Previous experiments in this chapter have demonstrated that although all 
cell lines express EMT-inducing transcription factors to some extent, only H357 cells 
display an epithelial phenotype as determined by high E-cadherin expression and 
low vimentin expression. Therefore, the H357 non-metastatic primary tumour 
derived cell line was treated with conditioned media from primary patient derived 
CAF (prepared as detailed in section 2.2.3.). H357 cells were collected after 
incubation with conditioned media for 24, 48 and 72 h for protein and mRNA 
analysis. H357 treated with conditioned media from NOF or SFM only were included 
as controls for comparison. 
As for previous experiments, E-cadherin expression was evident in all 
samples as well as an absence of vimentin staining and across three repeats levels 
were not significantly altered (Figure 4.15.). Protein expression of the EMT-inducing 
transcription factors slug, snail and ZEB1 was also observed for all treatment types 
at all the time points. There was no significant change in expression between any of 
the conditions used (Figure 4.16.). As for previous experiments, only slug and 
TWIST1 showed mRNA expression but statistical analysis did not reveal any 
significant differences between the treatment conditions compared to the SFM 









Figure 4.15. Protein levels of EMT markers in H357 cells treated with NOF and CAF 
conditioned media for 24, 48 or 72 h. Cell lysates from H357 cells treated with 
conditioned media from untreated normal oral fibroblasts (NOF, N), cancer-associated 
fibroblasts (CAF, C) or serum-free media as a control (SFM, SF). Lysates analysed by 
western blot for (A) E-cadherin and (B) vimentin. For each marker a representative blot 
is shown and, below, densitometry graphs showing relative expression as a mean of 
blots from three separate experiments (developed and analysed using LI-COR scanner 
and software, inserted ladder images shown at high contrast to allow visualisation). β-
actin included as a loading control plus untreated BICR22 lysates as a positive control 
for mesenchymal markers. Graphs display mean ± SD, analysed by one-way ANOVA, 




Figure 4.16. Protein levels of EMT-inducing transcription factors in H357 cells 
treated with NOF and CAF conditioned media for 24, 48 or 72 h. Cell lysates 
collected from H357 cells treated with conditioned media from untreated normal 
oral fibroblasts (NOF, N), cancer-associated fibroblasts (CAF, C) or serum-free media 
as a control (SFM, SF). Lysates analysed by western blot for (A) slug, (B) snail and (C) 
ZEB1. For each marker a representative blot is shown and below densitometry 
graphs showing relative expression as a mean of blots from three separate 
experiments (developed and analysed using LI-COR scanner and software, inserted 
ladder images shown at high contrast to allow visualisation). β-actin was included as 





Figure 4.17. mRNA expression of EMT markers in H357 cells treated with NOF and 
CAF conditioned media for 24, 48 or 72 h. Cell lysates collected from H357 cells 
treated with conditioned media from untreated normal oral fibroblasts (NOF) or 
cancer-associated fibroblasts (CAF) or serum-free media as a control (SFM). mRNA 
levels of EMT markers slug and TWIST1 measured by qRT-PCR using Taqman probes. 
ΔΔCT values plotted relative to control cells of each type and B2M reference gene. 
Controls normalised to 1 in each case. Graphs display mean ± SD from three 
separate experiments, analysed by two-way ANOVA. 
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4.2.5. Effect of fibroblasts on migration of OCCL 
Having investigated EMT as a possible mechanism by which CAF induce 
migration of oral cancer cells both in the primary and lymph node sites, this study 
aimed to look at the functional effect of fibroblasts on the migration of OCCL. There 
is already some evidence to suggest that oral fibroblasts can induce OCCL migration 
(Zhou et al., 2014) including senescent fibroblasts (Kabir et al., 2016). Therefore, the 
aim was to investigate whether myofibroblasts, senescent fibroblasts and CAF could 
induce migration in our cell line panel and to what extent this differed between the 
primary tumour and lymph node metastases-derived cell lines.  
Preliminary experiments were carried out with conditioned media (prepared 
as detailed in section 2.2.3.) from normal oral fibroblasts (NOF), experimentally-
derived myofibroblasts, H2O2-senesced fibroblasts and patient-derived CAF, which 
was added to wells of a 24 well plate. Serum-starved OCCL were then added to 
transwell inserts containing an 8.0 µm pore PET membrane and placed in the 
conditioned media wells. One experimental repeat of each condition treatment was 
carried out in triplicate, comparing to NOF controls in each experiment for all 
fibroblasts types. After 16 h, OCCL on the membrane were fixed, non-migrated cells 
swabbed from the upper side of the membrane and the remaining cells stained 
using crystal violet before being mounted on slides. Four images at x 10 
magnification were taken per membrane for quantification by converting them to 
binary images and counting the number of cells using the ImageJ “Analyse Particles” 
function (See Figure 2.3. for details). 
Firstly, the effect of conditioned media from experimentally-derived 
myofibroblasts was compared to NOF conditioned media. Both lymph node-derived 
metastatic OCCL (BICR22 and TR146) displayed significantly higher migration 
compared to the primary tumour derived OCCL (H357 and H376, p<0.0001, Figure 
4.18.). However, there was no significant difference between the number of 
migrated cells in the presence of myofibroblast and NOF conditioned media for any 
of the OCCL used. 
A slightly different pattern was observed when comparing the response to 
conditioned media from NOF and H2O2-senesced fibroblasts. The metastatic 
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primary tumour cell line H376 and both lymph node tumour-derived cell lines 
(BICR22 and TR146) had significantly higher numbers of migrated cells compared to 
the non-metastatic primary cell line H357 (p<0.0001, Figure 4.19.) which also had 
markedly lower numbers of migrated cells compared to the myofibroblast 
experiment. A significant increase in the number of migrated cells in response to 
the H2O2-senesced fibroblast conditioned media compared to NOF-conditioned 
media was seen for both the H357 (primary, p<0.0001) and BICR22 (metastatic, 
p<0.05) cell lines (Figure 4.19. B).  
The H357 cell line also had significantly lower number of migrated cells 
compared to the other OCCL (p<0.0001 comparing to H376, BICR22 or TR146) in 
experiments comparing the effect of NOF and patient-derived CAF conditioned 
media. However, no significant difference in migration level was observed in CAF-
conditioned media treated cells compared to those incubated with NOF conditioned 






Figure 4.18. Effect of myofibroblast conditioned media on OCCL migration. (A) 
Representative photomicrographs of migrated OCCL on the underside of a transwell 
insert membrane in wells containing conditioned media from either normal oral 
fibroblast control (NOF) or myofibroblasts (myo). Cells stained with crystal violet. x 
10 magnification, scale bars 200 µm. (B) Mean number of migrated cells from four x 
10 images per membrane calculated using ImageJ “Analyze particles” function. 
Graph shows mean of three membranes from one experimental repeat, analysed by 






Figure 4.19. Effect of H2O2-senesced fibroblast conditioned media on OCCL 
migration. (A) Representative photomicrographs of migrated OCCL on the 
underside of a transwell insert membrane in wells containing conditioned media 
from either normal oral fibroblast control (NOF) or H2O2-senesced fibroblasts 
(H2O2). Cells stained with crystal violet. x 10 magnification, scale bars 200 µm. (B) 
Mean number of migrated cells from four x 10 images per membrane calculated 
using ImageJ “Analyze particles” function. Graph shows mean of three membranes 






Figure 4.20. Effect of CAF conditioned media on OCCL migration. (A) 
Representative photomicrographs of migrated OCCL on the underside of a transwell 
insert membrane in wells containing either conditioned media from normal oral 
fibroblasts (NOF) or primary CAF. Cells stained with crystal violet. x 10 
magnification, scale bars 200 µm. (B) Mean number of migrated cells from four x 10 
images per membrane calculated using ImageJ “Analyze particles” function. Graph 
shows mean of three membranes from one experimental repeat (H376 (CAF) from 
one membrane due to lack of migration on further two membranes), analysed by 
one-way ANOVA, ****p<0.0001. 
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4.2.6. OCCL effect on differentiation and cytokine secretion in fibroblasts 
Cancer cells are thought to be able to generate a CAF-rich stroma through 
the secretion of a variety of growth factors including TGF-β1, which is often 
elevated in the tumour microenvironment. However, in oral cancer lymph node 
metastasis the source of CAF has not been established.  
Therefore, the aim was to determine if conditioned media from the OCCL 
panel used previously could affect CAF marker expression in NOF (conditioned 
media prepared as detailed in section 2.2.3.). NOF were incubated with conditioned 
media for 24 h before being collected for mRNA analysis by qRT-PCR. Only 
conditioned media from the non-metastatic primary tumour cell line (H357) caused 
a significant increase in αSMA expression (p<0.01, Figure 4.21. A). However, 
collagen I mRNA expression was not affected by incubation with conditioned media 
from any of the OCCL (Figure 4.21. B).  
Fibroblasts have also been implicated in aiding the generation of a tumour-
promoting inflammatory microenvironment. They are capable of secreting a variety 
of cytokines and chemokines that recruit inflammatory immune cells to the tumour 
site. These cells are in turn capable of promoting tumour survival, angiogenesis, 
metastasis and genomic instability. However, the role of immune cells and related 
signalling mechanisms in oral cancer lymph node tumours has not been elucidated. 
Therefore, the aim of this part of the project was to investigate how cytokine 
signalling by NOF was affected due to exposure to OCCL conditioned media.  
Secretion of IL-6 and CCL2 (MCP-1) was analysed by ELISA. OCCL conditioned 
media (prepared as detailed in section 2.2.3.) was added to NOF for 24 h. Fresh 
serum free media (SFM) was then replaced for a further 24 h before being collected 
for analysis. Conditioned media was normalised to cell number in each case. IL-6 
concentration was significantly increased as a result of incubation with conditioned 
media from all of the cell lines with the exception of H376 compared to the SFM 
control (p<0.05, Figure 4.22. A). CCL2 secretion was only significantly increased after 
incubation with conditioned media from the lymph node metastases-derived cell 
lines BICR22 and TR146 (p<0.05, Figure 4.22. B). The increases in secreted protein 
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levels were particularly great after exposure to TR146 conditioned media (p<0.0001, 
Figure 4.22. A&B). 
Cell lysates were also collected to allow for analysis of mRNA expression 
levels. Only TR146 conditioned media elicited a significant increase in IL-6 and CCL2 
mRNA expression (p<0.05, Figure 4.23. A&B). BICR22 showed a slight increase in 
CCL2 expression but this was not significant. mRNA expression of the cytokines IL-
1α, IL-1β and IL-8 was also assessed but expression of either IL-1 isoforms could not 
be detected. A large increase in IL-8 expression as a result of TR146 conditioned 
media treatment was also seen (p<0.05, Figure 4.23. C), with mean fold change 
















Figure 4.21. Effect of OCCL conditioned media on αSMA and collagen I mRNA 
expression by normal oral fibroblasts (NOF). mRNA expression of αSMA and 
collagen I (Col1A1) by NOF after 24 h treatment with cancer cell line (H357, H376, 
BICR22 and TR146) conditioned media as determined by qRT-PCR. Bars display the 
mean of three independent experiments ± SD. Results are displayed as ΔΔCT values 
comparing to SFM control and B2M as a reference gene. Results were analysed 










Figure 4.22. Effect of OCCL conditioned media on IL-6 and CCL2 secretion by 
normal oral fibroblasts (NOF). IL-6 and CCL2 concentration in NOF conditioned 
media after 24 h pre-treatment with cancer cell line (H357, H376, BICR22 and 
TR146) conditioned media or serum-free DMEM only (SFM), as determined by 
ELISA. Bars display the mean of three independent experiments ± SD. Results were 
analysed using one-way ANOVA comparing each cell line to the SFM control, 





Figure 4.23. Effect of OCCL conditioned media on IL-6, CCL2 and IL-8 mRNA 
expression by normal oral fibroblasts (NOF). mRNA expression of IL-6, CCL2 and IL-
8 by NOF after 24 h treatment with cancer cell line (H357, H376, BICR22 and TR146) 
conditioned media as determined by qRT-PCR. Bars display the mean of three 
independent experiments ± SD. Results are displayed as ΔΔCT values comparing to 
SFM control and B2M as a reference gene. Results were analysed using one-way 







This chapter has described experiments investigating the relationship 
between oral cancer cells and fibroblasts in the cancer stroma using in vitro cell co-
culture. Firstly, the ability to generate fibroblasts with myofibroblastic and 
senescent characteristics and marker expression from normal oral fibroblasts was 
demonstrated. Patient-derived CAF displayed expression of these same markers but 
often to a lesser extent. A panel of oral cancer cell lines derived from primary 
(metastatic and non-metastatic) and lymph node oral cancer tumours was used to 
allow a comparison of their responses to co-culture with experimentally and 
patient-derived CAF. A comparison of the results for each of the cell lines can be 
seen in Table 4.1. 
Although little effect of experimentally or patient-derived CAF conditioned 
media on EMT marker expression or migration was seen, both the metastatic 
primary tumour-derived and lymph node tumour-derived cell lines expressed 
mesenchymal markers and elevated migration ability. Lymph node tumour-derived 
cell lines, particularly the TR146 cell line, were also able to induce a robust 
chemokine and cytokine response in normal oral fibroblasts, above that induced by 
the primary tumour-derived cell lines. 
 
Table 4.1. Summary of fibroblast co-culture experiment results comparing 












































on EMT marker 
expression 
No effect seen Sig. increase in 




Sig. increase in 
ZEB1 and slug 




myofib. CM; ZEB1 
mRNA sig. 
increased in TR146 
in response to 
H2O2-senesced fib. 
CM but replicative 
senescent fib. CM 
caused a decrease 
in slug, snail and 
ZEB1 mRNA in 
TR146 
Effect of CAF 
conditioned media 
on EMT marker 
expression 
No effect seen / / 
Migration ability Lower compared 
to other OCCL. 
Sig. increased in 
response to H2O2-
senesced fib. CM 
Response either 
equal or elevated 
compared to H357; 
no response to CM 
observed 
Both elevated 
compared to H357 










αSMA but not 
collagen I mRNA 
expression 





Sig. increased IL-6 
secretion only 
No effect Both sig. increased 




of IL-6, IL-8 and 
CCL2 
Key: CM (conditioned media); sig. (significant(ly)); fib. (fibroblast) 
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Chapter 5: Modulation of vasculature and endothelial cell 
behaviour 
5.1. Introduction, hypothesis and aims 
Endothelial cells are a key component of the tumour microenvironment, 
lining blood and lymphatic vessels that are crucial to the growth of tumours as well 
as providing a route of metastasis. Higher blood and lymphatic vessel densities have 
been reported in primary OSCC tumours and linked to increased lymph node 
metastasis (Zhao et al., 2008; Shivamallappa et al., 2011). Additionally, data from 
other cancer types have provided evidence linking the presence of both 
inflammatory immune cells and CAF to increased vessel formation (Coppé et al., 
2006; Ding et al., 2014; Yamagata et al., 2017). Data from section 3.2.3. suggested 
that blood vessel densities are elevated in ECS+ lymph nodes, although no 
significant difference in lymphatic vessel density was observed, but there are 
currently little in vitro data to mechanistically underpin these findings. Therefore, 
the aim was to investigate the tubule forming ability of endothelial cells to model 
vessel formation in vitro in the presence of CAF and our panel of OCCL.  
Endothelial cells also contribute to the signalling milieu of the tumour 
microenvironment, interacting with CAF and immune cells as well as tumour cells 
themselves. The ability of endothelial cells to recruit inflammatory immune cells is 
also important as it facilitates the formation of an inflammatory microenvironment, 
which is conducive to tumour development. However, the role and behaviour of 
endothelial cells in the lymph node tumour microenvironment is less clear. 
Therefore, this part of the study aimed to investigate the inflammatory response of 
endothelial cells to the presence of tumour cells from primary and lymph node 
OSCC tumours and CAF in vitro.  
The hypothesis behind this part of the study was that both cancer cells and 
CAF have the ability to induce vessel formation by endothelial cells and that this is 
true of both primary and lymph node-derived oral cancer cell lines. It was also 
hypothesised that exposure to media conditioned by cancer cells and CAF induces 
chemokine and cytokine expression in endothelial cells, contributing to the 




1. To assess the effect of oral cancer cell line (OCCL) conditioned media on 
microtubule formation ability and proliferation of lymphatic and 
microvascular endothelial cells, and to compare the relative effect of 
primary tumour and lymph node tumour-derived OCCL 
2. To assess the effect of conditioned media from experimentally-derived CAF 
(both myofibroblasts and senescent fibroblasts, see section 4.2.1.) on 
microtubule formation and proliferation of lymphatic and microvascular 
endothelial cells. 
3. To measure the secretion and mRNA expression of key cytokines and 
chemokines by lymphatic and microvascular endothelial cells in response to 
incubation with conditioned media from primary tumour and lymph node-
derived OCCL and experimentally-derived CAF (both myofibroblasts and 
senescent fibroblasts, see section 4.2.1.). 
 
5.2. Results 
5.2.1. OCCL effect on endothelial cell behaviour in vitro 
Although there is some ex vivo evidence linking increased vessel formation 
to metastasis (Zhao et al., 2008; Shivamallappa et al., 2011), there are limited data 
from in vitro functional studies or using lymph-node derived cells or tissues. 
Therefore, the ability of our OCCL panel to alter microtubule formation by 
endothelial cells in vitro was assessed to allow a comparison of primary and lymph 
node-derived OCCL.  
Primary human dermal lymphatic endothelial cells (HLEC) and human dermal 
microvascular endothelial cells (HMEC) were resuspended in OCCL conditioned 
media (generated as described in section 2.2.3. but with the addition of 0.1% (v/v) 
FBS due to the intolerance of HLEC and HMEC to serum starvation) and added to 
wells of a 96-well plate containing growth factor-reduced Matrigel. HMEC/HLEC 
were also resuspended in DMEM + 0.1% (v/v) FBS only as a negative control and 
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DMEM + 0.1% (v/v) FBS containing VEGF-A (for HMEC) or VEGF-C (for HLEC) as a 
positive control. All conditions were performed in triplicate and after 16 h, tubules 
were observed to form spontaneously. One image per well was taken, tubules 
skeletonised and the number of junctions quantified (see Figure 2.4.).  
Significantly higher numbers of tubule junctions were found when HLEC 
were incubated with DMEM containing VEGF-C or conditioned media from any of 
the OCCL used compared to DMEM alone (p<0.05, Figure 5.1.) with the exception of 
TR146 (p=0.07). However, there was no significant difference in the number of 
tubule junctions in HMEC experiments under any of the conditions used (Figure 
5.2.). To control for differences in cell proliferation rate HLEC and HMEC were 
seeded at equal density and incubated with the same conditioned and control 
media as for microtubule assays in a 96-well plate without Matrigel. After 16 h, cell 
numbers were quantified using an MTS assay and comparing to a standard curve. 
Although there was a trend towards increased cell number in HLEC, this was not 
significant across three independent experiments (Figure 5.3. A). There was also no 






Figure 5.1. Effect of OCCL conditioned media on microtubule formation by HLEC. 
(A) Representative images of microtubules formed by HLEC after 16 h incubation 
with conditioned media from the stated cell type, serum-free DMEM only (SFM, 
negative control) or DMEM containing VEGF-C (positive control). 0.1 % (v/v) FBS was 
included in all conditions to prevent cell death. x 10 magnification, scale bars 100 
µm. (B) Quantification of tubule formation. One image from each well was 
skeletonised and the number of junctions counted. Graphs display mean ± SD from 
three independent experiments, analysed by one-way ANOVA comparing to SFM 




Figure 5.2. Effect of OCCL conditioned media on microtubule formation by HMEC. 
(A) Representative images of microtubules formed by HMEC after 16 h incubation 
with conditioned media from the stated cell type, serum-free DMEM media only 
(SFM, negative control) or DMEM containing VEGF-A (positive control). 0.1 % (v/v) 
FBS was included in all conditions to prevent cell death. x 10 magnification, scale 
bars 100 µm. (B) Quantification of tubule formation. One image from each well was 
skeletonised and the number of junctions counted. Graphs display mean ± SD from 
three independent experiments, analysed by one-way ANOVA comparing to SFM 





Figure 5.3. Effect of OCCL conditioned media on proliferation of HLEC and HMEC. 
MTS assay results from (A) HLEC and (B) HMEC after 16 h incubation with 
conditioned media from OCCL, serum-free DMEM media (SFM, negative control) or 
DMEM containing VEGF (positive control). 0.1 % (v/v) FBS was included in all 
conditions to prevent cell death. Cell numbers calculated in each experiment by 
comparing absorbances to a standard curve. Graphs represent the mean fold 
change in cell number ± SD from three separate experiments analysed by one-way 













5.2.2. Myofibroblast and senescent fibroblast effect on endothelial cell 
behaviour in vitro 
Research in other cancer types suggests that CAF are capable of altering 
endothelial cell behaviour and promoting vessel formation both in vitro and in vivo 
(Coppé et al., 2006; Ding et al., 2014). However, there is relatively little evidence 
connecting CAF to the promotion of vessel formation in OSCC. Therefore, the effect 
of conditioned media from experimentally derived-CAF, both myofibroblastic and 
senescent (as described in section 4.2.1.), on microtubule formation by HLEC and 
HMEC was assessed.   
Microtubule assays were carried out using the same experimental protocol 
and controls as for OCCL (section 5.2.1.) but with conditioned media from 
myofibroblasts generated through TGF-β1-treatment of normal oral fibroblasts 
(NOF) or senescent fibroblasts generated through H2O2-treatment of NOF (see 
section 4.2.1.). NOF conditioned media was included in all experiments for 
comparison. All conditions were performed in triplicate and after 16 h one image 
per well was taken for quantification as described previously (see Figure 2.4.).  
Although there appeared to be a slight upward trend, there was no 
significant difference in the number of tubule junctions found when HLEC were 
incubated with myofibroblast conditioned media although large variation in the 
SFM control was observed (Figure 5.4. A&B). Additionally, incubation with 
conditioned media from H2O2-senesced fibroblasts did not significantly affect the 
number of tubule junctions formed by HLEC (Figure 5.4. A&C). Quantification of the 
number of tubule junctions formed by HMEC incubated with myofibroblast 
conditioned media also suggested an upwards trend but did not reveal any 
statistically significant differences (Figure 5.5. A&B). However, the number of tubule 
junctions was significantly increased on incubation of HMEC with conditioned media 
from H2O2-senesced fibroblasts compared to the SFM control (p<0.05, Figure 5.5. 
A&C).  
The effect of fibroblast conditioned media on proliferation of HLEC and 
HMEC was also assessed by MTS assay using the same experimental protocol and 
controls as for OCCL (section 5.2.1.). Both control NOF and myofibroblast 
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conditioned media caused a significant increase in HLEC cell number compared to 
the SFM control (p<0.01, Figure 5.6. A). However, neither H2O2-senesced fibroblasts 
nor their corresponding control NOF caused a significant change in cell number 
although an upwards trend was observed (Figure 5.6. C). No effect on HMEC cell 
number as a result of incubation with any of the fibroblast conditioned medias was 










Figure 5.4. Effect of fibroblast conditioned media on microtubule formation by 
HLEC. (A) Representative images of microtubules formed by HLEC after 16 h 
incubation with conditioned media from normal oral fibroblasts (NOF), 
myofibroblasts (myo), H2O2-senesced fibroblasts (H2O2), serum-free DMEM media 
only (SFM, negative control) or DMEM containing VEGF-C (positive control). 0.1 % 
(v/v) FBS was included in all conditions to prevent cell death. x 10 magnification, 
scale bars 100 µm. (B,C) Quantification of tubule formation. One image from each 
well was skeletonised and the number of junctions counted. Graphs display mean ± 
SD from (B) three or (C) two independent experiments, analysed by one-way 





Figure 5.5. Effect of fibroblast conditioned media on microtubule formation by 
HMEC. (A) Representative images of microtubules formed by HMEC after 16 h 
incubation with conditioned media from normal oral fibroblasts (NOF), 
myofibroblasts (myo), H2O2-senesced fibroblasts (H2O2), serum-free DMEM media 
only (SFM, negative control) or DMEM containing VEGF-A (positive control). 0.1 % 
(v/v) FBS was included in all conditions to prevent cell death. x 10 magnification, 
scale bars 100 µm. (B,C) Quantification of tubule formation. One image from each 
well was skeletonised and the number of junctions counted. Graphs display mean ± 
SD from (B) three or (C) two independent experiments, analysed by one-way 





Figure 5.6. Effect of fibroblast conditioned media on proliferation of HLEC and 
HMEC. MTS assay results from HLEC (A,C) and HMEC (B,D) after 16 h incubation 
with conditioned media from normal oral fibroblasts (NOF) and either 
myofibroblasts (myo; A,B) or H2O2-senesced fibroblasts (H2O2; C,D) plus serum-free 
DMEM media (SFM, negative control) or DMEM containing VEGF (positive control). 
0.1 % (v/v) FBS was included in all conditions to prevent cell death. Cell numbers 
calculated in each experiment by comparing absorbances to a standard curve. 
Graphs represent the mean fold change in cell number ± SD from (A,B) three or 






5.2.3. OCCL effect on cytokine secretion by endothelial cells 
As well as forming vessel structures, endothelial cells are an important part 
of the tumour microenvironment signalling network, communicating with CAF, 
immune and tumour cells. The formation of an inflammatory microenvironment 
and recruitment of inflammatory immune cells is now known to be very important 
to tumour development and endothelial cells are capable of secreting a variety of 
cytokines and chemokines that promote this (Young, 2012). However, the role of 
endothelial cells in this capacity in OSCC and particularly within the lymph node is 
not well defined. Therefore, the effect of OCCL conditioned media on the secretion 
and expression of selected cytokines and chemokines by HLEC and HMEC was 
investigated.  
Secretion of IL-6 and CCL2 (MCP-1) by HLEC and HMEC was analysed by 
ELISA. OCCL conditioned media (produced as described in section 2.2.3. but with 
the addition of 1% (v/v) FBS due to the intolerance of HLEC and HMEC to serum 
starvation) was added to HLEC and HMEC for 24 h. Fresh serum free media (SFM, 
also with the addition of 1% (v/v) FBS) was then replaced for a further 24 h before 
being collected for analysis. Conditioned media was normalised to cell number in 
each case.  
There was a large variation in secretion levels of IL-6 by HLEC and HMEC in 
response to OCCL conditioned media. Although the mean concentration level was 
increased in all cases in response to OCCL conditioned media compared to the SFM 
control this was only significant in the case of H357 (for HLEC and HMEC, p<0.05, 
Figure 5.7. A&B) and BICR22 (for HLEC only, p<0.05, Figure 5.7. A). Media collected 
from HLEC and HMEC contained very high concentrations of CCL2 compared to that 
observed previously from NOF even under SFM control conditions (mean 
concentration 35 ng/ml for HLEC and 3 ng/ml for HMEC vs. 0.081 ng/ml in NOF 
control, see section 4.2.6 and Figure 4.22.). However, there was no significant 
change in CCL2 concentration following treatment with any of the OCCL conditioned 
medias when compared to the SFM control (Figure 5.7. C&D).  
Cell lysates were also collected for analysis of mRNA expression levels. There 
was little change in expression levels of IL-6 or CCL2 as a result of conditioned 
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media treatment from any of the OCCL used by HLEC (Figure 5.8. A&B) or HMEC 
(Figure 5.9. A&B). Only TR146 conditioned media elicited a significant increase in 
CCL2 mRNA expression in HLEC but the fold change was small (1.3-fold increase, 
p<0.05, Figure 5.8. B). HMEC IL-6 mRNA expression was also only significantly 
elevated due to BICR22 conditioned media exposure (p<0.01, Figure 5.9. A). mRNA 
expression of the cytokines IL-1α, IL-1β and IL-8 was also assessed.  Unlike NOF (see 
section 4.2.6.), both HLEC and HMEC displayed mRNA expression of both IL-1α and 
IL-1β but no significant change in expression levels was seen following conditioned 
media treatment (Figure 5.8. C&D; Figure 5.9. C&D). The largest mRNA response 
was seen for IL-8 with significant increases in expression by HLEC in response to 
both lymph node-derived cell lines (BICR22 and TR146, p<0.01, Figure 5.8. E). Mean 
fold change values for above 2 for IL-8 were also seen for BICR22 and TR146 
conditioned media-treated HMEC but these were not significant across three 






Figure 5.7. Effect of OCCL conditioned media on IL-6 and CCL2 production by HLEC 
and HMEC. Concentration of IL-6 (A,B) and CCL2 (C,D) in HLEC (A,C) or HMEC (B,D) 
conditioned media after 24 h pre-treatment with cancer cell line (H357, H376, 
BICR22 and TR146) conditioned media or serum-free DMEM only (SFM), as 
determined by ELISA. 1% (v/v) FBS was included in all conditions to prevent cell 
death. Graphs display the mean of four independent experiments ± SD, analysed by 




Figure 5.8. Effect of OCCL conditioned media on immune marker mRNA expression 
by HLEC. mRNA expression of (A) IL-6, (B) CCL2, (C) IL-1α, (D) IL-1β and (E) IL-8 by 
HLEC after 24 h pre-treatment with oral cancer cell line (H357, H376, BICR22 and 
TR146) conditioned media or serum-free DMEM only (SFM), as determined by qRT-
PCR. 1% (v/v) FBS was included in all conditions to prevent cell death. Bars display 
the mean of three independent experiments ± SD. Results are displayed as ΔΔCT 
values comparing to SFM control and B2M reference gene, analysed by one-way 




Figure 5.9. Effect of OCCL conditioned media on immune marker mRNA expression 
by HMEC. mRNA expression of (A) IL-6, (B) CCL2, (C) IL-1α, (D) IL-1β and (E) IL-8 by 
HMEC after 24 h pre-treatment with cancer cell line (H357, H376, BICR22 and 
TR146) conditioned media or serum-free DMEM only (SFM), as determined by qRT-
PCR. 1% (v/v) FBS was included in all conditions to prevent cell death. Bars display 
the mean of three independent experiments ± SD. Results are displayed as ΔΔCT 
values comparing to SFM control and B2M reference gene, analysed by one-way 
ANOVA comparing to SFM control, **p<0.01. 
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5.2.4. Myofibroblasts and senescent fibroblasts alter cytokine secretion by 
endothelial cells 
Endothelial cells are exposed to signals from a diverse range of cell types 
present in the tumour microenvironment, including CAF. Given that CAF are capable 
of both producing and responding to inflammatory signals, it is possible they also 
communicate with endothelial cells to promote the formation of an inflammatory 
microenvironment. However, this has not been investigated in OSCC. Therefore, the 
effect of conditioned media from experimentally derived-CAF, both myofibroblastic 
and senescent (as described in section 4.2.1.), on the secretion and expression of 
selected cytokines and chemokines by HLEC and HMEC was investigated.  
Secretion of IL-6 and CCL2 (MCP-1) was analysed by ELISA using the same 
experimental protocol as for OCCL (section 5.2.3.) but with conditioned media from 
myofibroblasts generated though TGF-β1-treatment of NOF or senescent fibroblasts 
generated through H2O2-treatment of NOF (see section 4.2.1.). NOF conditioned 
media was included in all experiments for comparison, as well as a serum-free 
media (SFM) control. mRNA analysis of the same cytokine and chemokine markers 
used in section 5.2.3. was also carried out. 
Myofibroblast, but not NOF, conditioned media caused a significant increase 
in IL-6 concentration in media collected from HLEC compared to the SFM control 
(p<0.01, Figure 5.10. A). Although mean IL-6 concentration was increased in HMEC 
media in response to incubation with myofibroblast conditioned media the change 
was not significant when compared to the SFM control (Figure 5.10. B). As observed 
in section 5.2.3., CCL2 secretion levels were extremely high for both HLEC and 
HMEC and no significant change in expression was observed as a result of 
myofibroblast conditioned media treatment (Figure 5.10. C&D).  
Analysis of IL-6 and CCL2 mRNA expression did not reveal any significant 
changes in expression in either HLEC or HMEC due to myofibroblast conditioned 
media treatment compared to the SFM control (Figure 5.11. A&B). The same was 
true when IL-1α and IL-1β were analysed although myofibroblast conditioned media 
treated HMEC had significantly higher expression of IL-1α compared to NOF treated 
HMEC (p<0.05, Figure 5.11. C&D). IL-8 mRNA expression levels were raised as a 
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result of myofibroblast conditioned media treatment for both cell types but this was 
not significant (Figure 5.11. E). 
No significant effect of H2O2-senesced fibroblast conditioned media on IL-6 
or CCL2 secretion was observed although there was a large variation in the 
concentration measured (Figure 5.12.). Furthermore, no significant change in IL-6 
mRNA expression was seen in either HMEC or HLEC as a result of conditioned media 
treatment (Figure 5.13. A). However, CCL2 mRNA levels were significantly elevated 
in H2O2-senesced fibroblast conditioned media treated HLEC compared to either the 
SFM or NOF conditioned media treated controls but the mean fold change was 
small (1.3-fold increase compared to SFM or NOF, p<0.05, Figure 5.13. B). Although 
HLEC displayed no significant change in IL-1α expression, there was a mean 2-fold 
increase in IL-1β expression in cells treated with H2O2-senesced fibroblast 
conditioned media although this was not significant compared to the SFM control 
(Figure 5.13. C&D). In addition, IL-8 expression by HLEC was significantly increased 
following incubation with conditioned media from H2O2-senesced fibroblasts 
(p<0.01, Figure 5.13. E). There was no significant change in IL-1α, IL-1β or IL-8 mRNA 
expression in HMEC cells although large variation was seen between repeats (Figure 





Figure 5.10. Effect of myofibroblast conditioned media on IL-6 and CCL2 
production by HLEC and HMEC. Concentration of IL-6 (A,B) and CCL2 (C,D) in HLEC 
(A,C) or HMEC (B,D) conditioned media after 24 h pre-treatment with normal oral 
fibroblast (NOF) or myofibroblast (myo) conditioned media  or serum-free DMEM 
only (SFM) as determined by ELISA. 1% (v/v) FBS was included in all conditions to 
prevent cell death. Graphs display the mean of three independent experiments ± 





Figure 5.11. Effect of myofibroblast conditioned media on immune marker mRNA 
expression by HLEC and HMEC. mRNA expression of (A) IL-6, (B) CCL2, (C) IL-1α, (D) 
IL-1β and (E) IL-8 by HLEC and HMEC after 24 h pre-treatment with normal oral 
fibroblast (NOF) or myofibroblast (myo) conditioned media or serum-free DMEM 
only (SFM) as determined by qRT-PCR. 1% (v/v) FBS was included in all conditions to 
prevent cell death. Bars display the mean of three independent experiments ± SD. 
Results are displayed as ΔΔCT values comparing to SFM control and B2M as a 
reference gene, analysed by one-way ANOVA comparing to respective SFM control 




Figure 5.12. Effect of H2O2-senesced fibroblast conditioned media on IL-6 and CCL2 
production by HLEC and HMEC. Concentration of IL-6 (A,B) and CCL2 (C,D) in HLEC 
(A,C) or HMEC (B,D) conditioned media after 24 h pre-treatment with normal oral 
fibroblast (NOF) or H2O2-senesced (H2O2) fibroblast conditioned media or serum-
free DMEM only (SFM) as determined by ELISA. 1% (v/v) FBS was included in all 
conditions to prevent cell death. Graphs display the mean of three independent 
experiments ± SD (HLEC IL-6 n=2 only due to anomalous result in 3rd experiment), 





Figure 5.13. Effect of H2O2-senesced fibroblast conditioned media on immune 
marker mRNA expression by HLEC and HMEC. mRNA expression of (A) IL-6, (B) 
CCL2, (C) IL-1α, (D) IL-1β and (E) IL-8 by HLEC and HMEC after 24 h pre-treatment 
with normal oral fibroblast (NOF) or H2O2-senesced (H2O2) fibroblast conditioned 
media or serum-free DMEM only (SFM) as determined by qRT-PCR. 1% (v/v) FBS 
was included in all conditions to prevent cell death. Bars display the mean of three 
independent experiments ± SD. Results are displayed as ΔΔCT values comparing to 
SFM control and B2M as a reference gene, analysed by one-way ANOVA comparing 




This chapter has described experiments investigating the effect of oral 
cancer cells and CAF on endothelial cell behaviour and immune marker expression 
in vitro. Firstly, assays related to vessel formation were carried out using both 
microvascular and lymphatic endothelial cells to test the hypothesis that primary 
tumour and lymph node metastases-derived OCCL and CAF can induce endothelial 
vessel formation. Tubule formation and proliferation assays were used and results 
are summarised in Table 5.1. OCCL conditioned media increased tubule formation in 
HLEC but only H2O2-senescent fibroblast conditioned media caused an increase in 
HMEC tubule formation. Proliferation rates were unchanged in both endothelial cell 
types with the exception of myofibroblast conditioned media-treated HLEC where 
an increase in cell number was observed. 
Secondly, the hypothesis that OCCL and CAF conditioned media can induce 
inflammatory cytokine and chemokine expression in endothelial cells was tested. 
The secretion and mRNA expression of selected inflammatory cytokines and 
chemokines by HLEC and HMEC after conditioned media treatment was assessed 
and the results are summarised in Table 5.2. OCCL and experimentally derived-CAF 
conditioned media treatment resulted in some increases in IL-6 secretion and 
mRNA expression. Further mRNA analysis also revealed IL-8 expression was often 
elevated as a result of conditioned media treatment. This was true for both HLEC 
and HMEC.  
 
Table 5.1. Summary of endothelial cell microtubule formation and proliferation 
assays comparing the effect of conditioned media from different OCCL and 
fibroblast types. 
 Lymphatic endothelial 
cells (HLEC) 
Vascular endothelial cells 
(HMEC) 
OCCL induction of tubule 
formation 
Significant increase due to 
conditioned media from 
all OCCL except TR146 
No significant effect 
OCCL effect on 
proliferation 




of tubule formation 
No significant effect No significant effect 
Myofibroblasts effect on 
proliferation 
Significant increase due to 
conditioned media from 
myofibroblasts and NOF 
No significant effect 
Senescent fibroblast 
induction of tubule 
formation 
No significant effect Significant increase due 




effect on proliferation 
No significant effect No significant effect 
 
 
Table 5.2. Summary of chemokine and cytokine response of endothelial cells to 
conditioned media from different OCCL and fibroblast types. 




OCCL effect on IL-6 and 
CCL2 secretion 
Some increase in IL-6 
(H357 and BICR22 
significantly) 
Some increase in IL-6 
(H357 significantly) 
OCCL effect on immune 
marker mRNA expression 
Significant increase in IL-8 
expression due to BICR22 
and TR146 conditioned 
media 
No other significant 
expression changes 
Significant increase in IL-6 
expression due to BICR22 
conditioned media 
Fold change >2 in IL-8 due 
to BICR22 and TR146 
conditioned media but 
not significant 
No other significant 
expression changes 
Myofibroblast effect on 
IL-6 and CCL2 secretion 
Significant increase in IL-6 
due to myofibroblast 
conditioned media. 
No significant effect 
Myofibroblast effect on 
immune marker mRNA 
expression 
No significant effect No significant effect 
Senescent fibroblast 
effect on IL-6 and CCL2 
secretion 
No significant effect No significant effect 
Senescent fibroblast 





CCL2 and IL-8 expression 
No significant effect for 
remaining markers 
No significant effect 
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Chapter 6: Discussion 
Lymph node involvement is the most important prognostic indicator in 
OSCC. Tumour presence in the lymph nodes results in a marked reduction in 
prognosis and survival rate and this is significantly worsened if tumours grow and 
infiltrate beyond the lymph node capsule into the surrounding neck tissue in a 
process called extracapsular spread (ECS) (Shaw et al., 2010). The prognostic 
significance of these processes make development of lymph node metastases and 
ECS important areas of study but the mechanisms underlying them are poorly 
understood.   
The role of the tumour microenvironment in promoting tumour 
development and metastasis is well established in OSCC and many other cancers. 
Cancer-associated fibroblasts (CAF) have been shown to play a particularly 
prominent role in promoting tumour development through the secretion of a 
variety of growth factors, cytokines and proteases and through their role in the 
maintenance of the extracellular matrix (ECM) (Madar, Goldstein and Rotter, 2013).  
The interaction of both CAF and tumour cells with endothelial cells and the immune 
system is also important, allowing the growth of new vessels and the formation of 
an inflammatory microenvironment. However, little is known about the nature and 
origins of the lymph node stroma and how it differs from the primary OSCC tumour 
stroma. Although there is growing evidence that tumour-stromal crosstalk 
promotes invasion, metastasis and EMT in primary OSCC, there is limited evidence 
for a role of the tumour microenvironment in promoting the growth and 
development of metastatic deposits in lymph nodes and particularly on ECS 
development.  
This is the first study to comprehensively examine stromal and EMT marker 
expression in OSCC lymph node metastases and their paired primary tumours, and 
to compare those findings between ECS+ and ECS- patients. In addition, the 
inclusion of primary and lymph node-derived oral cancer cells in co-culture with 
fibroblasts and endothelial cells in a range of functional and expression based 
assays provides a novel insight into the similarities and differences between these 
two distinct tumour sites. 
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The specific aims of this project were: 
1. To compare markers of stroma, vascularity and EMT in paired ECS positive 
(ECS+) and negative (ECS-) tumour tissue sections.  
2. To generate myofibroblast and senescent fibroblasts from primary normal 
oral fibroblasts (NOF) and compare key markers to primary OSCC CAF.  
3. To examine the effect of myofibroblast and senescent fibroblast conditioned 
media on EMT marker expression and migration of oral cancer cell lines 
(OCCL), including those derived from lymph node metastases.  
4. To examine the effect of conditioned media from OCCL, myofibroblasts and 
senescent fibroblasts on lymphatic and vascular endothelial cell vessel 
formation and growth.  
5. To examine the effect of co-culture of oral cancer cells, fibroblasts and 
endothelial cells on pro-inflammatory signalling.  
 
6.1. Investigating ECS ex vivo 
Despite their clinical significance, there is a lack of prognostic and diagnostic 
tools that can accurately predict lymph node metastasis (section 1.1.1.) and ECS 
occurrence (section 1.2.4.). As a result, many patients undergo elective neck 
dissection, which in many cases is unnecessary and results in significant morbidity. 
Using primary tumour clinicopathological data from the patient cohort used in this 
study it was not possible to predict ECS with the exception of primary tumour size, 
which was increased in ESC+ cases (section 3.2.1.). Other studies with much larger 
cohort sizes also do not report a direct link between primary tumour 
clinicopathological prognostic indicators and ECS (Wenzel et al., 2004; Michikawa et 
al., 2011) suggesting that likelihood of developing ECS is more complex than can be 
predicted from primary tumour pathology alone. It also highlights the need for 
investigation into more specific markers that can be used to predict ECS likelihood 
from primary tumours and explain its occurrence in lymph nodes. Due to its growing 
prominence in the cancer field, this project focussed on the tumour 
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microenvironment as well as the invasion-promoting EMT process by staining 
ECS+/- lymph nodes and their matched primary tumours for a range of markers.   
6.1.1. CAF marker expression in ECS 
This study found that percentage expression of the myofibroblast marker 
αSMA is enhanced in ECS+ lymph nodes and their paired primary tumours 
compared to ECS- specimens (section 3.2.2.). This agrees with and extends upon 
previous studies that identified elevated αSMA expression in primary OSCC tumours 
as a predictor of ECS (Kellermann et al., 2007; Marsh et al., 2011). Both of these 
previous studies carried out quantification by sorting primary tumour specimens 
into two or three categories based on the level of staining. In contrast, in this thesis 
percentage positive expression levels were calculated, reducing the subjectivity of 
the data collection. Nevertheless, the cohort size used here is smaller than these 
previous studies so validation of this finding in a larger sample size would give 
greater weight to this evidence. Increased αSMA expression in primary OSCC 
tumours has also been linked to increased recurrence and poor survival (Kellermann 
et al., 2007, 2008; Vered, Dobriyan, et al., 2010; Bello et al., 2011; Marsh et al., 
2011) but our novel finding that myofibroblast presence is elevated in ECS+ lymph 
nodes suggests they may also play a role in promoting lymph node tumour 
development and ECS. In addition, stroma was absent in four of the 20 ECS- lymph 
nodes whereas all of the ECS+ had an identifiable stroma which suggests that the 
presence of stroma may play a role in facilitating ECS development.  
Although these data provide strong evidence that a myofibroblast-rich 
stroma is important to the development of ECS there is also evidence that the CAF 
population is very heterogeneous and other CAF-characteristics may have 
significant prognostic implications. Of particular interest is the senescent CAF 
phenotype as this results in the secretion of many factors which influence cancer 
cell migration and invasion (Coppé et al., 2008). However, identification of a 
senescence marker for use in IHC is difficult. The best-characterised marker for 
senescence, senescence-associated β-galactosidase (SA-β-gal), can only be detected 
in fresh or frozen tissue and is not suitable for formalin-fixed paraffin embedded 
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(FFPE) tissue. Most other proposed senescence markers either detect growth arrest 
rather than senescence specifically (e.g. cell cycle arrest or DNA damage markers) or 
cannot be measured in fixed tissue (e.g. telomere length). Sudan Black-B, a 
histochemical stain of lipofuscin (an aggregate of oxidised proteins) has been 
proposed as a novel method of senescence detection in FFPE tissue 
(Georgakopoulou et al., 2013) but use of this stain has not been widely reported so 
requires independent validation to confirm its specificity. Nevertheless, if suitable 
markers can be identified, quantification of the senescent CAF population in these 
tumour specimens may yield interesting results. 
Myofibroblasts are key secretors and remodellers of the ECM, of which the 
main structural protein is collagen I. However, no significant difference in the 
presence of collagen I between ECS+ and ECS- specimens was seen in this study 
(section 3.2.2.). There are limited data related to collagen presence in metastatic 
OSCC lymph nodes but evidence from a breast cancer study using metastatic mouse 
models and human lymph node tissue samples showed that collagen I density was 
increased in lymph nodes with metastatic deposits compared to tumour-free nodes 
(Rizwan et al., 2015). This is backed up by research in other cancer types which 
linked increased collagen density and stiffness to a poor prognosis and the 
promotion of tumour invasion (Egeblad, Rasch and Weaver, 2010). However, there 
is currently limited evidence linking increased collagen deposition to OSCC 
progression (Ziober, Falls and Ziober, 2006; Salo et al., 2014) and research suggests 
that ECM deposition and structure is very heterogeneous between cancer types and 
even between patients (Pickup, Mouw and Weaver, 2014). Investigation into 
alternative collagen isoforms and ECM components may therefore be necessary to 
elucidate any prognostic link in this case. 
Additionally, ECM structure remodelling within metastatic lymph nodes may 
be an important and interesting avenue of research. Using a metastatic melanoma 
mouse model Riedel et al. (2016) found that collagen fibres were remodelled in late 
stage metastatic lymph nodes and that conduits were wider. Indeed there is a 
wealth of evidence to suggest that the structural organisation of collagen fibres and 
action of ECM-remodelling enzymes such as matrix metalloproteinases (MMPs), 
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impacts heavily on tumour behaviour (Egeblad, Rasch and Weaver, 2010). Elevated 
expression of MMPs in metastatic lymph nodes of breast cancer compared to 
tumour-free nodes has been reported (Daniele et al., 2010) and MMP-2 and -9 
expression has also been identified in OSCC lymph node deposits (Zhou et al., 2010) 
but the significance of this with regards to ECS is unknown. 
6.1.2. Altered vasculature and ECS 
This study also found an increase in microvascular density (MVD) in ECS+ 
lymph nodes compared to ECS- nodes but found no significant difference in MVD in 
the primary tumours of the two groups (section 3.2.3). Several previous studies in 
OSCC have linked high primary tumour blood vessel density to increased lymph 
node metastasis (Miyahara et al., 2007; Bolzoni Villaret et al., 2009) and deeper 
local invasion (Li et al., 2005), but did not report on the ability of primary tumour 
MVD to predict ECS. The only study looking in detail at blood vessel growth in OSCC 
lymph nodes found no difference in the number of vessels that co-stained with the 
proliferation marker ki67 when comparing nodes with and without metastatic 
deposits whereas extensive proliferating vessels were seen in the corresponding 
primary tumours (Naresh, Nerurkar and Borges, 2001). Surprisingly they also found 
that MVD was elevated in non-metastatic lymph nodes compared to metastatic 
nodes. However, this work was carried out in a very small cohort (n=9 OSCC cases), 
also included cases of laryngeal cancer and limited visual or quantification data 
were provided. Additionally, evidence from an in vivo mouse model of OSCC found 
that MVD is elevated in pre-metastatic tumour draining lymph nodes in response to 
implantation of metastatic cancer cells in the tongue compared to non-metastatic 
tumour cells (Mayorca-Guiliani et al., 2012). This suggests that MVD is increased in 
lymph nodes in preparation for colonisation by tumour cells. However, no 
comparison to ECS was carried out in either study so these data remain the first to 
suggest MVD is increased in ECS.  
Established systemic blood vessel markers were used in this study to allow a 
comparison with primary tumour MVD; however, several studies have instead 
focussed on the density of the lymph node-specific high endothelial venule blood 
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vessels (HEV). As for MVD, conflicting evidence has been reported showing that HEV 
density is elevated in lymph nodes with metastatic deposits (Lee et al., 2012) but 
also conversely that HEV density is increased in sentinel lymph nodes (SLN) prior to 
lymph node colonisation (Chung et al., 2012; Shen et al., 2014). However, the 
correlation between HEV density and ECS was not reported in either of these 
studies and so a comparison of blood vessel and HEV density in our cohort would be 
an interesting extension to this work.  
In contrast, this study found no significant difference in lymphatic vessel 
density (LVD) between the ECS+ and ECS- groups at either primary or lymph node 
sites (section 3.2.3.). Increased LVD has been linked to increased invasion and 
lymph node metastasis (Kyzas et al., 2005; Zhao et al., 2008) but available evidence 
on lymph node LVD changes are more conflicting. Increased LVD in SLN with 
metastatic deposits compared to those without has been previously reported 
(Wakisaka et al., 2015). However, LVD has also been reported to be elevated in all 
SLN regardless of metastatic status compared to non-SLN (Chung et al., 2012) and 
metastatic tumour cells have been shown to elevate LVD in pre-metastatic tumour 
draining lymph nodes to a greater extent than non-metastatic tumour cells 
implanted in to the tongue of mice (Mayorca-Guiliani et al., 2012). This suggests 
that, as for MVD, LVD is elevated in lymph nodes and that this promotes 
colonisation. However, it is unclear if further changes occur following metastasis 
and, as this study is the first to compare lymph nodes with and without ECS, there is 
currently no evidence to support the theory that lymph vessel density or growth is 
important to ECS. 
Another factor that may be as important as vessel density is the ability of 
tumour cells to invade into vessels. Clinicopathological data for this cohort found 
that higher numbers of ECS+ cases had primary tumour lymphovascular invasion 
compared to ECS- (40% vs. 25%) but this was not significant (section 3.2.1.). In 
contrast, other studies have found a link between lymphovascular invasion at the 
primary site and increased rate of lymph node metastasis and ECS (Jones et al., 
2009; Adel et al., 2015). Adel et al. (2015) used a comparatively large cohort of 571 
and found that when lymphatic and vascular invasion were considered as 
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independent factors only lymphatic invasion was a significant predictor of 
metastasis and ECS. This suggests that the ability of cancer cells to invade into 
vessels may be a better predictor of tumour metastasis than simply the presence of 
vessel structures. Pereira et al. (2018) examined the lymph nodes of head & neck 
cancer patients and observed isolated tumour cells at the leading edge of tumour 
masses in close association with blood vessels and, in a third of the samples, inside 
the vessel lumen. However, a correlation with clinical outcome or ECS was not 
reported.  
6.1.3. Macrophage in ECS 
When macrophage numbers were quantified contrasting results were seen 
depending on the primary tumour site, with an increase in macrophage density 
seen in ECS+ tongue specimens but a decrease seen for ECS+ floor of mouth 
specimens compared to their corresponding ECS- groups. This pattern was the same 
for lymph node and primary tumour sites (section 3.2.4.). The reason for this 
discrepancy is unknown but may be due to differences in environment found at 
each primary tumour site determining the level of macrophage recruitment. There 
was a large range in percentage positive cell numbers so it may also be that 
macrophage presence does not promote ECS directly but that the ability of primary 
tumours to attract macrophage to the tumour site may be reflected in their 
metastatic deposits. This is supported by the fact that macrophage percentage 
positivity correlated significantly between matched primary and lymph node 
tumour pairs. Most data relating to macrophages and OSCC development focus on 
the primary tumour where high macrophage numbers (using the CD68 marker as 
for this study) have been linked to higher rates of lymph node metastasis and poor 
prognosis (Weber et al., 2014; Ni et al., 2015; Yamagata et al., 2017). This supports 
the hypothesis that macrophages promote tumour development but as this is the 
first study to report on macrophage levels in patients with and without ECS, it is 
hard to draw definite conclusions. 
An important point raised by these studies is their disagreement as to the 
most appropriate microlocalisation to quantify macrophage numbers. Although the 
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majority of studies found macrophage density in the stroma adjacent to the 
invasive edge (as used in this study) had prognostic value (Fujii et al., 2012; Ni et al., 
2015; Hu et al., 2016; Yamagata et al., 2017), others reported correlations to 
prognostic factors when quantifying macrophages within the tumour itself (Weber 
et al., 2014; Hu et al., 2016). Quantification of macrophage within different tumour 
microlocalisations would provide an interesting extension to this study.  
Another important consideration to take into account is not only the 
numbers but also the polarisation of the macrophages present. As explained in 
section 1.7.1., macrophages may be one of two phenotypes: M1 (anti-inflammatory 
and anti-tumour) or M2 (pro-inflammatory and pro-tumour). The CD68 marker used 
here stains macrophages of both types. However, several studies either have 
focussed entirely on M2 macrophages using markers such as CD163, or have 
measured both M1 and M2 macrophages in order to calculate the degree of 
polarisation. Despite the emphasis on the importance of M2 macrophages with 
regards to cancer progression (Takeya and Komohara, 2016), the majority of OSCC 
studies found prognostic value in both total macrophage and M2 macrophage 
densities (Fujii et al., 2012; He et al., 2014; Weber et al., 2014; Hu et al., 2016; 
Yamagata et al., 2017). This could be explained by the observation that the majority 
of macrophages found in the vicinity of tumours are of the M2 phenotype, so both 
quantification methods may simply highlight the importance of macrophage 
recruitment to tumour progression.  
Nevertheless, determining the relative numbers of M1 and M2 macrophages 
in ECS+ and ECS- metastatic tumours would be an interesting avenue of research 
especially given the high numbers of native macrophages present in lymph nodes, 
which may therefore influence the lymph node response to tumour metastasis. The 
only paper to report on macrophages in the metastatic lymph nodes of OSCC 
patients, focussed on macrophages found in the lymph node sinus and how their 
polarisation correlated with clinical parameters in the primary tumour related to 
increased invasion and metastasis (Wehrhan et al., 2014). Interestingly, they 
observed no difference in the polarisation of these macrophages between tumour-
free and metastasis-containing nodes and hypothesised that changes to 
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macrophages in the primary tumour alter the phenotype of sinus macrophages to 
dampen the immune response of the lymph node prior to tumour colonisation. 
However, they did not look at tumour-associated macrophages or compare 
polarisation or density in ECS+ and ECS- lymph nodes. Determining if macrophage 
numbers or the degree of polarisation is altered due to ECS occurrence would clarify 
how effective anti-inflammatory treatments may be for preventing metastasis 
development in OSCC. 
6.1.4. EMT marker expression in ECS 
Expression of the EMT-inducing transcription factors slug, snail, TWIST1 and 
ZEB1 was observed in tumour and stromal cells at both lymph node and primary 
sites (section 3.2.5.). Antibodies for the snail family of EMT-inducing transcription 
factors showed a decrease in percentage positive expression in ECS+ tumour and 
stromal areas compared to ECS-. However, no difference in percentage positive 
expression of the TWIST1 or ZEB1 markers was observed.  
Although there is evidence that elevated expression of these EMT 
transcription factors is linked to increased lymph node metastasis and poor 
prognosis in primary tumour OSCC (Wang et al., 2012; Y. Zhou et al., 2015; Yao and 
Sun, 2017), their prognostic impact in OSCC metastatic lymph nodes has not been 
reported. However, other studies on snail expression have found few associations 
with adverse clinicopathological factors and no correlation with increased lymph 
node metastasis (Franz et al., 2009; Zhao et al., 2012), so the link of these factors to 
tumour development is not certain. Snail expression has been previously observed 
in OSCC lymph nodes (Schwock et al., 2010) but the significance of the depletion 
observed here is unknown.  
In a recent seminal paper, which carried out single-cell transcriptome 
analysis of a cohort of primary and matched metastatic OSCC tumours, expression 
of these transcription factors at both primary and lymph node sites was found to be 
lacking, with only slug expression detected (Puram et al., 2017). In addition, 
expression of epithelial markers persisted in the population but an expression 
signature of other EMT markers was identified, including podoplanin, vimentin and 
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TGF-β1, which could differentiate between the different tumours used. The authors 
suggested this represented a state of partial EMT (p-EMT) and demonstrated that 
high expression of this p-EMT signature was maintained in the matched lymph node 
metastases. High levels of the p-EMT expression signature in a TCGA dataset were 
also significantly correlated with ECS and other adverse clinicopathological factors. 
It may be that detecting differences in the levels of classical E-cadherin repressing 
transcription factors was not possible in this study due to the transient nature of 
EMT, or because the primary tumour EMT status is maintained in lymph node 
metastasis regardless of their ECS status. There is little other information available 
on the EMT status of OSCC lymph node tumours with regards to ECS. Lee et al. 
(2014) found that high vimentin, low E-cadherin expression in lymph node OSCC 
tumours was a better predictor of recurrence and distant metastasis than ECS 
status alone. In fact, these EMT marker expressing patients who were also ECS+ had 
a five times worse survival rate than ECS- patients. This agrees with the findings of 
Puram et al. (2017) and implicates EMT, but not specifically EMT transcription factor 
expression, in ECS occurrence.  
Interestingly, although there was no significant difference between the 
groups, levels of percentage expression correlated between the primary and lymph 
node sites for TWIST1 and ZEB1. This agrees with the findings of Vered, Dayan, et al. 
(2010), who found a positive correlation between lymph node and primary tumour 
expression levels of several EMT markers including TWIST1. Puram et al. (2017) also 
noted that the p-EMT signatures of paired primary and lymph node tumours 
matched using single cell transcriptome analysis, although some variability was 
evident. Overall, this suggests that expression of these EMT transcription factors in 
tumours is maintained at the lymph node site but that they may not be directly 
useful as prognostic markers for ECS.  
This study observed expression of all four transcription factors in stromal 
cells as well as within the tumour and quantified stromal expression separately 
although this yielded similar results to tumour areas. TWIST1 and ZEB1 positive cells 
particularly were observed more commonly in stromal areas. The cause and effect 
of stromal cell expression of these markers is not clear. Snail and slug expression 
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has been associated with myofibroblast activation (Francí et al., 2006) and co-
expression of snail and αSMA in the stromal invasive front has been previously 
reported in OSCC (Franz et al., 2009). A weak positive correlation was seen between 
snail/slug expression and αSMA expression in this study but, as for Franz et al. 
(2009), only αSMA was able to predict adverse clinical outcome. More investigation 
into the relationship between EMT transcription factor expression and fibroblast 
activation is needed to fully understand this phenomenon. 
6.1.5. Summary of IHC findings 
The IHC investigations reported here provide a novel insight into the tumour 
microenvironment of OSCC lymph nodes and how alterations to this may aid ECS 
development. They also highlight specific cell types that were altered in ECS+ nodes 
and therefore are potentially important to lymph node tumour development, 
notably CAF, endothelial cells and TAM. To follow on from this work, in vitro 
analysis of these cell types in relation to lymph node metastasis-derived oral cancer 
cell lines (OCCL) was carried out.  
 
6.2. Fibroblasts 
There is growing evidence in OSCC and other cancers that cancer-associated 
fibroblasts (CAF) can have a profound effect on many cancer processes including 
proliferation, migration, invasion and metastasis. Despite this CAF are still not well 
defined in terms of CAF-specific cell markers and also their origins (Madar, 
Goldstein and Rotter, 2013). The origin of CAF within the lymph node is also 
disputed, as although normal lymph nodes have minimal fibroblasts, abundant CAF 
are often present in association with metastatic deposits in lymph nodes. To study 
the interaction of CAF with lymph node and primary tumour OSCC cells in vitro, 
both myofibroblasts and senescent fibroblasts were generated to model the CAF 
phenotype and were then compared to primary patient-derived CAF.   
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6.2.1. Myofibroblast generation 
This study found a significant elevation in αSMA-positive myofibroblast 
presence in ECS+ lymph nodes and their matched primary tumours, which supports 
previous research that has linked myofibroblast presence to altered tumour 
behaviour (section 3.2.2. and discussion 6.1.1.). To investigate this relationship in 
vitro myofibroblasts were generated from normal oral fibroblasts (NOF) by treating 
them with TGF-β1. This resulted in a significant up-regulation of αSMA protein and 
mRNA levels (section 4.2.1.). The use of TGF-β1 to induce myofibroblast 
differentiation has been previously demonstrated successfully in primary oral 
fibroblast cultures in this lab and by others (Lewis et al., 2004; Kellermann et al., 
2008; Berndt et al., 2014; Elmusrati et al., 2017; Melling et al., 2018). TGF-β1 levels 
have also been found to be elevated in cancer, making this model physiologically 
relevant to the cancer setting (Levy and Hill, 2006). Nevertheless, it does represent 
a simplification of the in vivo tumour-stroma signalling situation and alternative 
methods have been proposed, such as the use of OCCL conditioned media (Lewis et 
al., 2004; Dudás, Bitsche, et al., 2011). However, in this study exposure of NOF to 
OCCL conditioned media for 24 h did not induce expression of myofibroblast 
markers (section 4.2.6.). Alteration to the experimental protocol and extension of 
incubation time could be used to fully investigate the relative effect of the OCCL 
panel on NOF differentiation. However, as the aim of generating these fibroblasts 
was to see how their conditioned media affected the signalling and behaviour of a 
panel of different OCCL, inducing differentiation using conditioned media would 
have added more unknown variables to the experimental design. Furthermore, 
Lewis et al. (2004) showed that blocking TGF-β1 prevented this conditioned media 
effect, which supports the use of TGF-β1 as an inducer in this study.  
6.2.2. Senescent fibroblast generation 
Senescent fibroblasts have also been identified as an important CAF 
phenotype in OSCC and other cancer types. The senescence-associated secretory 
phenotype (SASP) results in the secretion of proteases, chemokines, growth factors 
and other signalling molecules, many of which have been implicated in the 
promotion of cancer growth and invasion (Coppé et al., 2010). Therefore, 
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senescence was induced in primary NOF cultures using two different methods to 
serve as another model of CAF for use in further experiments. Firstly, senescence 
was induced using hydrogen peroxide (H2O2) and, secondly, replicative senescent 
cells were generated by prolonged culturing. 
NOF were exposed to H2O2 for 2 h and then cultured for a further 10 days to 
allow senescence to develop. At this time point over 75% of the cells were 
senescent according to results from a senescence-associated β-galactosidase (SA-β-
gal) assay. Use of H2O2 to induce senescence has been previously reported by this 
lab and others (Hassona et al., 2013; Kabir, 2015; Kabir et al., 2016). Furthermore, 
the use of hydrogen peroxide is physiologically relevant as reactive oxygen species 
(ROS) are known to be produced by both tumour cells and CAF (Costa, Scholer-
Dahirel and Mechta-Grigoriou, 2014). Hassona et al. (2013) showed that 
conditioned media produced by OSCC cells from a genetically unstable tumour 
contained ROS and could induce senescence in fibroblasts. The corresponding 
primary CAF were senescent, and displayed oxidative damage and a lack of 
antioxidant defences. Indeed there is growing evidence to suggest that the 
presence of ROS not only activates CAF but also affects their ability to crosstalk with 
cancer cells (Costa, Scholer-Dahirel and Mechta-Grigoriou, 2014).  
Replicative senescence occurs naturally as a result of telomere shortening 
due to prolonged culturing (Hayflick and Moorhead, 1961). SA-β-gal assays on NOF 
cultured to passage >30 to cause replicative senescence indicated over 80% of the 
cells were senescent. Given the link of OSCC with old age, this method is particularly 
relevant to this study.  
Nevertheless, alternative methods of senescence induction such as 
irradiation or treatment with the chemotherapeutic drug cisplatin could also have 
been utilised. These methods would be relevant to this study as they represent the 
potential impact of common OSCC treatments on the remaining CAF population. 
Cisplatin-induced fibroblast senescence has been previously studied in our lab and 
was shown to induce morphological and gene expression changes analogous to that 
seen in H2O2-senesced and replicative senescent fibroblasts, including high SA-β-gal 
positivity and increased p16 and p21 mRNA expression (Kabir, 2015; Kabir et al., 
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2016). This work went on to show that cisplatin-senesced oral fibroblast could 
promote the migration and invasion of primary OCCL, and that this was due, in part, 
to their elevated secretion of the pro-inflammatory cytokine CCL2. 
The main indicator of senescence used here was the SA-β-gal assay. This was 
first proposed by Dimri et al. (1995), who demonstrated, using primary human 
fibroblast cultures, that senescent cells display augmented expression of lysosomal 
β-galactosidase at pH 6.0. They reported an absence of positive SA-β-gal staining in 
quiescent cells generated through serum starvation and confluency of cell cultures. 
However, others have reported some false positive staining, particularly in over-
confluent or stressed cultures (Yang and Hu, 2005). To negate this, fibroblasts were 
seeded at low density and incubated in full serum media overnight before SA-β-gal 
assays were carried out. Other markers for senescence have been proposed 
including DNA damage and cell cycle arrest markers (such p21 and p16 used in this 
study) and heterochromatin formation (Matjusaitis et al., 2016). However, the large 
majority of these are not senescence specific and may also be expressed by 
quiescent cells or cells undergoing cellular stress so must be used with caution, and 
in combination, to avoid false positive results.  
6.2.3. Evaluation of the use of CAF models in vitro 
Primary CAF cultures were also used in this study to provide a better 
representation of the OSCC tumour stroma. OSCC-derived CAF have many 
advantages, particularly as they represent the true heterogeneity of the CAF 
population (Lim et al., 2011; Costea et al., 2013; Hassona et al., 2013; Madar, 
Goldstein and Rotter, 2013). Myofibroblast and senescent fibroblast markers were 
measured to allow a comparison to the experimentally-derived CAF discussed 
above. CAF displayed some increase in αSMA expression at the protein and mRNA 
level but this was not significant. CAF also expressed some markers of senescence 
although the percentage of SA-β-gal positive cells did not reach levels recorded for 
either H2O2-induced or replicative senescent fibroblasts (section 4.2.1.). This 
suggests that experimentally inducing myofibroblast differentiation or senescence 
produces cells with a more robust expression of commonly used markers for each 
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phenotype. However, it also highlights the heterogeneity of CAF as these results 
could be explained by the existence of multiple sub-types of fibroblast within the 
CAF population and/or the presence of CAF that are both senescent and αSMA-
positive. Hassona et al. (2013) found a correlation between senescence and αSMA 
expression in their panel of primary CAF cultures and also reported that prolonged 
TGF-β1 stimulation induced both αSMA and senescence marker expression in NOF. 
This supports data from our lab which showed that senescence induction in NOF 
using H2O2 or cisplatin is accompanied by an increase in αSMA expression although 
replicative senescent fibroblasts showed decreased αSMA expression compared to 
NOF (Kabir, 2015; Kabir et al., 2016). This complexity makes it hard to define the 
characteristics of a CAF population based on whole population samples. One 
method to mitigate this heterogeneity is the isolation and clonal expansion of 
specific cells within the primary CAF population as demonstrated by Sobral et al. 
(2011). However, when using this method, careful selection criteria must be 
employed to ensure that the cloned population is representative of the CAF 
population as a whole. 
Although primary CAF provide a more accurate representation of the in vivo 
situation, there are some advantages to the use of the experimentally-derived CAF 
models described above. Firstly, they are easier to source meaning more 
experiments can be carried out over a set period. They also allow both the control 
fibroblasts and “CAF” to be derived from the same patient source. This eliminates 
patient-patient variability as a source of difference in response, making the results 
more comparable. Although “normal” fibroblasts could be sourced from cancer 
patients, there is evidence that histologically normal cells in the vicinity of tumours 
may still exhibit genetic alterations analogous to those seen in malignant cells due 
to field cancerisation from prolonged carcinogen exposure (Rema et al., 2015). 
Additionally, this would increase the burden on the OSCC patients and so may not 
be possible if ethical approval or surgical support is not in place. 
There are competing theories as to the origins of lymph node CAF (Madar, 
Goldstein and Rotter, 2013). The theory that primary CAF travel with tumours to the 
secondary site and then aid the development of lymph node tumours supports the 
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use of primary tumour derived CAF as described here. However, if CAF are 
generated in situ due to cancer-derived signals then this may be less directly 
relevant to the lymph node situation. Characterisation of patient-derived primary 
tumour and lymph node metastases-associated CAF would allow for a more 
detailed comparison, especially if derived from the same patient. However, lymph 
node CAF are difficult to source without compromising the diagnostic pathology 
process for the patient. The predominant fibroblast population in the lymph node 
are fibroblast reticular cells (FRC, section 1.4.4.) and so investigation into their 
response to cancer cell signalling, particularly TGF-β1 signals, would be a useful next 
step. However, currently human FRC cultured cells are not available so primary 
tumour CAF provide the closest equivalent. Endothelial cells have also been cited as 
a source of CAF, with some reports stating that up to 40% of CAF display endothelial 
markers (Zeisberg et al., 2007) so their ability to transform into CAF could also be 
investigated. 
Having generated and sourced CAF for use in vitro, this study went on to 
investigate their influence on OSCC cancer cell line signalling and behaviours that 
relate to lymph node metastasis and ECS. 
 
6.3. EMT and migration in lymph node metastasis 
Epithelial-mesenchymal transition (EMT) is a key mechanism by which 
cancer cells gain the ability to migrate and invade into the surrounding tissues. EMT 
allows epithelial-like cells to lose their cell-cell adhesion contacts, remodel their 
cytoskeleton, and form invadopodia, allowing for individual cell movement (Figure 
1.2.). A crucial step in the EMT process is the down-regulation of E-cadherin due to 
the binding of transcriptional repressors such as slug, snail, TWIST1 and ZEB1 
(Krisanaprakornkit and Iamaroon, 2012).  
There are many known triggers of EMT, both intrinsic and extrinsic. Growth 
factors such as TGF-β1 and epidermal growth factor (EGF) have been identified as 
key initiators of EMT in cancer and have been used in OSCC to induce EMT in vitro 
(Qiao, Johnson and Gao, 2010; Richter et al., 2011; Yu et al., 2011). Fibroblasts, as 
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key growth factor secretors within the tumour microenvironment, are consequently 
an interesting avenue of study in relation to EMT. Therefore, co-culture of 
fibroblasts and oral cancer cells was employed to investigate this.  
6.3.1. EMT marker expression in oral cancer cell lines (OCCL) 
Evidence of EMT transcription factor expression was found in our primary 
and lymph node metastasis OSCC specimens although no clear difference was seen 
between ECS+ and ECS- patients (section 3.2.5. and discussion 6.1.4.). Nevertheless, 
elevated expression of EMT transcription factors and mesenchymal markers in the 
primary tumour has been linked to poor prognosis and higher rates of metastasis 
(Nijkamp et al., 2011; Wang et al., 2012; Ding et al., 2014; Y. Zhou et al., 2015; Yao 
and Sun, 2017). In concordance with this, in this study both the primary metastatic 
tumour (H376) and lymph node tumour derived (BICR22 and TR146) OCCL displayed 
expression of the mesenchymal marker vimentin and lacked expression of the 
epithelial marker E-cadherin. This was in contrast to the non-metastatic primary 
tumour-derived cell line H357 that showed strong E-cadherin expression and a lack 
of mesenchymal markers. Evaluation of EMT marker expression in a larger range of 
OCCL would be interesting to determine if marker expression is similar in other 
lymph node-derived cell lines compared to that observed here.  
6.3.2. Fibroblast effect on EMT marker expression by OCCL 
Conditioned media from myofibroblasts and senescent fibroblasts was 
added to the panel of OCCL outlined above in order to assess if there was any 
response in terms of EMT marker expression. In response to myofibroblast 
conditioned media, very few EMT-related protein and mRNA changes were 
observed with the only significant increases seen in mRNA expression of ZEB1 and 
slug in BICR22 and TR146 cell lines, respectively (section 4.2.2.). This is surprising 
given the reported link between myofibroblasts and EMT induction (Cirri and 
Chiarugi, 2011, 2012) but may be partly explained by the predominantly 
mesenchymal nature of the majority of the cell lines used here. As stated above, 
determining the EMT status of a wider range of lymph node-derived cell lines may 
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identify OCCL more susceptible to EMT induction in vitro. Nevertheless, Berndt et al. 
(2014), who used a similar experimental design to that employed here, reported 
only an upregulation of vimentin with no change in E-cadherin and no alteration to 
the mesenchymal markers N-cadherin and cytokeratin in the OCCL used. This 
suggests that, additionally, exposure of OCCL to myofibroblast conditioned media 
may not be sufficient to induce a full EMT transition within this time period.  
This study also reported very few changes to OCCL EMT marker expression 
in response to either H2O2-senesced or replicative senescent conditioned media 
(section 4.2.3.); with only slight alteration to mRNA expression of some of the EMT 
transcription factors observed. There are limited data relating directly to the ability 
of senescent fibroblasts to induce EMT in OSCC but some evidence from other 
cancer systems suggests senescent fibroblasts can induce EMT. For example, Taddei 
et al. (2014) incubated prostate cancer cells with conditioned media from 
replicative senescent and H2O2-induced senescent fibroblasts. They observed a 
significant up-regulation of ZEB1, ZEB2 and vimentin expression corresponding with 
a decrease in E-cadherin. Similar results using replicative senescent fibroblast 
conditioned media have been obtained in breast cancer (Coppé et al., 2008) and 
using epidermal keratinocytes (Malaquin et al., 2013) and these changes were also 
accompanied by an increase in invasive ability.  
In this study, CAF conditioned media also had no effect on the expression of 
EMT markers by the epithelial OCCL H357. This is in contrast to a previous study 
that demonstrated the ability of OSCC CAF conditioned media to induce decreased 
E-cadherin and increased vimentin expression in a panel of OCCL (Zhou et al., 2014). 
However, in that study, conditioned media was incubated with the OCCL for 2 
weeks and different cell lines were used which may explain this difference. This and 
other previously cited studies (Coppé et al., 2008; Malaquin et al., 2013) suggest 
that perhaps a longer incubation period is necessary, particularly for the 
development of phenotypical changes such as the loss of E-cadherin expression. 
Berdiel-Acer et al. (2011) investigated the timing of EMT in more detail by 
performing a time course analysis of EMT marker expression in colorectal cancer 
cells incubated with conditioned media from primary CAF. They showed that most 
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markers increase sequentially over time with some, such as slug, not showing up-
regulation until 72 h. Soon et al. (2013) measured vimentin and E-cadherin 
expression in breast cancer cell lines treated with CAF conditioned media after 6 
and 10 days of incubation. Although vimentin was upregulated by day 6, E-cadherin 
did not decrease until day 10 suggesting a longer incubation period may be needed. 
Nevertheless, several previous studies including those cited above used 24-48 h 
incubation periods and reported expression changes including E-cadherin and 
vimentin (Shintani et al., 2013; Taddei et al., 2014; Yu et al., 2014). 
As well as alterations to experimental timing and enlargement of the OCCL 
panel, alternative experimental set-ups could be employed, particularly to 
determine if direct cell contact is needed for EMT induction by fibroblasts. 
Alteration to EMT marker expression due to direct co-culture of cancer cells and 
fibroblasts has been demonstrated in other cancers (Gao et al., 2010) with one 
study in lung cancer reporting that the changes were more pronounced under 
direct co-culture conditions (Choe et al., 2013). However, care must be taken to 
ensure mesenchymal cancer cells and fibroblast cells can be separated at the end of 
the experimental period, for example by fluorescent cell tagging and separation by 
fluorescence-activated cell sorting (FACS) (Gao et al., 2010; Choe et al., 2013). 
Moreover, the use of 3D models would increase the complexity of co-culture 
and may better represent the interaction between tumour and stromal cells, as well 
as allowing the incorporation of an ECM. In vitro 3D models of oral mucosa and 
early invasive OSCC have been developed which include both epithelial/cancer cells 
and fibroblasts as well as an ECM (Colley et al., 2011) and have also been generated 
using TR146 cells (Moharamzadeh et al., 2008) and with the use of de-epitheliarised 
dermis with H357 cells (Kabir, 2015; Kabir et al., 2016). This could be used to look at 
the effect of including myofibroblasts, senescent fibroblasts or primary CAF on the 
expression of EMT markers by OCCL as well as their invasion pattern (see discussion 
6.3.3.). Increases in some EMT transcription factors in H357 cells due to the 
presence of some subsets of CAF has been demonstrated in preliminary 
experiments using 3D models in our lab (Kabir, 2015) but further data are needed to 
confirm and extend this result. Additionally, these models are designed to mimic 
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the oral mucosa environment through their use of an air-liquid interface and a 
distinct epidermal and dermal layer so are less relevant to the development of the 
lymph node metastatic tumour. Instead, the use of multicellular tumour spheroids 
could be employed (Stadler et al., 2015).  
6.3.3. Fibroblast effect on migration of OCCL 
The migratory ability of the panel of OCCL in response to fibroblast 
conditioned media was assessed using transwell assays (section 4.2.5.). This 
revealed that higher numbers of the lymph node metastases-derived cell lines 
BICR22 and TR146 migrated to the lower side of the membrane than the non-
metastatic primary tumour derived cell line H357. In two experiments the 
metastatic primary tumour derived cell line H376 displayed migrated cell numbers 
that were similar to BICR22 and TR146 but levels similar to the H357 cell line were 
observed in a further experiment using myofibroblast conditioned media. This 
highlights the variability of cell-based assays and the need for further repeats to 
fully draw conclusions from this work. The higher migratory ability of the H376, 
BICR22 and TR146 cell lines makes sense because these cell lines showed expression 
of mesenchymal markers, which is associated with an increase in migratory ability 
(section 4.2.2-3.). This matches to previous research showing OCCL with low E-
cadherin expression show greater levels of migration in a transwell assay 
(Yokoyama et al., 2001). In addition, when a primary and lymph node tumour cell 
line derived from the same patient were compared the metastatic cell line had a 
higher migratory and invasive capacity (Fujinaga et al., 2014). Although the authors 
did not report on EMT markers specifically, a microarray revealed an upregulation 
of the E-cadherin repressor snail in the metastatic cell lines, suggesting the 
metastatic cells may have been more mesenchymal in nature. 
The ability of myofibroblast, senescent fibroblast and CAF-derived 
conditioned media to induce OCCL migration compared to NOF was also assessed. 
Only H2O2-induced senescent fibroblast conditioned media caused a significant 
increase in migration (in H357 and BICR22 cells only). This agrees with and extends 
on previous research in our lab which also found that H2O2-induced senescent 
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fibroblast conditioned media significantly increased the migration of H357 cells 
using a similar experimental design to that employed here (Kabir, 2015; Kabir et al., 
2016). This previous work also reported that CAF conditioned media could increase 
the migration of H357 cells, in contrast to the preliminary findings here. However, 
only CAF derived from genetically unstable tumours (which were more senescent) 
caused a significant increase in migration, with CAF derived from genetically stable 
tumours inducing a response similar to the NOF control. This suggests that the 
factors secreted due to senescence induction may be important to the CAF ability to 
induce migration as both the genetically stable and unstable tumour-derived CAF 
displayed elevated expression of the αSMA myofibroblast marker. However, 
myofibroblast conditioned media has been shown to induce migration of H357 cells 
greater than the corresponding NOF (Melling et al., 2018) and a further study 
demonstrated that a panel of αSMA expressing CAF could increase the migration of 
several different OCCL significantly more than low αSMA expressing NOF (Zhou et 
al., 2014). However, they did not report on the senescent status of the CAF cultures 
or their genetic background. Together this highlights the inherent heterogeneity 
between different CAF cultures, meaning multiple samples are needed to determine 
which CAF characteristics and secreted factors are most associated with stimulation 
of migration.  
Furthermore, an interesting extension to these studies would be the 
inclusion of an ECM layer to assess the invasive ability of the different cell lines used 
here and their responses to conditioned media from the different fibroblast types. 
There is some existing evidence to suggest that myofibroblasts (Daly, McIlreavey 
and Irwin, 2008; Marsh et al., 2011; Melling et al., 2018), senescent fibroblasts 
(Kabir, 2015; Kabir et al., 2016) and primary CAF (Li et al., 2015; Lin et al., 2017) are 
able to increase invasion of OCCL in a transwell assay. However, assessing the 
relative response of the panel of OCCL used here would be an interesting extension 
to these previous findings. Furthermore, the use of multicellular 3D models would 
provide a more detailed insight into the invasion pattern and direct influence of CAF 
presence (see also 6.3.2. discussion). The enhanced ability of senescent fibroblasts 
and CAF to induce invasion of H357 cells compared to NOF in 3D de-epitheliarised 
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dermis models of oral mucosa has been demonstrated previously in our lab (Kabir, 
2015; Kabir et al., 2016) and demonstrated with further OCCL in a 3D biomatrix 
model by others (Costea et al., 2013). However, a confirmation of this result and 
comparison with the remaining cell types on this panel would provide an interesting 
extension to this work. As stated above, the use of tumour spheroids or a more 
relevant model to the lymph node microenvironment may also be needed to 
investigate lymph node metastases invasion more appropriately.  
 
6.4. Vasculature 
The ability of tumours to induce the formation of vascular and lymphatic 
vessels is important not only for the facilitation of tumour growth but also to 
provide a potential route of metastasis. Elevated vessel densities have been 
reported in the primary tumour and linked to increased invasion and lymph node 
metastasis (Miyahara et al., 2007; Zhao et al., 2008). However, the behaviour of 
endothelial cells in the lymph node tumour microenvironment and the extent to 
which new vessel growth occurs following tumour colonisation is less clear. This 
study found that blood vessel densities are elevated in ECS+ lymph nodes but no 
significant difference in lymphatic vessel density was observed (section 3.2.3. and 
discussion 6.1.2.). To extend this work, the effect of conditioned media from a panel 
of primary and lymph node metastases-derived OCCL (as used previously) on the 
tubule formation ability and proliferation of lymphatic and vascular endothelial cells 
was assessed.  
6.4.1. OCCL effect on endothelial cell microtubule formation 
Microtubule formation by human dermal lymphatic endothelial cells (HLEC) 
was significantly increased in the presence of conditioned media from all OCCL used 
compared to the media only control with the exception of TR146. This effect could 
not be attributed to proliferation, as there was no significant difference in cell 
number after the same time period, as assessed by MTS assay (section 5.2.1.). The 
ability of OCCL to induce tubule formation in HLEC has been previously 
demonstrated which supports this result (Zhuang et al., 2010). However, they found 
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that metastatic OCCL induced HLEC tubule formation to a greater extent than non-
metastatic cells which does not match to the finding here of no difference between 
non-metastatic and metastatic OCCL. However, in contrast, this previous study 
compared a metastatic OCCL generated through repeated in vivo selection for 
lymph node metastasis in mice to its human parental cell line rather than from a 
human metastatic tumour. They also carried out the tubule formation assays with 
fibronectin coated wells rather than using Matrigel and no images were provided to 
demonstrate the successful formation of tubules. Aside from this study, there is a 
lack of in vitro evidence in OSCC to supporting the finding here that cells derived 
directly from lymph node metastasis are capable of inducing lymphatic vessel 
formation equal to that of primary tumour cells. Nevertheless, some ex vivo 
evidence exists that suggests metastatic deposits alter lymphatic vasculature 
following colonisation (as discussed in section 6.1.2.). 
In contrast, microtubule assays carried out using human dermal 
microvascular endothelial cells (HMEC) found no difference in tubule formation in 
the presence of OCCL conditioned media compared to the media only control 
(section 5.2.1.). As for HLEC, there was no significant difference in cell number after 
the same time period under any of the media conditions used as determined by 
MTS assay. In vitro evidence of OCCL induction of microvascular tubule formation is 
lacking but co-expression of vascular and proliferative markers has been identified 
ex vivo in the primary tumour (Naresh, Nerurkar and Borges, 2001).  
6.4.2. Fibroblast effect on endothelial cell microtubule formation 
Ex vivo data have linked higher myofibroblast presence to elevated vascular 
and lymphatic vessel density in OSCC primary tumours (Ding et al., 2014; Lin et al., 
2017). However, this study found no direct correlation between percentage positive 
cell expression of αSMA and lymphatic or vascular vessel density in the primary and 
lymph node metastasis specimens used (section 3.2.3.). Nevertheless, there is no 
doubt that CAF and endothelial cells interact in the tumour microenvironment and 
that CAF are capable of secreting factors which promote vessel formation (Coppé et 
al., 2006; Cirri and Chiarugi, 2012). Incubation of HLEC or HMEC with conditioned 
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media from myofibroblasts or senescent fibroblasts did not result in any significant 
change in tubule formation with the exception of HMEC treated with H2O2-
senescent fibroblast conditioned media, which caused increased tubule formation 
compared to the media only control. However, this was based on two experimental 
repeats and the increase was not significant compared to NOF conditioned media 
(section 5.2.2.).  
There are little previous experimental data related to OSCC with which to 
compare these results. The ability of CAF-conditioned media to induce tubule 
formation in human umbilical vein endothelial cells (HUVEC) to a great extent that 
that of NOF has been shown in a Matrigel based tubule formation assay (B. Zhou et 
al., 2015). Myofibroblast (generated through tumour necrosis factor-α (TNFα) 
stimulation rather than TGF-β1) conditioned media also increased tubule formation 
compared to NOF by HUVEC in the same study.  
To extend these investigations, primary CAF conditioned media could be 
used. In addition, conditioned media from CAF co-cultured with different OCCL may 
better represent how the crosstalk between these two cell types can influence 
vessel formation and link this work back to lymph node metastasis development. 
Moreover, FRC have been identified as the principal VEGF secretors in the lymph 
node (Chyou et al., 2008) so their inclusion in a co-culture model may provide an 
important tool for the study of lymph node angiogenesis induction. 
6.4.3. Investigating endothelial cell behaviour in vitro 
Microtubule formation assays are a useful and well-used tool for 
investigating vessel formation in vitro. They provide a cheap, quick, and simple 
method that allows the assessment of attachment, migration and tubule formation 
processes of angiogenesis in one assay (Arnaoutova and Kleinman, 2010). However, 
they also have some limitations, which must be taken into consideration when 
drawing conclusions from this work. One of these is the use of Matrigel to represent 
the ECM. Matrigel is derived from mouse Engelbreth-Holm-Swarm (EHS) sarcoma, 
which was found to contain many of the same components as ECM basement 
membrane found in humans. However, as well as being derived from a mouse 
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rather than human tumour, it has also been reported that the composition and 
protein isoforms present may not be equivalent to that seen in vivo (Rowe and 
Weiss, 2008). Other problems such as batch-to-batch variability in protein and 
growth factor composition were controlled for here by minimising the number of 
batches used and using growth factor-reduced Matrigel.  
As well as alterations to the current method, alternative ways to investigate 
the relationship between endothelial cells, cancer cells and CAF could be employed. 
These include comparing the ability of different cell lines to adhere to endothelial 
cells using fluorescent cell labelling. Analysis of selected secreted factors by CAF and 
OCCL both in monoculture and co-culture could also be investigated, such as the 
expression of different VEGF isoforms. Increased secretion of VEGF-A and –C by 
metastatic OCCL has been demonstrated in vitro (Zhuang et al., 2010; Yanase et al., 
2014; Morita et al., 2015). In addition, it is known that myofibroblasts and 
senescent fibroblasts are capable of VEGF secretion (Coppé et al., 2006; Cirri and 
Chiarugi, 2012), but the relative effect of OCCL with different metastatic potential 
and origins on secretion levels of these factors by fibroblasts would provide an extra 
insight into this relationship. This would also link to ex vivo studies that found a link 
between high VEGF-A and –C expression, invasion pattern and lymph node 
metastasis using immunohistochemical and PCR methodology (Siriwardena et al., 
2008; Sales et al., 2016; Abdul-Aziz et al., 2017). To link this work to the 
development of lymph node metastatic tumours, VEGF secretion by FRC could be 
investigated with and without the presence of metastatic lymph node-derived 
OCCL. 
 
6.5. Cytokine secretion by OSCC stromal cells  
The generation of an inflammatory microenvironment and the presence of 
inflammatory immune cells, including macrophage, is known to be an important 
driver of tumour progression. Inflammatory cytokines and chemokines released by 
tumour and stromal cells drive this process and have wide-ranging effects on 
immune cell recruitment, vessel formation, ECM reorganisation and tumour 
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behaviour (Grivennikov, Greten and Karin, 2010). However, the importance of these 
molecules in the colonisation, development and invasive ability of lymph node 
metastases is less well studied, despite the stark difference in native cell population 
compared to the primary tumour site.   
The presence of macrophages within and surrounding tumour islands in 
primary and lymph node metastases was identified in this study (section 3.2.4. and 
discussion 6.1.3.) and it is clear from the literature that macrophages are important 
to tumour progression and promote invasion and metastasis (Takeya and 
Komohara, 2016). Therefore, secretion of the macrophage-attracting chemokine 
CCL2 alongside other key inflammatory cytokine molecules that have been 
previously implicated in the promotion of tumour invasion and metastasis (Mishra, 
Banerjee and Ben-Baruch, 2011; Voronov et al., 2013; Kabir et al., 2016), were 
investigated by co-culturing OCCL with stromal cells.  
6.5.1. OCCL effect on immune signalling by fibroblasts 
CAF play a key role in the modulation of the immune response to tumour 
presence. They are capable of secreting a wide range of cytokines and chemokines 
which affect immune cell recruitment, polarisation and function (Turley, Cremasco 
and Astarita, 2015). Signalling from cancer cells to fibroblasts can result in fibroblast 
activation, thereby promoting the formation of a pro-inflammatory, pro-tumour 
immune response in the tumour microenvironment. Although CAF have been 
shown to modulate immune function in many cancer models, their role in oral 
cancer development and particularly the development of lymph node metastasis is 
less well established. Therefore, this study looked at the effect of conditioned 
media from a panel of OCCL on cytokine and chemokine secretion by normal oral 
fibroblasts (NOF). 
CCL2 
Secretion and mRNA expression of CCL2, a potent macrophage attracting 
chemokine, was assessed because of the interest in the role of macrophage in oral 
cancer progression (see discussion 6.1.3.). Incubation of NOF with OCCL conditioned 
media for 24 h resulted in a significant increase in CCL2 secretion by NOF in the case 
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of the lymph node metastasis-derived OCCL (BICR22 and TR146) conditioned media 
only. This effect was particularly pronounced with TR146 conditioned media and 
this was matched by a significant increase in CCL2 mRNA levels in NOF, with a non-
significant increase seen for BICR22 conditioned media too (section 4.2.6.). This 
suggests that tumour cells at metastatic sites are more capable of activating 
fibroblasts to produce CCL2 than primary tumour cells. Whilst this is the first study 
to make this comparison in vitro, there is ex vivo evidence of CCL2 expression in 
OSCC metastatic lymph nodes although this has primarily focussed on immune cells 
rather than CAF. One study reported that the percentage of CCL2 positive immune 
cells was significantly higher in lymph nodes with metastatic deposits compared to 
tumour-free nodes but reported no difference between N0 and N+ primary tumours 
(Ferreira et al., 2008). Another reported that all sentinel lymph nodes had CCL2 
positive neutrophil regardless of metastatic status whereas they were present in 
only some primary tumours (Fujita and Ikeda, 2017). Although these results suggest 
that CCL2 may be important to tumour development in the lymph node, it remains 
unclear at what stage this occurs and what the role of fibroblast secretion is. 
Furthermore, these studies used very high-powered field for quantification (x 40 to 
x 100 magnification) increasing the risk of subjective bias and either used a very low 
sample size (<10 per group) (Ferreira et al., 2008) or did not carry out any 
quantification (Fujita and Ikeda, 2017). Therefore, a novel extension to this study 
would be the quantification of CCL2-expressing cells in lymph nodes, either using 
the ECS+/- cohort from this study and/or comparing to tumour free nodes.  
This is the first study to report on the effect of OCCL on NOF secretion of 
CCL2, and to compare primary and lymph node metastases-derived OCCL. However, 
increased CCL2 secretion by CAF as a result of co-culture with OCCL has been 
previously demonstrated (Li et al., 2014). This previous study also showed that CCL2 
production could promote OCCL migration and invasion and that this could be 
ablated using siRNA knockdown of CCL2. Additionally, previous work in our lab has 
shown CCL2 secretion is elevated in CAF from genetically-unstable tumours and 
upon senescence induction in NOF and that antibody blockage of secreted CCL2 
diminishes their pro-invasive effect on H357 cells (Kabir, 2015; Kabir et al., 2016). 
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This suggests that CCL2 secretion by fibroblasts has effects ranging beyond 
macrophage recruitment.  An extension of this study to look at the relative ability of 
primary and metastatic OCCL to induce CCL2 secretion in CAF and a comparison 
between secretion levels of CAF derived from primary tumour and lymph node 
metastasis would extend upon this and previous work.  
IL-6 
There has been considerable focus on the link between oral cancer 
progression and IL-6 secretion. Elevated IL-6 has been linked to the promotion of 
tumour survival, invasion, proliferation and angiogenesis in multiple cancer types 
(Ataie-Kachoie, Pourgholami and Morris, 2013). Elevated serum and tissue IL-6 
mRNA levels have been observed in OSCC and have been associated with increased 
incidence of lymph node metastasis and poor survival (Shinriki et al., 2011; Goda et 
al., 2017; Qin et al., 2018), making IL-6 a potentially useful prognostic biomarker. IL-
6 secretion by NOF was significantly increased following incubation with all OCCL 
conditioned medias except for media from the metastatic primary tumour OCCL 
H376. As for CCL2, this was particularly pronounced with TR146 conditioned media, 
which also resulted in significantly higher mRNA expression by NOF (section 4.2.6.). 
This suggests that both lymph node and primary tumour derived cell lines can 
induce IL-6 secretion by fibroblasts but that the level of induction varies more by 
cell line rather than by site. The inability of the metastatic primary tumour OCCL 
H376 to induce induction compared to the non-metastatic primary tumour OCCL 
H357 is surprising given the link between IL-6 and the induction of invasion (Qin et 
al., 2018). However, it maybe that H376 cells do not rely on this signalling 
mechanism to gain invasive ability and, given the multitudinous effects of IL-6, H357 
cells may gain other advantages from stimulating its production.  
Comparable studies are scarce but the ability of primary tumour-derived 
OCCL to induce IL-6 mRNA expression by fibroblasts when in co-culture has been 
reported (Dudás, Fullár, et al., 2011; Qin et al., 2018). This differs slightly to our 
results which found only TR146 conditioned media could induce increased IL-6 
mRNA expression in NOF whereas primary tumour-derived OCCL had no significant 
effect. This may be explained by the fact that these previous studies co-cultured 
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both cell types together in transwells and for a longer time period, which may have 
resulted in a sustained increase in gene expression as opposed to an immediate 
protein secretion response. Additionally, in each case only one cell line was used, 
for which metastatic status information was not available, so a direct comparison 
cannot be made.  
As reported for CCL2, increased IL-6 secretion has also been reported to be 
elevated following senescence induction in NOF and to be higher in CAF from 
genetically unstable tumours (Kabir, 2015; Kabir et al., 2016). This was confirmed by 
a further study that found IL-6 to be expressed more highly in CAF than NOF, or 
tumour cells, from the same patient (Qin et al., 2018). A comparison of primary 
tumour and lymph node tumour-derived CAF has not been carried out but would 
provide a valuable extension to this current work. 
Other interleukins 
The pro-inflammatory chemokine IL-8 (also known as CXCL8) is a key 
recruiter and activator of neutrophil and through its downstream signalling 
pathways has been shown to stimulate cancer cell survival and migration and 
induce angiogenesis (Waugh and Wilson, 2008). Elevated IL-8 expression has been 
previously linked to poor prognosis in OSCC (Fujita et al., 2014) and salivary IL-8 has 
been suggested as a potential biomarker for OSCC (Punyani and Sathawane, 2013). 
Although IL-8 is known to be expressed by fibroblasts (Turley, Cremasco and 
Astarita, 2015), the role and importance of fibroblast IL-8 production has not been 
widely reported. As seen for IL-6 and CCL2, NOF incubated with TR146 conditioned 
media expressed high levels of IL-8 mRNA (section 4.2.6.). The exact reason for the 
strong reaction of NOF to TR146 conditioned media is unknown. IL-8 expression by 
TR146 and in untreated NOF has been previously shown (Khurram et al., 2014) but 
the influence of TR146 conditioned media on NOF IL-8 expression is a novel 
extension to this. TR146 are derived from a lymph node metastasis of a well-
differentiated OSCC originating in the buccal mucosa but the nature of the immune 
response of this tumour is not known. It may be that a strong neutrophil and 
macrophage infiltrate was present at the tumour site, which would match to the 
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ability of TR146 to induce the high CCL2 and IL-8 expression levels seen in this 
study.  
mRNA expression of IL-1α was also assessed given its central role in immune 
response coordination but expression could not be detected in any of the NOF 
samples in this study. The same lack of response was found for IL-1β, a potent pro-
angiogenic cytokine (section 4.2.6.) whereas expression of both of these cytokines 
was detected in HMEC and HLEC using the same experimental protocol (section 
5.2.3-4). This lack of expression could be explained by the use of NOF rather than 
CAF, suggesting that OCCL conditioned media is not sufficient to induce expression 
of these molecules in healthy fibroblasts in the time period used. However, previous 
work in OSCC has shown that co-culture of OCCL and NOF could induce an increase 
in IL-1β mRNA expression (Dudás, Bitsche, et al., 2011) but this was carried out over 
7 days with both cell types present in a transwell system and used periodontal 
ligament fibroblasts which may explain the difference in results. Extending this work 
to include protein expression analysis may help determine the full expression 
pattern. Additionally, there is evidence that IL-1α and IL-1β secretion by tumour 
cells can alter CAF behaviour (Dudás, Fullár, et al., 2011; Bae et al., 2014), which 
suggests that investigation into IL-1 receptor expression in CAF or NOF may be a 
more interesting avenue of research. 
To fully assess the contribution of fibroblasts to immune signalling in lymph 
node tumours a microarray of common immune signalling molecules could be 
investigated to identify further targets for study. This could be done using either the 
same experimental design as used here to compare the effect of different OCCL 
conditioned media on NOF secretion, or compare CAF from multiple sites including 
lymph node metastases. Alternatively, the effect of CAF conditioned media on OCCL 
cytokine and chemokine secretion could be investigated. 
6.5.2. OCCL and CAF effect on immune signalling in endothelial cells 
The study of endothelial cells in the context of cancer has mainly 
focussed on vessel formation and the link of this to metastasis. However, it is 
now becoming clear that endothelial cells contribute to the immune response to 
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cancer, are capable of interacting with both innate and adaptive immune cells , 
and can produce a large range of immune signalling molecules (Young, 2012). 
Endothelial cells have been shown to mount an inflammatory response to stimuli 
such as bacterial or viral infection and in the presence of cancer cells. In the 
context of cancer, they have also been implicated in the induction of immune 
tolerance through the secretion of immune inhibitory molecules and antigen 
presentation to T lymphocytes (Young, 2012). This is a potentially important, but 
understudied, area of tumour immunobiology as endothelial cells form a barrier 
both to immune cells infiltrating into the tumour microenvironment and to 
metastasising tumour cells.  
OCCL induced cytokine/chemokine expression in endothelial cells 
To investigate chemokine and cytokine secretion in endothelial cells in 
response to OCCL conditioned media, expression of the cytokines IL-6, IL-1α, IL-
1β and the chemokines IL-8 and CCL2 was assessed in dermal vascular (HMEC) 
and lymphatic (HLEC) endothelial cells (section 5.2.3.). Secretion of IL-6 by HMEC 
and HLEC following incubation with OCCL conditioned media was increased in 
response to all OCCL although this was significant only in the case of H357 and 
BICR22-derived conditioned media. However, there was a large amount of 
variation in response level between experimental repeats. Surprisingly, high 
levels of the macrophage-attracting chemokine CCL2 were secreted in the media 
of HMEC and HLEC even under SFM control conditions (section 4.2.6. and 5.2.3.). 
The reason for this high level of secretion is unknown but suggests that 
endothelial cells may be important for the recruitment of macrophages. mRNA 
expression of all five signalling molecules was evident in both HLEC and HMEC 
including IL-1α/β, which is in contrast with the lack of expression in NOF (see 
section 6.5.1.). OCCL conditioned media treatment revealed only small changes 
in expression levels and these were mostly attributable to cells treated with 
conditioned media from the lymph node-metastasis-derived OCCL BICR22 and 
TR146. IL-6 mRNA expression was significantly increased only in HMEC treated 
with BICR22-derived conditioned media and IL-8 mRNA expression was increased 
in response to conditioned media from both lymph node-derived OCCL (BICR22 
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and TR146), but this was significant only for HLEC (section 5.2.3.). This shows 
that both lymphatic and vascular endothelial cells are capable of secreting a 
wide range of immune modulating molecules and that OCCL are capable of 
altering their expression to some extent. Evidence of IL-6 expression and 
secretion by endothelial cells is particularly interesting as elevated serum IL-6 
levels have been proposed as a biomarker for OSCC (Shinriki et al., 2011; Goda et 
al., 2017; Qin et al., 2018). A significant response of HLEC and HMEC to some of 
the OCCL observed here supports the idea that endothelial cells may be one of 
the cell sources contributing to this specific inflammatory response. However, a 
large inter-experimental variation was observed so further repeats are needed 
to clarify and establish this relationship.  
There are limited published data available for direct comparison but 
elevation of IL-6 and IL-8 mRNA expression in dermal HMEC as a result of co-
culture with an OSCC cell line has been previously reported (Neiva et al., 2009). 
This expression change was detected in a microarray but the effect was not 
validated using PCR or ELISA. Instead, the remaining part of the study focussed 
on inducing expression using VEGF or BCL-2 over-expression in the endothelial 
cells, and the effect of these cytokines on the tumour cells themselves. 
Therefore, it is unclear to what extent this result is reproducible in other OSCC 
model systems.  
Studies in other cancer types, including those analysing multiple markers 
through a gene microarray, most commonly highlight IL-6 and IL-8 as factors 
expressed by endothelial cells in response to cancer cell conditioned media or 
co-culture (Goerge et al., 2006; Mierke et al., 2008; Rhim et al., 2008; Wang et 
al., 2013; Jin et al., 2016). Some of these studies also reported that the more 
invasive cell lines could induce IL-8 expression to a greater extent (Goerge et al., 
2006; Mierke et al., 2008) which appears to be somewhat similar to our finding 
that only lymph node metastases-derived OCCL conditioned media significantly 
increased IL-8 mRNA expression in endothelial cells. However, how the invasive 
ability was determined was not defined by Goerge et al. (2006) and is unclear 
from available cell line data. Mierke et al. (2008) determined invasive ability by 
170 
 
the propensity of cell lines to invade into a collagen gel containing endothelial 
cells. However, both invasive and non-invasive cell line groups contained cell 
lines derived from lymph node metastases, which complicates this definition in 
terms of clinical relevance, and in comparison to this study. In addition, all of 
these studies used human umbilical vein endothelial cells (HUVEC) as opposed to 
adult dermal endothelial cells as used in this study. HUVEC are an embryonic cell 
line so dermal HMEC may provide a more relevant cell lines for adult cancer 
models. 
The extraction of endothelial cells from primary tumour and lymph node-
metastases tissue could alternatively be used to screen for OSCC specific 
markers. Isolation of lymph node endothelial cells from both mouse and human 
tissue using magnetic bead sorting has been reported (Clasper et al., 2008; 
Garrafa et al., 2015). Garrafa et al. (2015) also reported that secretion of IL-6, IL-
8 and CCL2 was significantly higher by lymphatic endothelial cells isolated from 
lymph nodes proximal to the tumour site compared to cells from distant lymph 
nodes. However, this methodology still needs optimisation and access to 
clinically relevant samples is hampered by the difficulty in obtaining patient 
lymph nodes without hindering diagnostic procedures. 
Fibroblast induced cytokine/chemokine expression in endothelial cells 
As previously discussed, CAF also play a role in the immune response to 
tumours and are known to interact with endothelial cells (discussion 6.4.2.). 
Therefore, the effect of myofibroblast and senescent fibroblast conditioned 
media on secretion of IL-6 and CCL2, and mRNA expression of IL-6, CCL2, IL-1α, 
IL-1β and IL-8 in HLEC and HMEC was assessed. However, few significant changes 
were observed following conditioned media treatment (section 5.2.4.). A small 
but significant increase in IL-6 secretion by HLEC was seen as a result of 
incubation with myofibroblast conditioned media treatment but no other 
expression changes were seen observed in either secretion or mRNA expression 
levels. H2O2-senesced fibroblast conditioned media did not alter IL-6 or CCL2 
secretion in either HMEC or HLEC. mRNA expression of most of the molecules 
studied showed an increase in expression as a result of H2O2-senescent 
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fibroblast conditioned media treatment but there was a large variation between 
experimental repeats and only CCL2 and IL-8 expression in HLEC were 
significantly increased. As for OCCL, this provides evidence that endothelial cells 
contribute to the inflammatory milieu of the tumour microenvironment but 
provides limited evidence that this is significantly altered by the presence of 
CAF. Further experimental repeats may be needed to clarify this due to the large 
variation in response between experiments.  
There are limited data looking at the effect of CAF on the endothelial 
immune response in cancer, making it hard to compare these findings to others . 
However, co-culture incorporating cancer cells, CAF and endothelial cells has 
been reported (Wang et al., 2017). This previous study reported that 
inflammatory marker expression was increased in tumour spheroids that 
contained fibroblasts and endothelial cells compared to tumour cell only 
spheroids but did not look at any of the markers used in this study. Models such 
as these or indirect co-culture using successive conditioned media treatments to 
incorporate all three cell types could be used to extend this work. However, 
especially given the inter-experiment variation seen already, care must be taken 
to reduce the variability between conditions and include adequate controls. 
 
6.6. Conclusion and impact 
This thesis has described data relating to the role of the tumour 
microenvironment in the growth and development of lymph node metastases in 
OSCC. This is the first study to comprehensively examine stromal and EMT markers 
in OSCC lymph node metastases and their matched primary tumours. It revealed 
the novel finding that αSMA-expressing myofibroblasts are more abundant in the 
stroma of ECS+ lymph nodes, as well as their matched primary tumours, and that 
microvascular vessel density is also elevated in ECS+ nodes. EMT marker expression 
in OCCL and patient tissues was investigated but more work is needed to determine 
the prognostic impact in lymph node metastases and the impact of CAF on 
expression levels in vitro. This work also demonstrated the ability of both primary 
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and lymph node metastases-derived OCCL to induce tubule formation by lymphatic 
endothelial cells. Furthermore, this report extended on previous findings by 
showing that OCCL can induce IL-6 and CCL2 secretion in NOF and that lymph node 
metastases-derived OCCL have a heightened ability to induce this inflammatory 
signalling response. Finally, inflammatory signalling in endothelial cells was 
investigated and the novel exposure of these cells to OCCL and fibroblast 
conditioned media gave some insight into the potentially important role of 
endothelial cells in the tumour immune response. 
This work has the potential to impact clinical outcomes and procedures for 
OSCC patients. The most immediate potential impact is the development of 
prognostic and diagnostic biomarkers for OSCC patients. Evidence from this study 
shows that αSMA positive fibroblast numbers are elevated in the stroma of ECS+ 
patients both in the primary tumour and in lymph node metastases. This suggests 
that identification of high αSMA levels either in the primary tumour or lymph node 
biopsy samples indicates a higher risk of ECS, which advocates for the need for neck 
dissection. Additionally, the ability of OCCL to induce IL-6 secretion in NOF supports 
the use of IL-6 as a cancer biomarker in OSCC, as has been previously suggested 
(Shinriki et al., 2011; Goda et al., 2017; Qin et al., 2018), and warrants more 
investigation in the context of ECS. 
In addition, the targeting of stromal cells as an alternative therapeutic 
strategy has great potential to improve the treatment options available to OSCC 
patients, especially those with lymph node metastasis and ECS, which are 
associated with treatment failure. The tumour microenvironment has been 
suggested as a source of therapeutic resistance (Sun, 2016), and so may provide an 
additional avenue of treatment options for patients for whom current  therapies are 
not successful. The greater genetic stability of stromal cells and their influence on 
the ECM, which is often a barrier for the delivery of drugs to solid tumours, makes 
them even more attractive. Many of the cell markers and molecules highlighted in 
this thesis are already being investigated as potential treatment targets in other 
cancer types. For example, anti-IL6 and anti-IL-6 receptor antibody therapeutics 
have entered clinical trials in a number of cancer types (Kumari et al., 2016). 
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Multitudinous mechanisms for targeting CAF and CAF signalling pathways have also 
been proposed, including targeting fibroblast activation protein (FAP) to kill CAF and 
administration of thrombospondin-1, which was shown to reduce CAF activation by 
down-regulating αSMA (Wang et al., 2014). Extending this current body of work, 
both in vitro and using clinical data/samples, may enable these stromal-targeted 
treatment strategies to be transitioned to OSCC in the clinic. 
 
6.7. Future work 
There are several ways by which the work detailed in this thesis could be 
extended to expand current knowledge of the OSCC lymph node tumour 
microenvironment.  
Firstly, further markers could be investigated by IHC to compare the tumour 
microenvironments of ECS+ and ECS- lymph node metastases. This could include 
senescence markers, other ECM components including MMPs, HEV density, 
proportions of M1 and M2 macrophage and the presence of other innate immune 
cells, such as neutrophil and mast cells.  
Secondly, characterisation of primary lymph-node derived CAF, especially if 
paired with their corresponding primary tumour CAF would provide a valuable 
insight into the similarities and differences between these two sites. This 
characterisation could take the form of whole genome sequencing or use 
microarrays to assess expression of particular markers, such as cytokines and 
chemokines. Another important cell type for the study of lymph node CAF 
development are FRC as they are the predominant fibroblast population in the 
lymph node and so have been proposed as a major source of lymph node CAF. The 
effect of TGF-β1 or OCCL conditioned media on activation marker expression, pro-
angiogenic factor secretion and expression of pro-inflammatory molecules could be 
investigated. 
There are many experiments that could be used to directly expand the in 
vitro work described in this thesis. OCCL cytokine and chemokine expression and 
relative ability to promote monocyte differentiation and macrophage migration 
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could be investigation using established markers and transwells assays. The effect 
of CAF on both of these behaviours would also provide a valuable extension to this.  
Finally, the development of 3D models incorporating myofibroblasts, 
senescent fibroblasts or primary CAF as well as OCCL would extend the experiments 
described here investigating migration and EMT expression in OCCL. Both invasion 
patterns and EMT marker expression could be assessed in parallel providing a 
valuable comparison. These could take the form of previously developed oral 
mucosa models or utilise spheroid culture to form an environment more analogous 
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Appendix A: IHC blocking experiments 
 
 
Appendix Figure A.1. SNAI1/2 antibody immunohistochemical (IHC) blocking 
control experiment. Representative images of IHC staining taken from the same 
slide location from either the negative control (anti-rabbit secondary antibody (Ab) 
only), SNAI1/2 primary Ab (Abcam ab85936) plus anti-rabbit secondary antibody, or 
SNAI1/2 Ab pre-incubated with the peptide from which it was raised (ab19126) plus 
anti-rabbit secondary antibody. Both primary Ab only and the peptide-blocked 
primary Ab mix were incubated overnight at 4°C before use. x 10 magnification, 







Appendix B: SYBR green primer melt curves 
 
 
Appendix Figure B.1. SYBR green primer melt curves. Melt curves generated during 
qRT-PCR analysis using SYBR green primers for α-smooth muscle actin (αSMA), 
p16INK4a (p16), p21/cip-1 (p21) and U6 endogenous control reference gene. Primer 







Appendix C: TWIST1 antibody optimisation (Abcam ab50887) 
 
 
Appendix Figure C.1. Optimisation and use of TWIST1 antibody (Abcam ab50887) 
for western blot. Western blot (left) shows results of optimisation experiment using 
untreated cell lysates (20 µg/lane) and antibody diluted 1/50 and blocked with 5% 
(w/v) BSA (as recommended by manufacturer). A specific band at 21 kDa was 
observed in BICR22 and TR146 cell lines alongside a non-specific 100 kDa band for 
all cell lines. Western blots using experimental samples (example on right) did not 
show any specific bands despite prolonged exposure time. Protein presence was 
confirmed using Ponceau staining and by labelling for β-actin expression (lower 
blot). Experimental sample blots used the same western blot conditions and were 
loaded with 20 µg/lane of cell lysate (treated with either normal oral fibroblast (C) 
or H2O2-treated fibroblast (H) conditioned media). All blots developed using ECL and 
x-ray.  
